 
 
SCYNEXIS, Inc.  
Clinical Trial Protocol  
Open -Label Study to Evaluate the Efficacy and Safety of  SCY -078 
(Ibrexafungerp) in Patients with Fungal Diseases that are Refractory to, 
Resistant to  or Intolerant of Standard Antifungal Treatment ( FURI ) 
SCYNEXIS  Protocol Number  SCY- 078-301 
 
 
 
Original Protocol Issue Date:   30 November 2016  
Protocol Amendment 1 Issue Date:   [ADDRESS_973900] 2019  
Protocol Amendment 3 Issue Date:   [ADDRESS_973901] be informed that the information is privileged  or 
confidential  and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure 
will apply equally to all  future information supplied to you which is indicated as 
privileged  or confidential . 

SCYNEXIS, Inc.  IND #107,[ADDRESS_973902]   
  
Sponsor  SCYNEXIS , Inc.  
 
 
  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 3 2.0 Protocol Approvals  
 
  PROTOCOL ID: SCY- 078-[ADDRESS_973903] Antifungal 
Treatment ( FURI ) 
SCYNEXIS , Inc. Approval:  
 
 
  
[ADDRESS_973904] Plaza, 13th Floor  
Jersey City, NJ [ZIP_CODE] Phone: +[PHONE_14858] Fax: +[PHONE_14859]  
E-mail: [EMAIL_13680]   Date  
 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 4 Investigator Agreement Statement  
PROTOCOL  ID: SCY- 078-[ADDRESS_973905] Antifungal 
Treatment ( FURI ) 
 
I understand that all documentation provided to me by [CONTACT_27367] , Inc. or its designated 
representative(s) concerning this study that has not been published previously will be kept 
in the strictest confidence. This documentation includes the study protocol, Investigator’s 
Brochure, case report forms, and other scientific data. This study will not commence 
without the prior written approval of a properly constituted Institutional Review Board or 
Ethics Committee. No changes will be made to the study protocol w ithout the prior written 
approval of SCYNEXIS , Inc. and the Institutional Review Board/Ethics Committee, except 
where necessary to eliminate an immediate hazard to the subject . All patien ts will provide 
a written informed consent prior to participation. If the patient is not able to provide written 
consent due to the severity of their illness and I consider the patient’s condition to be life -
threatening or highly debilitating without participation in this clinical study, I will obtain 
written consent from a legal representative (LAR) of the patient.  Once the patient is able 
to provide oral or written consent, I will obtain appropriate consent. If the patient is capable 
of giving consent but does not give consent to continue, the patient will be withdrawn from 
the trial.  
I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I have read, understood and 
agree to abide by [CONTACT_27368], and in 
compliance with International Conference on Harmonization (ICH) guidelines, Good 
Clinical Practices (GCP), Safety Reporting obligations and any applicable local 
requirements.  
 
Principal Investigator’s Signature   [CONTACT_27439]’s Name (Printed )   
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973906] Information  ................................................................................................ 2 
2.0 Protocol Approvals  ................................................................................................. 3 
3.0 Table of Contents  .................................................................................................... 5 
4.0 Abbreviations  ........................................................................................................ 11 
5.0 Protocol Synopsis .................................................................................................. 14 
6.0 Schematic of Study Design ................................................................................... 22 
7.0 Background Information and Scientific Rationale  ............................................... 23 
7.1 Background Information ............................................................................... 23 
7.2 Rationale for the Study ................................................................................. 30 
8.0 Study Objectives  ................................................................................................... 31 
8.1 Primary Objectives ........................................................................................ 31 
8.2 Secondary Objectives .................................................................................... 31 
8.2.1  Overall Secondary Objectives ................................................................... 31 
8.2.2  Disease- Specific Secondary Objectives  .................................................... 31 
9.0 Study Endpoints  .................................................................................................... 31 
9.1 Primary Endpoints  ........................................................................................ 31 
9.2 Secondary Endpoints  .................................................................................... 32 
9.2.1  Overall Secondary Endpoints  ................................................................... 32 
9.2.2  Disease- Specific Secondary Endpoints  ..................................................... 32 
10.0  Study Design ......................................................................................................... 34 
10.1  Overall Description of the Study .................................................................. 34 
10.2  Blinding, Randomization and Stratification  ................................................. 37 
10.3  Study Duration .............................................................................................. 37 
10.4  Number of Centers  ........................................................................................ 37 
11.0  Study Population  ................................................................................................... 37 
11.1  Inclusion Criteria  .......................................................................................... 37 
11.2  Exclusion Criteria  ......................................................................................... 47 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973907]  .......................................................................................... 56 
14.1.6  Prior and Concomitant Medications  ......................................................... 56 
14.1.7  Study Drug Dispensing, Collection and Accountability Review .............. 57 
14.1.8  Study Drug Dosing ................................................................................... 57 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973908]. George’s Respi[INVESTIGATOR_6015] (SGRQ)  ..................................... [ADDRESS_973909] and Medical Research Council (MRC) Dyspnea 
Scale  [ADDRESS_973910]  ............................................................................. 77 
16.4  Overdose  ....................................................................................................... 78 
16.5  Pregnancy  ...................................................................................................... 78 
16.6  Unexpected Adverse Event  ........................................................................... 78 
16.7  Grading of Adverse Events  ........................................................................... 79 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 8 16.8  Causality Assessment .................................................................................... 79 
16.9  Adverse Event Collection Timeframe  .......................................................... 80 
16.10  Serious Adverse Event Reporting Requirements  .......................................... 80 
16.11  Adverse Event and Serious Adverse Event Follow -up ................................. 80 
16.12  Serious Adverse Event Reporting – Procedures for Investigators  ................ [ADDRESS_973911] Management .............................. 81 
17.1  Data Collection and Reporting...................................................................... 81 
17.2  Study Monitoring  .......................................................................................... 82 
17.3  Investigator Study Files  ................................................................................ 82 
17.4  Retention of Records ..................................................................................... 82 
18.0  Analytical Plan  ...................................................................................................... 83 
18.1  Sample Size Determination ........................................................................... 83 
18.2  Analysis Populations  ..................................................................................... 83 
18.3  Interim Analyses and Supplemental Analysis  .............................................. 84 
18.4  Efficacy  ......................................................................................................... 84 
18.4.1  Enrollment Categories  .............................................................................. 84 
18.4.2  Efficacy Assessments ................................................................................ 84 
18.4.3  Efficacy Analyses  ..................................................................................... 91 
18.4.4  Data Review Committee  ........................................................................... 92 
18.4.5  Investigator’s Assessment of Overall Response  ....................................... [ADDRESS_973912] of the Study ........................................................................ 95 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973913]/Ethics Committee Review  ................................ [ADDRESS_973914] Confidentiality ................................................ 96 
19.6  Study Termination ........................................................................................ 96 
19.7  Financial Disclosure ...................................................................................... 96 
20.0  References  ............................................................................................................. 97 
21.0  Appendices  ............................................................................................................ 99 
21.1  Appendix A: Protocol Revision History ....................................................... 99 
21.1.1  Protocol Amendment 3 ............................................................................. 99 
21.1.2  Protocol Amendment 2 ........................................................................... 104 
21.1.3  Protocol Amendment 1 ........................................................................... 113 
21.2  Appendix B: Prohibited Medications and Medications to be Administered 
with Caution  ................................................................................................................ 122 
21.2.1  Prohibited Medications  ........................................................................... 122 
21.2.2  Medications to be administered with Caution and Monitored as Appropriate
 123 
21.3  Appendix C: Sample Eligibility Form ........................................................ 124 
21.4  Appendix D: Vulvovaginal Signs and Symptoms Scale ............................. [ADDRESS_973915] Aspergillus spp. 25 
Table 2  Disease - Specific Secondary Endpoints  ............................................................ 33 
Table 3  Summary of Overall Treatment and Follow -Up Schedule for All Subjects 
Except VVC Subjects  ....................................................................................................... 35 
Table 4  Summary of Overall Treatment and Follow -Up Schedule for VVC Subjects .. 35 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 10 Table 5  Eligible Fungal Diseases  ................................................................................... 38 
Table 6  Ibrexafungerp Monotherapy Dosing Regimen (Excluding VVC)  .................... 49 
Table 7  Ibrexafungerp Monotherapy Dosing Regimen for VVC  .................................. 50 
Table 8  Ibrexafungerp Combination Therapy Dosing Regimen .................................... 50 
Table 9  Schedule of Visits for Targeted Physical Examinations by [CONTACT_715005] 
(Excluding VVC)  .............................................................................................................. 58 
Table 10  Schedule of Visits for Mycological Assessments by [CONTACT_715005] 
(Excluding VVC)  .............................................................................................................. 60 
Table 11:  Fungal Isolates to be Collect for the Study.  .................................................. 62 
Table 12  Schedule of Visits for Recommended Imaging Assessments by [CONTACT_715006], if obtained for Routine Care (Excluding VVC)  ................................................. 64 
Table 13  Schedule of Visits for Recommended Serological Assessments by [CONTACT_715006] (Excluding VVC) ................................................................................................. 65 
Table 14  Schedule of Treatment Visits and Procedures (All Fungal Diseases Except 
VVC)  ....................................................................................................................... 72 
Table 15  Schedule of Treatment Visits and Study Procedures for VVC  ..................... 75 
Table 16  Efficacy Time Points and Outcome Definitions for Primary and Secondary 
Endpoints  ....................................................................................................................... 86 
Table 17  EORTC -MSG General Criteria for Global Responses to Antifungal Therapy  
 ....................................................................................................................... 90 
 
 
  
SCYNEXIS, Inc.  IND #107,[ADDRESS_973916] disk  
CDC  Centers for Disease Control and Prevention  
CFR  Code of Federal Regulations  
CI confidence interval  
CL/F  clearance/fraction absorbed  
CLSI  Clinical and Laboratory Standards Institute  
Cmax maximum concentration  
CMC  chronic mucocutaneous candidiasis  
CPA  chronic pulmonary aspergillosis  
CPK  creatine phosphokinase  
CRO  contract research organization  
CRP  c-reactive protein  
CT computerized tomography  
CYP  cytochrome  
D day 
D/I disseminated/invasive  
DF dimorphic fungi  
DRC  Data Review Committee  
DVD  digital versatile disk  
SCYNEXIS, Inc.  IND #107,[ADDRESS_973917]  
ITT intent to treat  
IV intravenous  
KOH  potassium hydroxide  
LAM  lactation amenorrhea method  
LDH  lactate dehydrogenase  
MALDI -TOF  matrix -assisted laser desorption/ionization  
MEC  minimum effective concentration  
MedDRA  Medical Dictionary for Regulatory Activities  
MIC  minimum inhibitory concentration  
MRC  Medical Research Council  
MRI  magnetic resonance imaging  
SCYNEXIS, Inc.  IND #107,[ADDRESS_973918]. George’s Respi[INVESTIGATOR_714974]  
β-hCG  β-human chorionic gonadotropin  
 
   
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 14 5.0 Protocol Synopsis  
Title:  Open -Label Study to Evaluate the Efficacy and Safety of  SCY -078 (Ibrexafungerp)  in Patients with 
Fungal Diseases that are Refractory to , Resistant to  or Intolerant of Standard Antifungal Treatment ( FURI ) 
Primary Objectives:  
The primary objectives listed below apply to all eligible fungal diseases:  
• To evaluate the efficacy of ibrexafungerp in the treatment of severe fungal diseases  as determined 
by a Data Review  Committee ( DRC) at the primary time point  for the fungal disease  
• To evaluate the safety of ibrexafungerp  
 
Overall Secondary  Objectives:  
The overall secondary objectives listed below apply to all eligible fungal diseases:  
• To evaluate the efficacy of ibrexafungerp as determined by [CONTACT_715007]  
• To evaluate the efficacy of ibrexafungerp as determined  by [CONTACT_737]  
• To determine the efficacy of ibrexafungerp by [CONTACT_209058]  
• To determine the efficacy of ibrexafungerp by [CONTACT_715008]  
• To evaluate the efficacy of ibrexafungerp by  [CONTACT_715009]  
• To evaluate the efficacy of ibrexafungerp by [CONTACT_715010] (refractory, resistance, relapse, 
intolerance , toxicity, need for oral therapy ) 
• To determine All- Cause Mortality (ACM)  
• To evaluate the pharmacokinetics (PK) of ibrexafungerp by [CONTACT_715011] -Specific Secondary Objectives:  
• To evaluate the efficacy of ibrexafungerp  as determined by [CONTACT_715012]- specific endpoints (see  
below ).  
Primary Endpoints:   
The primary endpoints listed below apply to all eligible fungal diseases:  
• Efficacy as measured by [CONTACT_715013]: 
TOC for V ulvovaginal Candidiasis ( VVC , Day 17), Chronic Mucocutaneous Candidiasis ( CMC,  
EOT or Day 84), Chronic Pulmonary Aspergillosis ( CPA , EOT or Day 90),  Allergic 
Bronchopulmonary Aspergillosis ( ABPA , EOT or Day 90) (whichever comes first) and at  
EOT for all other diseases  as determined by a DRC  
• Safety as measured by: [CONTACT_5292], vital signs, AEs , and laboratory tests   
Overall Secondary Endpoints:  
The overall secondary endpoints listed below apply to all eligible fungal diseases:  
• The percentage of subjects who achieve Global Response at additional time points as applicable for 
each disease, disease category  and reason for enrollment  (Table 16  in the full protocol), as 
determined by [CONTACT_715014]  
• The percentage of subjects who achieve Clinical Response by [CONTACT_715015], disease category and reason for enrollment  (Table 16
 in the full protocol), as 
determined by [CONTACT_715016]  
• The percentage of subjects who achieve Mycological Response by [CONTACT_715015], disease category and reason for enrollment  (Table 16  in the full protocol ), as 
determined by [CONTACT_715017], Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 15 • The percentage of subjects who achieve Clinical Response by [CONTACT_715018] , disease category and 
reason for enrollment at time points applicable for each disease ( Table 16  in the full protocol), as 
determined by [CONTACT_715019] I nvestigator  
• The percentage of subjects who achieve Mycological Response by  [CONTACT_715018] , disease category  
and reason for enrollment  at time points applicable for each disease ( Table 16  in the full protocol), 
as determined by [CONTACT_715019] I nvestigator  
• The percentage of subjects with a recurrence of the baseline fungal disease at the 25 -Day FU for 
VVC and at the  6-Week FU for all other diseases  as determined by [CONTACT_16009] 
• ACM at Day 30 for Invasive Candidiasis (IC) and c andidemia  and at Day 42 for all diseases  
• Time to death from any cause  
• Describe ibrexafungerp  plasma concentrations  
 
Disease -Specific Secondary Endpoints:  
Disease -specific secondary endpoints, as assessed by [CONTACT_715020] / Candidemia disease -specific endpoints  
• Completion of study drug a ntifungal treatment (i.e. no recurrence, no use of other antifungal 
treatment, no discontinuation for any reason)  
Acute or Chronic Severe Mucocutaneous Candidiasis  
• Percentage subjects with mycological cure by [CONTACT_2006] 84  
• Percentage subjects with clinical response by [CONTACT_2006] 30 and Day 84  
• Percentage of subjects with continued symptom relief at 6-week FU  
Chronic Pulmonary Aspergillosis (CPA) disease -specific endpoints  
• Six-Minute Walk test and MRC Dyspnea Score at Day 90 and Day 180  
• Weight change at Day 90 and Day 180  
• Improvement in inflammatory markers (CRP, plasma viscosity, albumin, platelet count, disease -
specific immunoglobulin levels) at Day 90 and Day 180  
• Change in total IgG  and Aspergillus  IgG at Day 90 and Day 180, if elevated at Baseline  
• All-cause mortality  at Day 90, Day 120 and Day 180  
• Recurrence at Day 180 
Allergic Bronchopulmonary Aspergillosis (ABPA) disease- specific endpoints :  
• Percentage of subjects who exhibit a Global Response at Day 42  
• Percentage of subjects with Clinical Improvement (as measured on a 4 -point scale) at TOC, Day 90, 
Day 180, then every 3 months while on therapy, and 6- month follow -up (FU)  
• Percent decline in total IgE (baseline IgE minus time point IgE/baseline IgE) at Day 42 and Day 90  
• Number of subjects who experience an ABPA exacerbation at the 3 -month and 6 -month FUs  
• Time to first ABPA exacerbation  
• Change in lung function (FEV1 and FVC) at Day 42  
• Number of Asthma exacerbations and ABPA exacerbations at the 3 -month and 6 -month FUs  
• All-cause mortality  at Day 90, Day 120 and Day 180  
Invasive Pulmonary Aspergillosis (IPA) disease -specific endpoint  
• The percentage of subjects who attain a galactomannan index (GMI) decrease including absolute and percent reduction from Baseline to Weeks 1, 2, 4 and 6, when feasible  
• Time to achieve a clinically meaningful GMI absolute and percent decrease  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 16 • All-cause mortality  at Day 84  
Disseminated/invasive dimorphic fung al disease -specific endpoint  
• All-cause mortality  at Day 84  
Other emerging fungi including yeasts and molds disease -specific endpoint  
• All-cause mortality  at Day 84  
Study Phase:  3 
Study Design:  This is a multicenter, open -label, non -comparator, single -arm study to evaluate the 
efficacy, safety and PK of ibrexafungerp in male and female subjects ≥[ADDRESS_973919] of care ( SOC ) antifungal treatment  is not appropriate due to 
refractoriness, resistance, relapse, intolerance, toxicities , need for oral therapy or other reasons .  
Subjects must have a documented eligible fungal disease that has been refractory to, has relapsed after,  or 
subject has  intolerance to  or demonstrated toxicities resulting from an  approved SOC  antifungal treatment  
as listed in the full protocol, or isolate is resistant to , or has a high MIC and is unlikely to respond to 
antifungal SOC . Subjects are also eligible if, in the judgement of the Investigator , continued IV  antifungal 
therapy is not feasible or desirable due to clinical or logistical circumstances or if other oral antifungal 
alternatives are not appropriate. Subjects should meet these and other study criteria to be considered for 
enrollment. Inclusion of each subject in the study must be approved by [CONTACT_1034] (or Sponsor designee)  
prior to initiation of study drug.  
The study will be conducted at approximately 40 sites globally and is planned to enroll and treat 
approximately 220 (+10%) subjects.  
For all subjects except VVC subjects, there will be a Screening visit, a Baseline visit (also considered Day 
1), several  scheduled visits depending on the subject’s fungal disease, an EOT  visit and a follow -up visit 
[ADDRESS_973920] a Screening visit, a Baseline/Day 1 visit, and scheduled visits on Day  4, Day 
7 (EOT),  Day 17 (TOC), 25 -day FU (Day 32) and 35 -day FU (Day 42). VVC subjects will receive 
treatment every three days for a total of three dosing days (i.e., on Days 1, 4 and 7). The EOT and 35- Day 
FU visits may be a phone contact [CONTACT_715021] [ADDRESS_973921] be obtained for any extension of treatment beyond 180 days. Subjects with VVC 
will receive oral doses of 375 mg BID every three days for a total of three dosing days (Day 1, Day 4 and 
Day 7) . Subjects who have a recurrence after TOC (VVC subjects) or EOT (other subjects), may be 
considered for re enrollment upon discussion with the sponsor.   
Efficacy  evaluations will consist of clinical evaluations of the signs and symptoms of infection, 
mycological testing, imaging and serological testing as applicable for each fungal disease. Additional procedures will be conducted for selected fungal diseases.  
PK: T
he PK data obtained from this study will be part of the Population PK analyses that will be 
performed.  For subjects who are willing to participate in the PK sampling, blood samples will be collected 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 17 on Day 2 (one sample collected anytime post dosing ), Days 3 to 5 (one sample collected predose on any 
of these days) and Days 7 to 10 (one sample collected predose on any of these days).  Additional blood PK 
samples will be collected when clinically indicated . Tissue samples collected as part of SOC procedures 
(e.g., biopsies) may be sent for drug concentration analysis, when available.  
Subjects will be evaluated for safety  throughout the study, including parameters such as physical exam, 
vital signs, adverse events ( AEs) and concomitant medications, and safety laboratory tests (hematology, 
blood chemistry and urinalysis).  
Results from the study will be analyzed against historical and concurrent SOC -treated subjects, who will 
be selected from literature reviews and other data resources.  
Target Population: Male and female subjects ≥ 18 years of age with documented eligible severe fungal 
diseases for whom SOC  antifungal treatment is not appropriate  due to refractoriness, resistance, 
intolerance, relapse, toxicities , need for oral therapy  or other reasons.  
KEY  Inclusion Criteria:  
Subject must fulfill all of the following KEY criteria at Screening and/or Baseline to be eligible for study 
admission:  
1. Subject is a male or female adult ≥18 years of age on the day the study informed consent form (ICF) 
is signed.  
2. Subject has a documented eligible fungal disease that has been refractory  or resistant  to SOC , has 
relapsed after, or the subject has intolerance to or demonstrated toxicities resulting from an approved 
SOC antifungal treatment. The subject is also eligible if, in the judgement of the Investigator, long -
term IV antifungal therapy  is not feasible or desirable due to clinical (isolate is resistant to or has a 
high MIC and is unlikely to respond to antifungal SOC) or logistical circumstances or if other antifu ngal alternatives are not appropriate.  
 A summary of eligible fungal diseases is listed below and a detailed description of diagnostic, refractoriness, intolerance, toxicity and relapse criteria is available in Table 5  in the full protocol:  
• Acute or chronic invasive candidiasis, including candidemia  
• Acute or chronic severe mucocutaneous candidiasis, including:  
o Esophageal candidiasis (EC)  
o Oropharyngeal candidiasis (OPC)  
o Chronic mucocutaneous candidiasis (CMC)  
o Vulvovaginal candidiasis (VVC)  
• Disseminated/invasive dimorphic fungi:  
o Coccidioidomycosis  
o Histoplasmosis  
o Blastomycosis  
• Chronic Pulmonary Aspergillosis (CPA)  
• Allergic Bronchopulmonary Aspergillosis (ABPA)  
• Invasive Pulmonary Aspergillosis (IPA)  
• Other emerging fungi including yeasts and molds (e.g., sachromycetes, scopulariopsis , 
mucorales ) 
 
KEY  Exclusion Criteria:  
Subject  will be excluded from participation in the study if he /she meets any  of the following KEY 
exclusion criteria  at Screening and/or Baseline:  
SCYNEXIS, Inc.  IND #107,[ADDRESS_973922] has an inappropriately  controlled fungal disease  source (e.g., persistent catheters, devices, 
identified undrained abscess) that is likely to be the source of the fungal disease . 
3. Subject is hemodynamically unstable and/or requiring vasopressor medication for blood pressure 
support.  
4. Subject has abnormal liver test parameters: AST or ALT >[ADDRESS_973923] and/or total bilirubin >[ADDRESS_973924]. 
Note : Subjects with unconjugated hyperbilirubinemia with a diagnosis of Gilbert’s disease are not 
excluded . 
5. Subject is unlikely to survive 30 days.   
Study Drugs:  
Ibrexafungerp citrate drug product for oral administration will be supplied as compressed oral tablets 
containing 250 mg of ibrexafungerp active ingredient on a free base basis.  In addition to the active 
ingredient, the  oral tablet formulation also contains silicified microcrystalline cellulose, crospovidone, 
mannitol, colloidal silicon dioxide, magnesium stearate (non- bovine), and butylated hydroxyanisole.  
Ibrexafungerp is packaged in bottles containing 30 tablets.  
Ibrexafungerp tablets are to be stored at room temperature: between 15° C and 25°C with allowable limited 
excursions of up to 30° C. 
Randomized Treatment Groups: This is an open- label, non -comparator, single -arm study. All subjects 
will receive ibrexafungerp monotherapy except subjects with refractory or relapsing invasive pulmonary 
aspergillosis (IPA) , mucormycosis  or other molds  with unpredictable ibrexafungerp activity , who will 
receive combination therapy. Combination therapy may also be administered to other subjects based on Investigator’s judgement and contingent on Sponsor approval. Subjects will receive ibrexafungerp on an inpatient or outpatient basis, as needed for each fungal disease.  
Ibrexafungerp Monotherapy for All fungal Diseases, Excluding VVC  
Subjects will receive ibrexafungerp monotherapy given as an initial loading dose of 750 mg (3 tablets of 
250 mg each) given BID (total daily dose = 1500 mg) during the first 2 days of treatment and then 
subsequent oral doses of 750 mg (3 tablets of 250 mg each) QD for up to [ADDRESS_973925] basis. Subjects may be considered for re -enrollment upon  
discussion with the sponsor.    
If subjects cannot swallow the whole tablet, the tablets may be split. In the event subjects experience gastrointestinal intolerance on the 750  mg QD dose, the tablets may be split and/or administered at 10 to 
20-minute intervals. The daily dose may also be given as 375 mg (1 and ½  tablets) BID for subjects 
experiencing gastrointestinal intolerance.  
Ibrexafungerp Monotherapy for VVC  
Subjects with VVC will receive ibrexafungerp monotherapy given as oral doses of 375 mg BID (total 
daily dose = 750 mg)  every three days for a total of three dosing days (Day 1, Day 4 and Day 7).  Subjects 
treated for VVC who have a recurrence may receive additional cycles of ibrexafungerp treatment similar to the initial regimen  upon discussion with the Sponsor .   
Ibrexafungerp Combination Therapy  
Monotherapy with ibrexafungerp is not recommended for refractory or relapsing IPA or mucormycosis . 
All subjects enrolled for refractory or relapsing IPA or mucormycosis should receive ibrexafungerp given 
SCYNEXIS, Inc.  IND #107,[ADDRESS_973926] no 
culture isolate available (to confirm susceptibility to ibrexafungerp), combination therapy should be considered and discussed with the Sponsor. Combinati on therapy will also be allowed for other subjects 
based on Investigator’s judgement and contingent on Sponsor approval.  
Acceptable antifungal therapy includes voriconazole, isavuconazole, posaconazole, or amphotericin B 
(AMB) at the doses recommended per their label.  When used in combination with the azoles, the dose of 
ibrexafungerp should be reduced from 750 mg to 500 mg.  
The following combination options are allowed:  
• addition of ibrexafungerp to any ongoing antifungal therapy  
• replacement of one (toxic/ineffective) element of a two -antifungal combination therapy with 
ibrexafungerp  
• replacement of current monotherapy with a new combination, generally:  
o replacement of AMB monotherapy with an azole plus ibrexafungerp combination, or  
o replacement of an azole monotherapy with an AMB plus ibrexafungerp combination  
• continuation of an azole plus echinocandin combination where the subject could go home on an oral 
regimen by [CONTACT_715022], Randomization and Stratification:  This is an open- label study  
Study Evaluations  
Efficacy Evaluations: Efficacy evaluations will consist of clinical evaluations of the signs and symptoms 
of infection, mycological testing (including, but not limited to, fungal culture, KOH  and other fungal 
stains , and T2 testing ), imaging (e.g., CT, MRI, X -Ray or ultrasound) and serological testing (including, 
among others, ß- D-glucan  levels , GM and fungal antibody titers) as applicable for each fungal disease. 
Additional procedures ( esophagoscopy, spi[INVESTIGATOR_038], St. George’s Respi[INVESTIGATOR_6015] [SGRQ] , 6-
Minute Walk test and Medical Research Council [ MRC]  Dyspnea Scale ) will be conducted for selected 
fungal diseases.  
Efficacy will be assessed primarily in terms of Global Response at TOC for VVC (Day 17), EOT visit or 
Day 84 ( CMC)  or Day 90 (CPA  and ABPA) whichever comes first , and at EOT for all other fungal 
diseases, as determined by [CONTACT_73628]. Global Response will be a composite global outcome 
composed of  clinical (including radiological, when applicable)  and mycological (including serological) 
responses. In addition to the primary endpoint, Global Response, Clinical Response and Mycological Response  will be assessed  as secondary endpoints at the  disease specific primary time point and at 
additional time points , for the determination of efficacy  by [CONTACT_715023].  
Other secondary efficacy  assessments will include recurrence and survival . Recurrence will be evaluated 
at the 6 -Week FU visit after EOT for all subjects, except VVC subjects, who will be assessed for 
recurrence at the 25 -Day FU visit. Survival will be determined on Day 30 for patients with invasive 
candidiasis and candidemia, and  on Day 42 for all subjects. Additional disease -specific efficacy endpoints 
will be evaluated for selected fungal diseases at additional time points.  
Efficacy outcomes will be based on EORTC -MSG Consensus Criteria except for diseases not defined in 
the EORTC -MSG Consensus Criteria such as ABPA, CPA , CMC and VVC. The efficacy time points and 
outcome definitions for the primary and secondary endpoints are detailed in Table 16  in the full protocol. 
Criteria for the DRC assessment of response will be further detailed in the DRC Charter.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 20 Phamacokinetic Evaluations:  For subjects who are willing to participate in the PK sampling, up to three 
(3) blood samples will be collected at the following visits and sampling windows: Day 2 (one sample 
collected anytime post dosing), Days 3 to 5 (one sample collected predose on any of these days), and Days 
7 to 10 (one sample collected predose o n any of these days). Additional blood PK samples will be collected 
when clinically indicated.  
Procedures for collecting, storing, and shippi[INVESTIGATOR_714975]. The sparse samples collected in this study will be analyzed using Population PK (Pop PK) 
analysis methods to estimate PK parameters (C max, AUC, clearance/fraction absorbed [CL/F]) as 
applicable.  Further analysis of possible metabolites may be performed.  
Safety Evaluations: Safety will be evaluated throughout the study, including the following parameters: 
AEs, treatment discontinuations, general physical examination, vital signs, safety laboratory tests and 
concomitant medications. A final safety assessment will be conducted at the 3 5-Day FU visit ( 35 days 
after EOT) for VVC subjects and at the 6 -Week FU (6 weeks after the EOT) for all other subjects.  
Statistical Analyses:   
All statistical analyses will be performed using SAS® version 9.3 or later. Descriptive statistics (i.e., number of subjects, mean, standard deviation, median, minimum, maximum) will be presented for all 
continuous variables; number and percentage of subjects will be presented for categorical variables. For 
parameters measured over time, observed data and changes from B aseline  will be described for each time 
point.  
Outcome analyses will include results by [CONTACT_715018],  disease category , enrollment reas on, and when 
relevant and sufficient number of cases allow , by [CONTACT_715024], FKS mutations, etc.  Overall response will also be present ed for all disease 
categories combined . Unless otherwise stated, data will be analyzed as is with no imputation.  Details of 
the statistical analysis will be provided in a statistical analysis plan, which will be approved prior to final database lock.  
Sample Size Determination: This is an exploratory study and no formal sample size calculations will be  
performed. A total of [ADDRESS_973927] intolerance to  or demonstrated toxicities resulting 
from an approved SOC  antifungal treatment.  
Analysis Populations  
The study populations to be used in the analyses are defined as follows:  
• Intent -to-Treat Population : The intent -to-treat ( ITT) population will include all subjects who are 
enrolled in the study and receive at least 1 dose of study drug.   
• Myco -ITT: The Myco -ITT population will include all ITT subjects with confirmed pathogens and 
who also had all necessary cultures or mycology tests to estimate mycological response . 
• Per-Protocol Population:  The per-protocol ( PP) population will include all ITT subjects who 
received  enough drug to enable clinical efficacy judgment  as determined by [CONTACT_715025] , who have an EOT 
(TOC for VVC , CMC, CPA and ABPA ) assessment and who have no major protocol violations.  
• Safety Population:  The safety population will include all subjects who receive at least one dose of 
study medication and have at least one safety assessment post Baseline . 
• Pharmacokinetic Population : The PK  population will include all enrolled subjects who provide at 
least one PK  sample  and no deviations significant enough to affect the interpretability of PK data.  
Efficacy Analysis  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 21 The primary efficacy endpoint is the percentage of subjects with Global Response (clinical, radiological 
and mycological) as determined by [CONTACT_715026] (Day 17), CMC ( EOT or Day 84), CPA 
(EOT or Day 90) and ABPA ( EOT or Day 90)  (whichever comes first) , and at EOT for all other diseases. 
Results will be presented separately for each disease category along with a 95% confidence interval (CI) for a single binomial proportion in the ITT , Myco -ITT and PP populations  where sufficient cases are 
available . In addition, the number of subjects with a successful response across all disease categories will 
be summarized as a response rate and 95% CI. Secondary endpoints will be presented with 95% C is for 
the ITT , Myco -ITT and PP populations using the same approach as for the primary endpoint. The 
estimated response rates and 95% CIs outlined will also be assessed relative to the external data described in the Study Design section above.  
The percentage of subjects surviving at the defined time points will be presented for the ITT , Myco -ITT 
and PP populations. A Kaplan Meier plot will also be produced summarizing the survival curve over time 
and the median time to death.  A subject without a reported death will be censored at the point of last time 
the subject was known to be alive.  
For primary and overall secondary endpoints, presentations by [CONTACT_715027], if numbers 
allow. Data for all subjects will be presented by [CONTACT_715018], disease category , reason for enrollment 
and receipt of combination therapy (Yes/No).  
If data are missing and the subject has not been deemed a success or failure the outcome will be categorized as unknown / not evaluable . 
Data Review Committee:  A DRC Charter will provide detailed criteria to be used for the baseline and 
outcome analysis of subjects in this study. The analysis criteria will be based on the definitions captured in Table 16 using EORTC -MSG Consensus Criteria as reference for all diseases except ABPA, CPA , 
CMC and VVC.  Adaptations to the EORTC -MSG criteria adopted by [CONTACT_715028] . 
Pharmacokinetics:  
The concentration versus time data from the sparse PK samples collected in this study will be analyzed using a Pop  PK model to estimate Cmax, AUC and CL/F, as applicable. The PK analysis will be conducted 
on the PK Population.  Further analysis of possible metabolites may be performed.  
Safety  Analysis  
All safety analyses will be conducted in the safety population; all safety variables will be listed.  
Incidence and severity of treatment -emergent AEs , AEs leading to discontinuation and SAEs and their 
relationship to treatment will be summarized.  Also data on AEs leading to death, AEs of special interest, 
AEs leading to withdrawal and AEs by [CONTACT_715029].  
Early discontinuation of study drug treatment will be presented and will include the reasons for and timing of such discontinuations. Abnormal physical examinations associated with  adverse events will be listed. 
Concomitant medications will be summarized.  
Laboratory evaluations will be summarized as observed values and changes from Baseline; shifts with 
respect to the laboratory reference range will be summarized.  Vital signs will be summarized as observed 
values and changes from Baseline.  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and presented by 
[CONTACT_6657].  Concomitant medications will be classified based on the World 
Health Organization´s (WHO) Drug Dictionary terminology.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 22 6.0 Schematic of Study Design 
 
 
Figure 1 Schematic of Study Design 
 
 
End of Treatment (EOT) 
(last dose of study drug, up to 180 days  of treatment  
with ibrexafungerp)  
6-Week Follow -up 
(6 weeks after E OT) 
 
 
Screening  
(Day -1) 
Ibrexafungerp Loading Dose  
Baseline (Day 1) & Day 2  
 
 
Ibrexafungerp Maintenance Dose  
Day 3 to EOT  
Additional Follow -ups 
(3 and 6 m onths  
after EOT ,  
for ABPA subjects only ) 
ALL FUNGAL DISEASES 
EXCEPT VVC  
VVC 
Ibrexafungerp Dosing  
Baseline (Day 1), Day 4 & Day 7  
End of Treatment (EOT)  
Day 7  
(last dose of study drug)  
  
Test of Cure (TOC)  
Day 17  
25-Day Follow -up 
(25 days after EOT)  
35-Day Follow -up 
(35 days after EOT)  
 
All subjects : Survival Status at study Day 42 ([ADDRESS_973928] dos e of study drug)  and at Day 30 for IC / 
candidemia  
Re enrol lment of subjects after TOC (VVC) or EOT (all others) may be considered 
upon discussion with the sponsor  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 23  
7.0 Background Information and Scientific Rationale  
7.1 Background Information  
Ibrexafungerp (formerly “SCY -078”) is a member of a new class of antifungal agents, the 
triterp enoids. It is a semi- synthetic triterpene derivative of the natural product enfumafungin. 
Ibrexafungerp is  a structurally distinct glucan synthesis inhibitor (GSI) that inhibits the synthesis 
of the fungal cell wall polymer β -(1,3) -D-glucan. Time kill studies have demonstrated that 
ibrexafungerp has fungicidal in vitro  activity against Candida spp. isolates similar to that observed 
with the echinocandins.  
Ibrexafungerp is being developed as the first oral and intravenous (IV) GSI for the treatment and 
prevention of fungal diseases caused by [CONTACT_695109], Aspergillus and other fungal species with the 
potential to provide the therapeutic advantages of both an IV and oral formulation. 
Fungal diseases caused by [CONTACT_27383]., Aspergillus  spp., Pneumocystis , dimorphic fungi, etc., 
have limited treatment options and represent a growing threat, particularly to patients with 
compromised immune systems , including patients receiving cancer chemotherapy, hematopoietic 
stem cell transplantation and solid organ transplantation, and patients with advanced human immunodeficiency virus (HIV) -infection. Invasive fungal diseases caused by [CONTACT_715030]. Despi[INVESTIGATOR_714976], t he overall 
mortality rate of invasive fungal infections remains high, particularly in the most profoundly 
immunocompromised patient populations
1,2,13.   
While four classes of antifungal agents are currently available to treat these infections, only 
flucytosine and azoles are available for oral therapy.  Concerns about flucytosine toxicity and rapid 
emergence of resistance on therapy, limits i ts clinical utility.  The emergence of resistance (clinical 
and mycological) to azoles and more recently to echinocandins3,4, and the toxicity associated with 
polyenes , signals the need for new agents that are well tolerated and that retain activity against 
resistant strains.  
Ibrexafungerp retains activity in vitro and  in vivo against both azole -resistant and the majority of 
clinical isolates containing FKS  gene mutations, which confer echinocandin resistance. Unlike 
echinocandins, ibrexafungerp is orally bioavailable, with in vitro  and in vivo  activity against 
Candida, Aspergillus  and other fungal genera.  Ibrexafunger p offers an oral non- azole treatment 
alternative for these infections .  
This includes e.g. patients with Candida infections who are failing therapy clinically or for whom 
azole therapy is not advisable due to infection with an isolate with a high likelihood of azole non-
susceptibility (e.g. C. glabrata, C. krusei, C. auris ), or other Candida spp. isolates with 
documented non- susceptibility to azoles based on MIC determination6. 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973929] and mold isolates 
using the Clinical and Laboratory Standards Institute (CLSI) and European Committee on 
Antimicrobial Susceptibility Testing ( EUCAST) methods. Overall, the epi[INVESTIGATOR_714977], broad- spectrum activity against the majority of 
the clinical isolates tested. These studies have lai d the foundation in support of the use of 
ibrexafungerp for the treatment of invasive fungal diseases.  
 
Activity against Candida spp.  
Ibrexafungerp has been evaluated against >[ADDRESS_973930] shown that ibrexafungerp retains activity (i.e., no 
significant change in minimum inhibitory concentration [MIC] when compared to wild type) 
against >90% of azole -resistant strains and >70% of Candida strains with FKS  mutations 
commonly associated with echinocandin resistance. Interestingly, although ibrexafungerp and the 
echinocandins share a similar mechanism of action (β -[1,3] -D-glucan synthesis inhibition), their 
clearly different molecular structure provides them with some differentiating characteristics in 
terms of microbiological activity.  
Ibrexafungerp was evaluated in vitro  against approximately [ADDRESS_973931] approximately 70% of the isolates containing the 
most commonly reported FKS  mutation associated with echinocandin resistance in C. glabrata  
(S663P in FKS2  and S645P in FKS1 ). Sel ection of ibrexafungerp resistance in vitro  occurs at a 
low frequency. A deletion at position F659 in FKS2  of C. glabrata was the predominant mutation 
observed in these studies; notably, ibrexafungerp did not select for mutations at positions S663 or S645. These results suggest that ibrexafungerp inhibits glucan synthase in a manner different from 
that of echinocandins. 
The in vitro  studies also included a number of multidrug- resistant isolates. Consistent with the data 
described above, ibrexafungerp was active against >70% of these isolates. Ibrexafungerp has also 
demonstrated activity against life -threatening and multidrug- resistant C. auris  strains recently 
highlighted as a clinical alert by [CONTACT_715031]. In a recent study, Ibrexafungerp demonstrated 
potent in vitro  activity against >100 different C. auris  isolates and results showed potent activity 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973932] 
methods. The studies included 41 A. fumigatus , 48 A. flavus , 21 A. niger , and 27 A. terreus  wild-
type isolates as well as 16 azole- resistant isolates: 14  A. fumigatus , and one each A. niger , and A. 
terreus.  In these studies, microbiological outcome is reported as MEC  (minimum effective 
concentration). Overall, ibrexafungerp was active against all the Aspergillus  strains evaluated with 
MEC values similar to those obtained for caspofungin. Furthermore, there were no significant 
differences in the ibrexafungerp MEC values obtained between the wild- type and azole -resistant 
strains. Details are provided in Table [ADDRESS_973933] Aspergillus spp . 
Aspergillus  spp N Microbiologic 
Outcomea Ibrexafungerp  Caspofungin  
A. fumigatus      
WT 41 MEC Range  0.008 – 0.5 0.015 – 0.125  
Azole -R 14 0.03 – 0.5 0.015 – 0.125  
A. flavus      
WT 48 MEC Range  0.015 - 8 0.015 – 0.125  
Azole -R NT   
As. terreus      
WT 27 MEC Range  0.008 – 0.125  0.015 – 0.125  
Azole -R 1 0.125  0.03 
A. niger      
WT 29 MEC Range  0.008 – 0.125  0.015 -0.06 
Azole -R 1 0.06 0.06 
Abbreviations: Azole -R = azole -resistant; MEC = minimum effective concentration; 
NT = none tested ; WT = wild type  
a: Values in μg/mL  
The potent in vitro  activity of ibrexafungerp against Aspergillus  species was confirmed in a recent 
study that included >500 clinical isolates. MEC 50 and MEC 90 values for the 311 isolates tested 
were <0.063 and 0.125 µg/mL, respectively.  
Ibrexafungerp was evaluated for in vitro  activity against [ADDRESS_973934] 9.2 and CLSI M38A methodologies. All strains were obtained from clinical samples 
(respi[INVESTIGATOR_696], cutaneous, biopsies, exudates, abscesses a nd wounds) between 2000 and 2017, and 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973935] WT and azole- R strains of A. fumigatus . Isolates of Aspergillus alliaceus  were the only 
ones showing reduced susceptibility to ibrexafungerp, with MEC 90 >16 µg/L (EUCAST) and 16 
µg/L (CLSI). Overall, there was good agreement between results obtained using EUCAST and 
CLSI methodologies.  
The in vitro  activity of ibrexafungerp was evaluated alone and in combination with amphotericin 
B, isavuconazole, or voriconazole against a panel of clinical A. fumigatus  isolates, which included 
four wild -type A. fumigatus  strains and 2 strains with elevated amphotericin B and azole MICs 
(one of which has a CYP51 mutation at F46Y). The combination of ibrexafungerp with all three 
antifungals demonstrated synergy in most wild- type strains tested, and although ibrexafungerp 
retained activity against azole res istant isolates, it showed no synergistic effect against these 
strains . One exception was the combination of ibrexafungerp and amphotericin B, which was 
synergistic against the CYP51 mutant resistant strain.  
 
Activity against Dimorphic Fungi  
Ibrexafungerp was evaluated for in vitro  activity against isolates of Coccidioides  spp., Blastomyces  
spp. and Histoplasma spp. Ibrexafungerp was evaluated against [ADDRESS_973936] 5 clinical isolates of 
Coccidioides immitis. The results of this evaluation revealed that the respective MICs for these 
dimorphic fungi ranged from <0.125 to 0.25 ug/ml. 
 
Non-clinical models of invasive fungal diseases  
The antifungal efficacy of ibrexafungerp has been evaluated in several murine models of 
disseminated candidiasis and aspergillosis. In a disseminated C. albicans  model, ibrexafungerp  
was more active than fluconazole at all doses.  Murine models of ibrexafungerp in disseminated 
candidiasis caused by C.  glabrata, C. auris,  and C. tropi[INVESTIGATOR_714978]. The plasma area under the concentration -time curve (AUC) necessary to achieve 
target efficacy in these models was estimated to be 15.4 ±  2.2 μM•h.  
In murine models of disseminated A. fumigatus  infection, treatment with ibrexafungerp  resulted in 
improved survival, similar to that achieved with voriconazole treatment groups.  
The data available from all of the in vitro  and in vivo  studies conducted to date provide significant 
support for the use of ibrexafungerp in the treatment of invasive fungal diseases.  
The efficacy of ibrexafungerp in combination with isavuconazole in the treatment of experimental 
invasive pulmonary aspergillosis in persistently neutropenic rabbits was evaluated and established the foundation for further clinical evaluation. A neutropeni c New Zealand White rabbit model of 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 27 experimental invasive pulmonary aspergillosis was used. Treatment groups included rabbits 
receiving ibrexafungerp (formerly known as SCY -078, thus abbreviated here as “SCY”) at 
2,5 mg/kg/day IV (SCY2.5) and 7.5 mg/kg/day IV (SCY7.5), isavuconazole at 40 mg /kg/day 
orally (ISA40), the combination of SCY2.5 + ISA40, the combination of SCY7.5 + ISA40, or untreated control rabbits. Treatment started 24 hours after endotracheal administration of an A. fumigatus  inoculum and continued QD for up to 12 days. Blood s amples for galactomannan index 
(GMI) antigenemia and serum (1 →3)-β-D-glucan (BDG) levels were obtained every other day. 
Rabbits treated with SCY2.5+ISA40 and SCY7.5+ISA40 had prolonged survival in comparison 
to those of SCY2.5- treated, SCY7.5- treated, ISA40 -treated or untreated control rabbits (p<0.05). 
In addition, groups of SCY2.5+ISA40 and SCY7.5+ISA40 demonstrated lower pulmonary infarct 
scores in comparison to those of single therapy ISA40. These outcome variable data correlated 
directly with a significant decline of GMI antigenemia and serum BDG levels during therapy in comparison to progressive GMI and BDG levels of untreated control rabbits. These preclinical 
data indicate a synergistic response resulting from the co- administration of ibrexafungerp w ith an 
azole antifungal.  
 
Nonclinical experience  
The toxicity and toxicokinetic profile of ibrexafungerp following a once daily (QD) oral (gavage) 
administration to Sprague -Dawley rats for [ADDRESS_973937] of tissues from all animals.  
In rats, no new toxicities or target organs of toxicity were identified (compared to experience in 
shorter terms studies), and the no- observed -adverse -effect -level (NOAEL) was established, which 
corresponded to mean maximum concentration (C
max) and AUC up to the last measurable 
concentration (AUC last) values on Day 182 of 3290 ng/mL and 73,700 hr•ng/mL in males, and 
4060 ng/mL and 87,300 hr•ng/mL in females, respectively. Likewise, in dogs, no new toxicities 
or target organs of toxicity were identified (compared to experience in shorter terms studies) and the NOAEL was established, which corresponded to mean C
max and AUC last values on Day 273 of 
1600 ng/mL and 26,700 hr•ng/mL in males, and 2390 ng/mL and 46,100 hr•ng/mL in females, 
respectively.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 28 Therefore, as no new toxicities were identified following daily oral dose administration to rats and 
dogs for up to 6 and 9 months, respectively, per ICH M3(R2) dose administration duration in the clinical setting for greater than 6 months is supported. 
The in vitro  studies indicated that ibrexafungerp metabolism was predominantly oxidative, with 
cytochrome P450 (CYP) 3A being the primary enzyme involved in its oxidative metabolism. 
Strong inhibitors of CYP3A would be expected to increase plasma levels of ibrexafungerp and its concurrent administration should be avoided. 
Clinical experience  
To date, the oral formulations of ibrexafungerp have been evaluated in over 1,500 subjects and 
patients included in multiple Phase 1 and two Phase 2 studies. 
Ibrexafungerp was generally well tolerated following single oral doses of up to 1600 mg and 
multiple oral doses of up to 800 mg/day for 28 consecutive days in Phase 1 studies. Reported 
adverse events (AEs) after oral administration have been generally tran sient and primarily mild to 
moderate in intensity. The most frequently reported AEs have been mild gastrointestinal events (nausea, vomiting, diarrhea and abdominal pain). 
A Phase 2 study of oral ibrexafungerp as step -down therapy from IV echinocandin in patients with 
invasive candidiasis has been completed. This was a multicenter, randomized, open- label study in 
which, following three to ten days of IV echinocandin therapy, 21 subjects received either 
ibrexafungerp 500 mg QD with a 1000 mg loading dose (6 patients), ibrexafungerp 750 mg QD 
with a 1250 mg loading dose (7 patients) or standard of care ( SOC ) treatment (8 patients with 
either oral fluconazole 400  mg QD with an 8 00 mg loading dose or IV micafungin 100 mg QD for 
up to 28 days). Ibrexafungerp was well tolerated in this study with an AE profile typi[INVESTIGATOR_714979].  The results from this study also indicated that the higher 
dose of ibrexafungerp tested (750 mg QD) is predicted to achieve the target exposure at steady 
state in the majority of patients.  
Two Phase 2 studies of oral ibrexafungerp in patients with vulvovaginal candidiasis (VVC) have 
been completed. Both were multicenter, randomized, active -controlled, evaluator or double -blind 
studies of oral ibrexafungerp in adult female patients with VVC. The results from both studies 
were consistent with oral ibrexafungerp achieving high clinical cure and mycological eradication 
rates. Specifically, in the Phase 2b study DOVE (204) in subjects with acute VVC, a 600 mg single 
day dose (administered as 300 mg every 12 h)  of ibrexafungerp resulted in a clinical cure rate of 
52% at day 10 (TOC) and 70% at Day 25 with mycological eradication achieved by 63% of 
subjects by [CONTACT_4475] 10. In these studies, ibrexafungerp was well tolerated with the most common AEs being mild gastrointestinal events.  The high clinical cure rates observed are supportive of the 
clinically relevant antifungal activity of ibrexafungerp in this form of Candida infection.  
According to the Infectious disease society of America (IDSA) treatment guidelines,6 patients with 
severe acute Candida vulvovaginitis, fluconazole, 150 mg, given every 72 hours for a total of 2 or 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973938] severe disease, 750 mg, given every 72 hours for a total of three 
doses is recommended in this protocol for acute VVC. 
A preliminary efficacy review of the 20 subjects who completed therapy under this study, SCY -
078-301, was conducted by [CONTACT_715032] (Data Review Committee, DRC). These [ADDRESS_973939] common fungal species 
being C. glabrata, C. krusei , and C. albicans . Ibrexafungerp treatment ranged from seven to 90 
days, with a mean duration of ~37 days. P er DRC evaluation at end of treatment, 11 patients 
achieved a Complete or Partial Global Response and six patients a stable- disease response. Only 
two patients showed progression of disease and one patient’s outcome was considered indeterminate.  
Several drug -drug interaction studies have been conducted. Ketoconazole (a strong inhibitor of 
CYP3A) induces a significant (5- fold) increase in ibrexafungerp exposure while diltiazem (a 
moderate inhibitor of CYP3A) induces a mild to moderate (<3 fold) increase in ibrexafungerp  
exposure. Ibrexafungerp did not have any effect on rosiglitazone (a CYP2C8 substrate) exposure, 
had only a mild effect (less than a 0.5- fold increase) on the AUC of tacrolimus (a CYP3A and P -gp 
substrate) and had no effect on the C
max of tacrolimus.  
Based on the cumulative in vivo  animal efficacy data and animal and human safety data, the target 
plasma exposure for clinical efficacy and safety in invasive candidiasis is 15.4 μM•hr (11.2 μg•hr/mL). A simulation using a population PK model was performed based on pooled data from heal thy volunteers and patients. This simulation was used to predict the percentage of patients 
with AUCs greater than or equal to this target efficacy and safety exposure and the simulated plasma time course of the planned oral dosing regimen for ibrexafungerp, which consists of a two-
day loading dose regimen of 750 mg BID administered on Day 1 and Day  2 followed by [CONTACT_715033] 750 mg QD starting on Day 3. The results of the simulation indicate that 
ibrexafungerp given 750 mg BID for two days followed by 750 mg QD results in over 80% of the 
population reaching or exceeding the exposure target of AUC
0-24 ≥11.2 μg•hr/mL  in the majority 
of subjects. The exposure achieved by [CONTACT_715034] a  Phase 1 study 
(SCY -078- 111) in 16 healthy volunteers in which oral ibrexafungerp was administered at doses of 
750 mg BID on Days 1 and 2 followed by 750 mg QD on Days 3 – 7. The geometric mean AUC 0-24 
on Day 1 was 16 μg•hr/mL, indicating that target exposures were achieved within the first day. In 
the same study, steady state was reported by [CONTACT_2006] 4 and the AUC 0-24 on Day 7 was 28 μg•hr/mL, 
urine concentrations of ibrexafungerp of 10 of 16 subjects were above 0.5 μg /mL at Day 7.  
Additionally, based on a simulation using the population PK model, ibrexafungerp can be 
administered as 750 mg BID on Day 1 and Day 2 followed by 375 mg BID starting on Day 3. This 
alternative dosing regimen results in the same exposure (AUC) and C avg with a minor reduction in 
Cmax, in comparison to the primary dosing regimen described above. 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973940] the full spectrum of Candida species, including difficult to treat 
organisms, and affording the added flexibility of oral step down and earlier hospi[INVESTIGATOR_2345]. 
For additional information on ibrexafungerp, please refer to the Investigator’s Brochure. 
7.2 Rationale for the Study  
This study is being conducted to evaluate the efficacy, safety and PK of ibrexafungerp  in male and 
female subjects > [ADDRESS_973941] has intolerance to or demonstrated toxicities resulting from an approved SOC  
antifungal treatment, or has an isolate resistant t o, or that has a high MIC and is unlikely to respond 
to SOC  antifungal treatment. Subjects are also eligible if, in the judgement of the Investigator, 
continued IV antifungal therapy is not feasible or desirable due to clinical or logistical 
circumstances or if other oral antifungal alternatives are not appropriate. Refractoriness, defined 
as persistent clinical, radiological or mycological evidence of fungal disease, and intolerance, including presence of, history of or anticipated toxicities (e.g. drug- to-drug interactions) associated 
with administration of SOC antifungal agents, will be determined by [CONTACT_737].
 
The primary efficacy endpoint of the study is Global Response (composite assessment of clinical, radiological and mycological responses) as determined by a Data Review Committee (D RC). The 
primary endpoint will be determined at the TOC  visit for VVC , CMC, CPA and ABPA and at the 
EOT visit for all other fungal disease s.
7,8 Clinical response will be evaluated by [CONTACT_715035]/or imaging scans, if applicable. Mycological response will be assessed by [CONTACT_715036] ( fungal culture, KOH  and other fungal stain s, T2 testing) and/or 
serological testing (including GMI, Cocci dioides  titers, and β -D-glucan levels , among others),
9 if 
applicable. Recurrence will be assessed at the 25 -Day FU visit ( 25 days after EOT ) for subjects 
with VVC and at the 6 -Week FU visit ( 42 days after EOT ) for all other subjects as a secondary 
efficacy endpoint. Recurrence is defined as Global Response at EOT (TOC for VVC) but re -
emergence of the baseline fungal disease (with the same fungal species and involving the same site) during the post treatment follow-up. 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 31 8.0 Study Objectives  
8.1 Primary  Objective s 
The primary objectives listed below apply to all eligible fungal diseases : 
• To evaluate the efficacy of ibrexafungerp in the treatment of severe fungal diseases by a 
Data Review  Committee ( DRC) at the primary time  point  for the fungal disease  
• To evaluate the safety of ibrexafungerp  
8.2 Secondary  Objectives  
8.2.1 Overall Secondary Objectives  
The overall secondary objectives listed below apply to all eligible fungal disease s: 
• To evaluate the  efficacy of ibrexafungerp  as determined b y the DRC at other time points  
• To evaluate the efficacy of ibrexafungerp as determined by [CONTACT_941] I nvestigator  
• To determine the efficacy of ibrexafungerp by [CONTACT_209058] 
• To determine the efficacy of ibrexafungerp by [CONTACT_715037]  
• To evaluate the efficacy of ibrexafungerp by [CONTACT_715009]  
• To evaluate the efficacy of ibrexafungerp by [CONTACT_715010] (refractory, resistance, 
relapse, intolerance, toxicity, need for oral therapy)   
• To determine All- Cause Mortality (ACM)  
• To evaluate the pharmacokinetics (PK) of ibrexafungerp by [CONTACT_329940]  
8.2.2 Disease-Specific Secondary Objectives  
• To evaluate the efficacy of ibrexafungerp as determined b y other disease- specific endpoints  
(Table 2 ) 
9.0 Study Endpoints  
9.1 Primary  Endpoint s 
The primary endpoints listed below apply to all eligible fungal diseases:  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 32 • Efficacy as measured by [CONTACT_715038] (Day 17) , CMC ( EOT or Day 84 ), CPA (EOT or Day 90) and A BPA ( EOT or Day 
90) (whichever comes first) and at  
EOT for all other diseases as determined by a D RC  
• Safety as measured by: [CONTACT_5292], vital signs, AEs, and laboratory tests  
9.2 Secondary  Endpoints  
9.2.1 Overall Secondary Endpoints  
The overall secondary endpoints listed below apply to all eligible fungal diseases:  
• The percentage of subjects who achieve Global Response at additional time points as 
applicable for each disease, disease category  and reason for enrollment  (Table 16 ), as 
determined by [CONTACT_715014]  
• The p ercentage of subjects who achieve Clinical Response by [CONTACT_715039], disease category  and reason for enrollment  (Table 16), as 
determined by [CONTACT_715019] I nvestigator  
• The percentage of subjects who achieve Mycological Response by [CONTACT_715039], disease category  and reason for enrollment  (Table 16), as 
determined by [CONTACT_715019] I nvestigator  
• The percentage of subjects who achieve Clinical Response by [CONTACT_715018] , disease 
category and reason for enrollment  at time points applicable for each disease ( Table 16), 
as determined by [CONTACT_715016]  
• The percentage of subjects who achieve Mycological Response by [CONTACT_715018] , disease 
category and reason for enrollment at time points applicable for each disease ( Table 16), 
as determined by [CONTACT_715016]  
• The percentage of subjects with a recurrence of the baseline fungal disease at the 25-Day 
FU for VVC and at the 6 -Week FU  for all other diseases  as determined by [CONTACT_16009]  
• ACM at Day 30 (I nvasive candidiasis  and c andidemia ) and Day 42 for all  diseases  
• Time to death from any cause  
• Describe ibrexafungerp plasma concentrations  
9.2.2 Disease-Specific Secondary Endpoints   
Disease- specific secondary endpoints, as assessed by [CONTACT_16009] ( Table 2 ) 
 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 33 Table 2 Disease - Specific Secondary Endpoints  
Disease -Specific Secondary Endpoints  
Acute Invasive candidiasis / Candidemia   
• Completion of study drug antifungal treatment (i.e. no recurrence, no use of other antifungal 
treatment, no discontinuation for any reason)  
Acute or Chronic Severe Mucocutaneous Candidiasis  
• Percentage subjects with mycological cure at Day 84  
• Percentage subjects with clinical response by [CONTACT_2006] 30 and Day 84 
• Percentage of subjects with continued symptom relief at 6- week FU  
Chronic Pulmonary A spergillosis (CPA)  disease -specific endpoints  
o Six-Minute Walk T est and MRC Dyspnea Score at Day 90 and Day 180 
o Weight change at Day 90 and Day 180 
o Improvement in inflammatory markers (CRP, plasma viscosity, albumin, platelet count, 
disease- specific immunoglobulin levels) at Day 90 and Day 180 
o Change in total IgG and Aspergillus  IgG at Day 90 and Day 180, if elevated at Baseline 
o All-cause mortality at Day 90, Day 120 and Day 180 
o Recurrence at Day 180  
Allergic B ronchopulmonary A spergillosis (ABPA)  disease -specific e ndpoints :  
o Percentage of subjects who exhibit a Global Response at Day 42  
o Percentage of subjects with Clinical Improvement (as measured on a 4 -point scale)  at 
TOC, Day 90, Day 180, then every 3 months while on therapy, and 6-Month FU 
o Percent decline in total IgE (baseline IgE minus time point IgE/baseline IgE) at Day [ADDRESS_973942] ABPA exacerbation  
o Change in lung function (FEV1 and FVC) at Day 42 
o Number of Asthma exacerbations and ABPA exacerbations at the 3-M onth and 6-Month 
FUs 
o All-cause mortality at Day 90, Day 120 and Day 180 
Invasive Pulmonary A spergillosis (IPA)  disease -specific endpoint  
o The percentage of subjects who attain a GMI decrease including absolute and percent 
reduction from Baseline to Weeks 1, 2, 4 and 6, when feasible 
o Time to achieve a clinically meaningful GMI absolute and percent decrease  
o All-cause mortality  at Day 84  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 34 Disseminated/invasive dimorphic fung al disease -specific endpoint  
o All-cause mortality  at Day 84  
Other emerging fungi including yeasts and molds  disease -specific endpoint  
o All-cause mortality  at Day 84  
Abbreviations: CRP=c -reactive protein; FEV1 = forced expi[INVESTIGATOR_714980]; FVC  = forced 
vital capacity; FU = Follow -up; GMI=galactomannan index; IgE=immunoglobulin E; MRC=Medical Research 
Council; TOC=test of cure   
10.0 Study Design  
10.1 Overall Description of the Study  
This is a multicenter, open -label, non- comparator, single -arm study to evaluate the efficacy, safety 
and PK of ibrexafungerp in male and female subjects ≥[ADDRESS_973943] has intolerance to or demonstrated toxicities resulting from an approved SOC  
antifungal treatment as listed in Table 5  (Eligible Fungal Diseases) , or has an isolate resistant to, 
or that has a high MIC and is unlikely to respond to  antifungal SOC . Subjects are also eligible if, 
in the judgement of the I nvestigator, continued IV antifungal therapy is not feasible or desirable 
due to clinical or logistical circumstances or if other oral antifungal alternatives are not appropriate. Subjects should meet these and other study criteria to be considered for enr ollment. Inclusion of 
each subject in the study must be approved by [CONTACT_1034] (or Sponsor designee) prior to initiation 
of study drug.  
The study will be conducted at approximately 40 sites globally and is planned to enroll and treat 
approximately 220 (+10%) subjects.  
Study Schedule  
For all subjects except VVC subjects, there will be a Screening visit, a Baseline visit (also 
considered Day 1), several scheduled visits depending on the subject’s fungal disease, an EOT  
visit and a follow -up visit [ADDRESS_973944] . Following Screening, eligible subjects will receive the study drug loading dose on 
Days 1 and 2 and the study drug maintenance dose from Day 3 up to EOT. A summary of the 
overall treatment and follow -up schedule for these subjects is provided in Table 3 . 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 35 Table 3 Summary of Overall Treatment and Follow -Up Schedule for All Subjects 
Except VVC Subjects  
Pre-study 
Activities  Ibrexafungerp  
Loading Dose  Ibrexafungerp  
Maintenance 
Dose  TOC  
EOT  6-
Week  
Follow
-Up Additional 
Follow -
Ups 
Screeninga 
(Days -1 [-
3]) Day 1a 
(Baseline) & 
Day 2  Day 3 to EOT  EOT or Day 84 
(CMC)  
EOT or Day 90 
(CPA and ABPA)  
whichever comes 
first Last dose of 
study drug 
(up to 180 
days from 
Day 1)  6 
weeks 
(±7 
days) 
after 
EOT  3 and 6 
months 
after EOT 
for ABPA 
subjects 
only 
Abbreviations: ABPA = allergic bronchopulmonary aspergillosis; CMC = chronic mucocutaneous candidiasis; CPA = chronic 
pulmonary aspergillosis; EOT = end of treatment; TOC = test of cure 
a: Screening and Baseline (Day 1) may occur on the same day.  
 
Subjects with VVC will have a Screening visit, a Baseline/Day 1 visit, and scheduled visits on 
Day 4, Day 7 (EOT), Day 17 (TOC), 25- day FU ( Day 32) and 35- day FU ( Day 42). VVC subjects 
will receive treatment every three days for a total of three dosing days  (i.e., on Days 1, 4 and 7) . 
The EOT and 35- Day FU visits may be a phone contact [CONTACT_715040]. A summary of 
the overall treatment and follow -up schedule for VVC subjects is provided in Table 4 . 
 
Table 4 Summary of Overall Treatment and Follow- Up Schedule for VVC Subjects  
Pre-study 
Activities  Ibrexafungerp  
Dosing  EOT  
(Phone/on 
site) TOC  25-D ay FU  35-Day FU  
(Phone/on site)  
Screeninga 
(Day -1) Day 1a (Baseline)  
Day 4 and Day 7  Day 7  (+1) Day 17 (±3) Day 32 (25 days 
after EOT; [ADDRESS_973945] dose)  Day 42 (35 days 
after EOT; [ADDRESS_973946] dose)  
Abbreviations: EOT = end of treatment; FU = follow up; TOC = test of cure;  VVC = vulvovaginal candidiasis  
a:  Screening and Baseline (Day 1) may occur on the same day.  
 
Study Treatments  
Eligible subjects (excluding VVC subjects) will receive ibrexafungerp monotherapy given as an 
initial loading dose of [ADDRESS_973947] two days of treatment (Day 1 and Day 2) and 
then subsequent oral doses of 750 mg QD for up to 180 days depending on fungal disease. 
Ibrexafungerp given as combination therapy will be required for all  subjects with refractory or 
relapsing IPA, mucormycosis and other molds with unpredictable ibrexafungerp activity based on 
Investigator ’s judgement and contingent on Sponsor approval. The treatment duration may be 
extended beyond [ADDRESS_973948] a recurrence after EOT 
may also be considered for re enrollment upon discussion with the sponsor. Subjects  who are re 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 36 enroll ed will follow the protocol defined visit schedule. 
Subjects with VVC will receive oral doses of 375 mg BID (total daily dose = 750 mg) every three 
days for a total of three dosing days (Day 1, Day 4 and Day 7).  Subjects  treated for VVC who 
have a recurrence after TOC may receive additional cycles of ibrexafungerp treatment, similar to 
the initial regimen , upon discussion with the sponsor. 
 
Study Assessments  
Efficacy, PK and safety will be evaluated in this study. 
Efficacy  evaluations will consist of clinical evaluations of the signs and symptoms of infection, 
mycological testing (including, but not limited to, fungal culture, KOH  and other  fungal stains , 
and T2 test ing), imaging (e.g., CT, MRI, X-Ray or ultrasound) and serological testing (including, 
among others, ß-D-glucan levels , GM and fungal antibody titers) as applicable for each fungal 
disease. Additional procedures ( esophagoscopy, spi[INVESTIGATOR_038], St. George’s Respi[INVESTIGATOR_6004] [SGRQ] 6-Minute W alk Test and Medical Research Council [ MRC ] Dyspnea Scale ) 
will be conducted for selected fungal diseases.  
Efficacy will be assessed primarily in terms of Global Response at TOC for VVC  (Day 17), CMC  
(EOT or day 84), CPA  (EOT or Day 90)  and ABPA  (EOT or Day 90)  (whichever comes first) , 
and at EOT  for all other fungal diseases, as determined by [CONTACT_715041] C. Global Response 
will be a composite global outcome composed of clinical (including radiological, when applicable) 
and mycological (including serological) responses. In addition to the primary endpoint , Global 
Response , Clinical Response and Mycological Response will be assessed as secondary endpoints 
at the primary time point for the determination of efficacy ( TOC ) for VVC , CMC, CPA and ABPA, 
and EOT  for all other eligible fungal diseases ) and at additional time points by [CONTACT_715042]. Efficacy outcome definitions and time  points for each fungal disease 
are listed in Table 16  and will be defined in the DRC Charter. 
Other secondary efficacy assessments will include recurrence and survival. Recurrence will be 
evaluated at the 6 -Week FU visit after EOT for all subjects, except VVC subjects , who will be 
assessed for recurrence at the 25 -Day FU  visit. Survival will be determined primarily on Day 30 
for IC/Candidemia and on Day 42 for all subjects . Additional disease -specific efficacy endpoints 
will be evaluated for selected fungal diseases at additional time  points ( Table 2 ). 
PK: The PK data obtained from this study will be part of the Population PK analyses that will be 
performed.  For subjects who are willing to participate in the PK sampling, blood samples will be 
collected on Day 2 (one sample collected anytime post dosing), Days 3 to 5 (one sample collected predose on any of these days) and Days 7 to 10 (one sample collected predose on any of these days). Additional blood PK samples will be collected when clinically indicated.  
Subjects will be evaluated for safety  t
 hroughout the study, including parameters such as physical 
exam, vital signs, AEs and concomitant medications, and safety laboratory tests (hematology, 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 37 blood chemistry and urinalysis). A final safety assessment will be conducted at the 35-Day FU 
visit ( 35 days after EOT) for VVC subjects and at the 6- Week  FU (6 weeks after the EOT) for all 
other subjects.  
Results from the study will be analyzed against historical and concurrent SOC -treated subjects, 
who will be selected from literature reviews and other data resources.  
10.[ADDRESS_973949] is expected to complete the study, including all follow -up survival visits, within 
approximately 222 days from Baseline/Day 1.  
10.4 Number of Centers  
Approximately 40 study centers will participate in the study worldwide . 
11.0 Study Population 
The study population will include male and female adult subjects ≥[ADDRESS_973950] fulfill all of the following criteria at Screening and/or Baseline to be eligible for 
study admission:  
1. Subject is a male or female adult ≥18 years of age on the day the study informed consent form 
(ICF) is signed.  
2. Subject has a documented eligible fungal disease that has been refractory  or resistant  to SOC , 
has relapsed after, or the subject has intolerance to or demonstrated toxicities resulting from 
an approved SOC antifungal treatment (as defined in Table 5 ). The subject is also eligible if, 
in the judgement of the Investigator, long- term IV antifungal therapy is not feasible or 
desirable due to clinical (isolate is resistant to or has a high MIC and is unlikely to respond to antifungal SOC) or logistical circumstances or if other antifungal alternatives are not appropriate.  
 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 38  
Table 5 Eligible Fungal D isease s 
 Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
Acute or chronic invasive 
candidiasis , including 
candidemia  • Histopathologic, cytopathologic , or direct microscopic 
examination of a specimen obtained by [CONTACT_80605][INVESTIGATOR_714981] a normally sterile site showing yeast 
cells—for example, Candida species showing 
pseudohyphae or true hyphae  
OR 
• Recovery of a Candida spp. by [CONTACT_640726] a sample 
obtained by a sterile procedure (including a freshly placed [<24 h ago] drain) from a normally sterile site 
showing a clinical or radiological abnormality consistent 
with an infectious disease process  
OR 
• Blood culture positive for Candida  spp. 
OR 
• Alternative approved diagnostic method such as T2 testing  or ß-D-glucan levels (two consecutive positive 
test results ), and at least one of the following: 
temperature ≥38°C or <36°C, systolic blood pressure <90 mmHg or a decrease of >30  mmHg from normal 
baseline, local signs or symptoms or radiologic findings of invasive candidiasis   For acute invasive candidiasis, including candidemia 
refractoriness is defined as meeting one or more of the following criteria:  
• Persistence of mycological evidence of Candida infection 
after >3 days of SOC  antifungal therapy. Acceptable 
mycological evidence for this study includes:  
o Persistently positive culture from a normally sterile site  
o Persistently positive T2 test  
o ß-D- glucan with elevated values equal to or increasing 
from Baseline (i.e., before start of SOC  antifungal 
therapy)  
• Antifungal susceptibility results indicating that the Candida isolate is not susceptible to the SOC  antifungal therapy 
being administered, indicating a high risk of therapeutic 
failure  
• Antifungal susceptibility results or local epi[INVESTIGATOR_714982]  (e.g., Candida auris )  
For chronic disseminated candidiasis refractoriness is defined 
as any of the following: 
• Persistent clinical manifestations such as debilitating fever after 12 weeks of initiating SOC  antifungal treatment  
• Lack of changes in radiological imaging lesions >12 weeks 
after starting SOC  antifungal treatment  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 39  Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
Acute  or chronic severe 
mucocutaneous 
candidiasis , including:  
• Esophageal candidiasis (EC)  
• Oropharyngeal candidiasis (OPC)  
• Chronic 
mucocutaneous 
candidiasis (CMC)  
• Vulvovaginal candidiasis (VVC)  • EC: Clinical manifestations and endoscopic findings 
consistent with EC plus potassium hydroxide (KOH) or fungal stain from biopsy or brushing indicating yeast 
infection.  
• OPC , CMC : Evidence of clinical manifestations and 
mycological documentation (positive fungal stain from 
biopsy or positive  Candida spp. culture obtained from the 
affected site).  
• VVC: Evidence of clinical manifestations with total 
composite signs and symptoms score of 4 or more in the 
vulvovaginal signs and symptoms (VSS) Scale 
(Section  21.4 [Appendix D]) and a positive Candida spp. 
culture obtained from a vaginal sample.  
 For EC and OPC , refractoriness is defined as meeting the 
following criteria:  
• Lack of clinical improvement or worsening of infection 
after receipt of SOC  antifungal therapy for at least 7 
consecutive days  
For CMC , refractoriness is defined as meeting the following 
criteria:  
• Lack of clinical improvement or worsening of the mucocutaneous manifestations of CMC after receipt of 
SOC  antifungal therapy for at least 21 consecutive days  
For VVC, refractoriness is defined as meeting any of the 
following criteria:  
• Lack of clinical improvement or worsening of the infection after receipt of SOC  antifungal therapy with documentation 
of persistence of Candida spp. in a vaginal sample obtained 
after completion of SOC  antifungal therapy  
• Recurrent VVC caused by [CONTACT_715043]  
• Recurrent VVC caused by [CONTACT_715044] a MIC 
for fluconazole ≥ 16 µg/mL  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 40  Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
Disseminated/invasive 
dimorphic fungi:  
• Coccidioidomycosis  
• Histoplasmosis  
• Blastomycosis  • Recovery in culture from a specimen obtained from the 
affected site, in a host with a temporally related illness 
consistent with a fungal infectious disease process  
OR 
• If a culture is negative or not obtained, histopathologic or 
direct microscopic demonstration of appropriate 
morphological forms for dimorphic fungi having truly distinctive appearance  
OR 
• Positive blood culture  
OR 
• Demonstration of fungal antibody in a two- dilution rise 
measured in two consecutive blood samples tested 
concurrently in the setting of a temporally related 
infectious disease process  For disseminated/invasive dimorphic fungi , refractoriness is 
defined as meeting any of the following criteria:  
• Relapse after therapy with a SOC  antifungal agent (azole or 
amphotericin B)  
• Intolerance, anticipated intolerance including high risk for drug interactions, or current or past toxicity to administered 
antifungal  
• Failure of current therapy as judged by [CONTACT_715045] a minimum of 1 month of SOC  antifungal therapy  
• Isolate with a MIC indicating a high probability of therapeutic failure for the intended antifungal agent (e.g., fluconazole MIC > 8  µg/mL) 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 41  Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
Chronic Pulmonary 
Aspergillosis (CPA)  CPA  diagnosed according to the European Respi[INVESTIGATOR_3764] 
2016 guideline, including:  
• Thoracic imaging (preferably by [CONTACT_4654]) consistent with 
CPA,  such as:  
o Aspergilloma  
o Chronic cavitary pulmonary  aspergillosis  
o Subacute invasive aspergillosis (1- 3 months)  
AND  
• Direct evidence of Aspergillus  infection or an 
immunological response to Aspergillus  spp. 
o Percutaneous biopsy showing fungal hyphae on 
microscopy or growing Aspergillus  spp. from a 
pulmonary lesion, OR  
o Respi[INVESTIGATOR_714983]/or growing Aspergillus  spp. and/or 
with a positive Aspergillus  PCR  
AND  
o High Aspergillus  IgG in a serum sample 
AND  
• Active mycobacterial infection ruled out  
• Disease present for at least 3 months  
• Disease requires antifungal treatment for CPA, in the 
opi[INVESTIGATOR_714984] , refractoriness is defined as meeting any of the 
following criteria:  
• Suboptimal clinical response (per the I nvestigator’s 
judgment)  of CPA signs and symptoms after receipt of SOC  
antifungal therapy for at least 6 weeks, including:  
o Significant hemoptysis  
o Weight loss  
o Persistent fatigue  
o Productive cough  
• Presence of new or worsened CPA signs and symptoms 
(expected to respond to antifungal treatment) while 
receiving SOC  antifungal therapy for at least 6 weeks  
• Persistence of azole- resistant Aspergillus  spp. positive 
sputum or BAL cultures after at least 3 months of SOC  
antifungal therapy  
• Radiologic evidence of lack of improvement, such as:  
o New cavities  
o Increased peri -cavity infiltrates  
o New fungal ball  
 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 42  Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
Allergic 
Bronchopulmonary 
Aspergillosis (ABPA)  • Presence of all of the following: (1) asthma; (2) 
immediate cutaneous hyperreactivity on Aspergillus  skin 
test or serum A. fumigatus -specific IgE > 0.35 kUA/L; 
and (3) elevated serum total IgE > 1,000 IU/mL  (2.4 
mg/L) .  
AND  
• Presence of two of the following features: (1) precipi[INVESTIGATOR_714985] A. fumigatus  in serum; 
(2) fixed or transient radiographic pulmonary opacities; (3) peripheral blood eosinophil count > 1,000 cells/ µL; 
(4) bronchiectasis on chest HRCT scan, (5) infection with azole -resistant but ibrexafungerp- susceptible 
Aspergillus  spp.   Not responsive, intolerant or demonstrated toxicity to SOC  
glucocorticoids or azole therapy as judged by [CONTACT_941] I nvestigator  
Invasive Pulmonary 
Aspergillosis (IPA)  
 Mycological evidence:  
• Histopathologic, cytopathologic, or direct microscopic 
examination of a specimen obtained by [CONTACT_80605][INVESTIGATOR_714981] a normally sterile site showing hyphae forms accompanied by [CONTACT_715046] 
• Recovery of an Aspergillus  spp. by [CONTACT_640726] a sample 
obtained by a sterile procedure from a normally sterile 
site (excluding BAL) showing a clinical or radiological 
abnormality consistent with a pulmonary invasive 
aspergillosis  
OR 
• Alternative approved diagnostic method from serum or 
BAL, such as PCR or GMI test (for serum GMI: two 
consecutive positive test results; for BAL, one positive 
test) For IPA, refractoriness is defined as meeting the following 
criteria: 
• Suboptimal response (per the I nvestigator’s judgment) to an 
approved SOC  antifungal treatment for IPA (i.e., 
voriconazole, isavuconazole, posaconazole, or amphotericin 
B at the doses recommended per their label), defined as  
radiological, serological or clinical signs of lack of response or increased fungal burden, such as any of the following:  
o Increased size or number of radiologic infiltrates not 
associated with resolution of neutropenia  
o Increased GMI levels  
o Lack of clinically meaningful reduction in serum GMI 
levels compared to a sample obtained prior to initiation of an acceptable antifungal therapy after at least 7 days 
of antifungal therapy  
 
Monotherapy with ibrexafungerp is not recommended for 
refractory  or relapsing IPA. All s ubjects enrolled for refractory 
or relapsing IPA should receive combination antifungal therapy. 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 43  Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
PLUS  
Clinical evidence  
• At least one of the following clinical signs or symptoms: 
temperature ≥38°C or <36°C, systolic blood pressure <90 
mmHg or a decrease of >30 mmHg from normal baseline, 
local signs or symptoms  AND  
• radiologic findings compatible with pulmonary invasive aspergillosis (Chest CT or MRI)  
PLUS  
Subject Risk Factors, such as:  
• Recent history of neutropenia, or  
• Allogeneic stem cell transplant recipi[INVESTIGATOR_841], or  
• Prolonged (>3 weeks) corticosteroid therapy, or  
• Recent treatment with other recognized T -cell 
immunosuppressant, such as cyclosporine, TNF -α 
blockers, specific monoclonal antibodies or nucleoside analogues during the past 90 days  
• Other underlying condition known to have increased risk 
for invasive aspergillosis (e.g. influenza , pneumonia)  The following combination options are allowed:  
• addition of ibrexafungerp  to any ongoing antifungal  
• replacement of one (toxic/ineffective) element of a two 
antifungal combination therapy with ibrexafungerp  
• replacement of current monotherapy with a new combination, generally:  
o replacement of amphotericin B monotherapy with an 
azole plus  ibrexafungerp combination, or  
o replacement of an azole monotherapy with an amphotericin B plus  ibrexafungerp combination  
• continuation of an azole plus echinocandin combination
 
where the subject could go home on an oral regimen by [CONTACT_715047] e 
ibrexafungerp monotherapy, upon discussion with the Sponsor.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 44  Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
Other emerging fungi 
including yeasts and 
molds  (e.g., 
sachromycetes , 
scopulariopsis ) 
 • Histopathologic, cytopathologic, or direct microscopic 
examination of a specimen obtained by [CONTACT_80605][INVESTIGATOR_714981] a normally sterile site showing fungal 
cells.  
OR 
• Recovery of a fungal species by [CONTACT_640726] a sample 
obtained by a sterile procedure from a normally sterile site, wound or lesion consistent with known 
pathophysiology of the organism  
AND  
• Radiological imaging showing evidence consistent with 
an infectious disease process  
AND  
• Fungus  (genus species) is known to be  generally 
susceptible to ibrexafungerp in vitro  
OR 
• Fungal susceptibility of the isolate showing MICs for 
ibrexafungerp ≤ 4  ug/mL  For other emerging fungi , refractoriness is defined as meeting 
any of the following criteria:  
• Subject intolerant of available therapeutic options  
• Suboptimal response per the I nvestigator’s judgement  
• Limited or no therapeutic options available  
For subjects without culture i solate available (to confirm 
susceptibility to ibrexafungerp) , combination therapy should be 
considered and discussed with the S ponsor.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 45  Eligibility Criteria  
Fungal Disease  Diagnostic Criteria  Refractoriness /Resistance /Intolerancea/Toxicityb/Relapsec 
Criteria  
Abbreviations: ABPA=allergic bronchopulmonary aspergillosis; ALT= alanine aminotransferase; AST=aspartate aminotransferase; B AL=bronchoalveolar 
lavage; CMC=chronic mucocutaneous candidiasis; CPA=chronic pulmonary aspergillosis; CT=computerized tomography; EC=esophageal candidiasis; 
GMI=galactomannan index; HRCT= high resolution computerized tomography; Ig=immunoglobulin; IPA=invasive pulmonary aspergillos is; 
MIC=minimum inhibitory concentration; MRI=magnetic resonance imaging; OPC=oropharyngeal candidiasis;  PCR= polymerase chain reaction; 
SOC =standard of care; TNF = tumor necrosis factor; VSS=vulvovaginal signs and symptoms; VVC=vulvovaginal candidiasis . 
a: Intolerance for any of the eligible diseases above is defined as presence or history of administration- related AEs (e.g., infusion reaction, hypersensitivity 
reactions, etc.) to the standard antifungal being administered or intended for treatment of the current funga l disease.  
b: Toxicity  for any of the eligible diseases above is defined as the degree to which a substance (antifungals) can damage an individual a s well as cause a 
negative effect on a substructure of an individual such as a system or organ. The toxicity should be of a severity or prognosis such that, as per the Investigator´s judgement, it is in the best interest of the subject to modify his/her antifungal therapy. Example of toxicities include:  
• Nephrotoxicity defined as elevation of serum creatinine level by 2 times the baseline value or any value above the upper limi t of normal (ULN), in a 
repeat test at least 24 hours apart.  
• Hepatotoxicity defined as elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >[ADDRESS_973951].  
• Other events not related to the subject’s condition and that started after initiation of the standard antifungal agent, such as visual disturbances, cutaneous reactions, neurological reactions, histamine reactions, etc.  
• Drug -drug interactions of the standard antifungal agent with other therapi[INVESTIGATOR_714986], which are either assoc iated with a 
documented toxicity or are likely to result in toxicity.  
c:  Relapse  is defined as  deterioration or worsening of a fungal disease after an initial improvement to therapy. 
 
 
 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973952] is able to tolerate medication orally or through a nasogastric (NG) tube or 
percutaneous endoscopic gastrostomy (PEG) tube.  
4. Subject and/or legal guardian is/are able to understand and sign a written ICF, which must 
be obtained prior to treatment and any study- related procedures.  
5. Subject and/or legal guardian is able to understand and sign a consent or authorization 
form, which shall permit the use, disclosure and transfer of the subject’s personal health information. (e.g., in the US, a Health Insurance Portability and Accountability Act 
[HIPAA] authorization form).  
6. Subject and/or legal guardian is able to understand and follow all study- related procedures 
including study drug administration.  
7. Subject is not pregnant and is highly unlikely to become pregnant or to impregnate a partner 
since he/she meets at least one of the following criteria:  
a. Subject is a female subject who is not of reproductive potential and is eligible 
without requiring the use of contraception. A female subject who is not of reproductive potential is defined as one who: (1) has reached natural menopause (defined as 6 months  of spontaneous amenorrhea with serum follicle -stimulating 
hormone levels in the postmenopausal range as determined by [CONTACT_12082], or 12 months of spontaneous amenorrhea); (2) is [ADDRESS_973953] -surgical bilateral 
oophorectomy with or without hyster ectomy; or (3) has undergone bilateral tubal 
ligation. Spontaneous amenorrhea does not include cases for which there is an 
underlying disease that causes amenorrhea (i.e., anorexia nervosa).  
b. Subject is a male subject who is not of reproductive potential and is eligible without 
requiring the use of contraception. A male subject who is not of reproductive potential is defined as one who has undergone a successful vasectomy. A successful 
vasectom y is defined as (1) microscopic documentation of azoospermia, or (2) a 
vasectomy more than [ADDRESS_973954]’s preferred method of contraception, or, if 
sexually active, use (or have their partner use) 2 acceptable methods of contraception starting from the time of consent through 28 days after the completion of study therapy. Acceptable methods of birth control are hormonal 
contraception (including but not limited to oral, injectable or implantable methods), intrauterine device, diaphragm with spermicide, condom, and vasectomy. Hormonal contraception (including but not limited to oral, injectable or implantable methods), must not be used alone as a method of contraception because it is unknown if the effect of ibrexafungerp may reduce the effica cy of hormonal 
contraceptives.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 47 Periodic abstinence (calendar, symptothermal, post -ovulation methods), 
withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea 
method (LAM) are NOT acceptable methods of contraception. 
NOTE:  Women of childbearing potential must have a negative urine or serum pregnancy 
test (β -human chorionic gonadotropin) prior to enrollment (performed by [CONTACT_779]’s local 
laboratory). 
11.[ADDRESS_973955] will be excluded from participation in the study if he or she meets any  of the following 
exclusion criteria  at Screening and/or Baseline : 
1. Subject has an invasive fungal disease with central nervous system involvement unless the subject is planned to receive combination therapy with ibrexafungerp and other antifungal. 
2. Subject has an inappropriately controlled fungal disease source (e.g., persistent catheters, 
devices, identified undrained abscess) that is likely to be the source of the fungal disease.  
3. Subject is hemodynamically unstable and/or requiring vasopressor medication for blood 
pressure support. 
4. Subject has abnormal liver test parameters: AST or ALT >[ADDRESS_973956] and/or total bilirubin >[ADDRESS_973957].  
Note : Subjects with unconjugated hyperbilirubinemia with a diagnosis of Gilbert’s disease 
are not excluded .  
5. Subject is unlikely to survive [ADDRESS_973958] has received any other investigational drug (i.e., new chemical entity) within at least 
30 days (or [ADDRESS_973959]) before signing the ICF. 
11. Subject is an employee of SCYNEXIS, Inc., the I nvestigator, or contract research organization 
involved in the study, or an immediate family member (partner, offspring, parents, siblings, or sibling’s offspring) of an employee involved in the study. 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973960] or legal representative is/are unable to provide written informed consent for any 
reason.  
13. Subject is unlikely to comply with protocol requirements.  
11.[ADDRESS_973961] may be discontinued from the study or study drug for any of the following reasons:  
• Withdrawal of consent  by [CONTACT_3184]/or subject’s legal guardian;  
• Investigator or S ponsor decision that withdrawal is in the subject’s best interest ; 
• Deterioration of the clinical condition or delayed response requiring, in opi[INVESTIGATOR_684], alternative therapy;  
• Occurrence of an AE that, in the opi[INVESTIGATOR_2511] I nvestigator, warrants discontinuation of 
the subject from the study drug;  
• Pregnancy;  
• Lost to follow up (every attempt should be made to contact [CONTACT_423]) . 
The reason for a subject’s discontinuation of treatment or withdrawal from the study will be clearly 
documented in the source documents and on the electronic case report form ( eCRF ). 
For VVC subjects, all TOC procedures should be performed for subjects who discontinue from 
the study before the TOC visit, and all 25- Day FU procedures should be performed for subjects 
who discontinue from the study after the TOC visit but before the 25- Day FU visit .  
For all other fungal diseases, at the time of discontinuation, all EOT procedures should be performed for subjects who discontinue from treatment on or before the EOT visit  and the 6- Week 
FU visit should also be completed. All 6-Week FU procedures should be performed for subjects 
who discontinue from the study after the EOT visit and on or before the 6- Week FU visit.  All 
follow up visits should be completed for discontinued subjects regardless of need for additional 
antifungal therapy.  
11.4 Replacement of Discontinued Subjects  
Subjects who discontinue early from randomized treatment will not be replaced.  
12.0 Study Treatment s 
12.1 Study Treatment Groups  
This is an open- label, non- comparator, single -arm study. All subjects will receive ibrexafungerp 
monotherapy except subjects with refractory or relapsing invasive pulmonary aspergillosis  (IPA) , 
who will receive combination therapy. Combination therapy may also be administered to other 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 49 subjects based on Investigator ’s judgement and contingent on Sponsor approval. Subjects will 
receive ibrexafungerp on an inpatient or outpatient basis, as needed for each fungal disease. 
12.1.1  Ibrexafungerp Monotherapy for All Fungal Diseases, Excluding  VVC 
Subjects will receive ibrexafungerp  monotherapy given as an initial loading dose of 750 mg (3 
tablets of 250 mg each) given BID (total daily dose = 1500 mg) during the first 2 days of treatment 
and then subsequent oral doses of 750 mg (3 tablets of 250 mg each) QD for up to 180 days, depending on fungal disease.  
Table 6 Ibrexafungerp Monotherapy Dosing Regimen (Excluding VVC) 
 Treatment Days  Ibrexafungerp Dosing Regimen  Total Ibrexafungerp 
Daily Dose  
Loading Dose  
 Study Days 1 and 2  750 mg BID:  
750 mg (3 tablets x 250  mg) AM  
750 mg (3 tablets x 250  mg) PM  1500 mg  
Maintenance Dose  Study Day 3 to EOT  750 mg QD:  
750 mg (3 tablets x 250  mg) 750 mg 
Alternative 
Maintenance Dose  Study Day 3 to EOT  375 mg BID:  
375 mg (1.5 tablets x 250 mg) AM  
375 mg (1.5 tablets x 250 mg) PM  750 mg  
Abbreviations: AM = morning; BID = twice a day; EOT = end of treatment; PM = evening; QD = once a day; 
VVC = vulvovaginal candidiasis  
Treatment beyond [ADDRESS_973962] basis. Subjects  with a recurrence after TOC 
(VVC) or EOT (all other diseases) may be considered for re -enroll ment upon discussion with the 
Sponsor.   
If subjects cannot swallow the whole tablet, the tablets may be split. In the event subjects 
experience gastrointestinal intolerance on the 750  mg QD dose, the tablets may be split and/or 
administered at 10 to 20- minute intervals. The daily dose may also be given as 375 mg (1 and ½ 
tablets) BID for subjects experiencing gastrointestinal intolerance. 
12.1.2  Ibrexafungerp Monotherapy for VVC  
Subjects with VVC will receive ibrexafungerp monotherapy given as oral doses of 375 mg BID 
(total daily dose = 750 mg) every three days for a total of three dosing days (Day 1, Day 4 and 
Day 7).  Subjects  treated for VVC who have a recurrence after TOC may receive additional cycles 
of ibrexafungerp treatment similar to the initial regimen , upon discussion with the sponsor. 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 50 Table 7 Ibrexafungerp Monotherapy Dosing Regimen for VVC 
Treatment Days  Ibrexafungerp Dosing Regimen  Total Ibrexafungerp 
Daily Dose  
Study Day 1  375 mg (1 ½ tablets x 250  mg) AM  
375 mg (1 ½ tablets x 250 mg) PM  750 mg  
Study Day 4  375 mg (1 ½ tablets x 250  mg) AM  
375 mg (1 ½ tablets x 250 mg) PM  750 mg  
Study Day 7  375 mg (1 ½ tablets x 250  mg) AM  
375 mg (1 ½ tablets x 250 mg) PM  750 mg  
Abbreviations: AM = morning; PM = evening; VVC = vulvovaginal candidiasis  
12.1.[ADDRESS_973963] no culture isolate available (to confirm susceptibility to ibrexafungerp), combination therapy should be considered and discussed with the Sponsor. Combination therapy will also be allowed 
for other subjects based on Investigator ’s judgement and contingent on Sponsor approval.  
Acceptable antifungal therapy includes voriconazole, isavuconazole, posaconazole, fluconazole or 
amphotericin B (AMB) at the doses recommended per their label.  When used in combination with 
the azoles, the dose of ibrexafungerp should be reduced from 750 mg to 500 mg. 
 
Table 8 Ibrexafungerp – Azole Combination Therapy Dosing Regimen  
 Treatment Days  Additional 
Antifungal  + Ibrexafungerp Dosing Regimen  Total Ibrexafungerp 
Daily Dose  
Loading Dose  
 Study Days 1 and 2  Per label  + 500 mg BID:  
500 mg (2 tablets x 250 mg) AM  
500 mg (2 tablets x 250 mg) PM  1000 mg  
Maintenance 
Dose  Study Day 3 to EOT  Per label  + 500 mg QD:  
500 mg (2 tablets x 250 mg) 500 mg 
Abbreviations: AM = morning; EOT = end of treatment; PM = evening; QD = once a day  
The following combination options are allowed: 
• addition of ibrexafungerp to any ongoing antifungal therapy 
• replacement of one (toxic/ineffective) element of a two -antifungal combination therapy 
with ibrexafungerp 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 51 • replacement of current monotherapy with a new combination, generally:  
o replacement of AMB monotherapy with an azole plus ibrexafungerp combination, or  
o replacement of an azole monotherapy with an AMB plus ibrexafungerp combination  
• continuation of an azole plus echinocandin combination where the subject could go home 
on an oral regimen by [CONTACT_715048]  
12.1.4  Dietary Requirements  
Oral study drug should be taken with approximately 8 oz/240 mL of water, preferably with food. 
For subjects on continuous feeding via an NG or PEG tube, the drug should be crushed and 
administered with approximately 8 oz/[ADDRESS_973964] one hour before drug administration and should be flushed with approximately 20 mL of water before and after drug administration. 
12.2 Study Drugs  
12.2.1  Ibrexafungerp Description  
Study Drug Identifier:  Ibrexafungerp  
Empi[INVESTIGATOR_333486]:  C50H75N5O11 (citrate salt)  
Molecular Weight:  922.18 (citrate salt)  
Physical Description:  White to off -white solid  
Chemical Name:  (1S,4aR,6aS,7R,8R,10aR,10bR ,12aR,14R ,15R )-15-[[(2R)-2-amino -
2,3,3- trimethylbutyl]oxy] -8-[(1R)-1,2-dimethylpropyl] -14-[5-(4-
pyridinyl) -1H-1,2,4- triazol- 1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a -
dodecahydro -1,6a,8,10a -tetramethyl- 4H-1,4a-propano- 2H-
phenanthro[1,2 -c]pyran -7-carboxylic acid, citrate salt]  
 
Figure 2 Chemical Structure of Ibrexafungerp  Citrate  

SCYNEXIS, Inc.  IND # 107,[ADDRESS_973965] for oral administration will be supplied as compressed oral 
tablets containing 250 mg of ibrexafungerp active ingredient on a free base basis.  In addition to 
the active ingredient, the oral tablet formulation also contains silicified microcrystalline cellulose, 
crospovidone, mannitol, colloidal silicon dioxide, magnesium stearate (non -bovine), and butylated 
hydroxyanisole. Ibrexafungerp is packaged in bottles containing 30 tablets. 
Labels  on the bottles of ibrexafungerp will include information  as required by [CONTACT_715049] :  
• Sponsor information 
• Protocol number  
• Protocol visit number  
• Place to write the subject number  
• Route of administration  
• Lot number  
• Product name [CONTACT_715074] 
• Contents, e.g. number of tablet count per bottle  
• Storage conditions  
• Name [CONTACT_715075]  
• Caution statement according to local regulations: "Caution:  New Drug – Limited by [CONTACT_715050] ” 
12.2.[ADDRESS_973966] or appropriate designee at each clinical research site will be responsible for the 
study drug. Ibrexafungerp tablets are to be stored at room temperature: between 15°C and 25°C 
with allowable limited excursions of up to 30°C.  
For long- term storage at the site, study drug supplies must be kept in a secure area (e.g., locked 
cabinet) and stored at room temperature.  
The site will be required to keep a temperature log to establish a record of compliance with these storage conditions. All study drug will be kept in a secure cabinet or room with access restricted to necessary clinic personnel.  
12.3 Drug Accountability  
The I nvestigator or designee will inventory and acknowledge receipt of all shipments of the study 
drug. Drug accountability logs will be used to maintain accurate records of receipt, dispensing, 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973967] for study drug destruction. 
Drug supplies will be maintained in a secure, limited -access storage area under the recommended 
storage conditions. 
The study drug supplied for this study is only for use in subjects who were properly consented and 
enrolled under this protocol. 
A study site designee (e.g., pharmacist, study nurse/coordinator) will:  
• Record the treatment in the drug accountability log. 
• Count the number of tablets per bottle before dispensing to subject. 
• Report and document any study medication issues such as contamination, crushed or broken 
tablets, incorrect labelling.  
o All product quality complaints should be reported to the S ponsor. 
• Collect and count the number of tablets remaining at the EOT visit.  
Review subject diary card and remaining study drug count, record any unused or remaining drug 
in the drug accountability log and eCRF, and note any discrepancies and reason for discrepancies.  
12.[ADDRESS_973968] the study medication 
(including empty bottles/units) with them at each visit.  Compliance will be assessed based on 
remaining study drug as compared to what should have been taken and the subject diary where the subject will enter the details of dosing.  Details of treatment including any missing dose will be 
recorded on the eCRF. Sites are encouraged to contact [CONTACT_89826] S ponsor for concerns 
of compliance with the treatment regimen, especially for subjects who  miss doses due to problems 
with tolerability.  
13.0 Non- Study Treatments  
13.1 Prior and Concomitant Medications  
All medications (including prescription and over -the-counter medications, supplements, and 
herbal products) taken from 30 days before Baseline/Day  1 through TOC (Day 17)  for VVC and 
EOT for all other fungal diseases will be recorded on the eCRF. Immunosuppressants (e.g., 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 54 chemotherapy, corticosteroids, T -Cell imm unosuppressants) used up to [ADDRESS_973969] 
enrollment will be recorded on the eCRF. Antifungal medications administered for the treatment 
of the eligible fungal infection if  received for ≥[ADDRESS_973970]  as clinically relevant , as judged by [CONTACT_332500]. Only  the use of other antifungal medications, antibiotics for any reason or 
medications to treat an AE will be recorded after EOT (TOC for VVC subjects) and through the 
last observation in the study (35- Day FU for VVC, 6 -Month FU for ABPA and 6- Week FU for all 
other fungal diseases). Start and stop times of concomitant medications taken during antifungal 
therapy will be recorded on the eCRF. Subjects will also record any new concomitant medications taken between visits in the subject diary. 
See Section  13.2 and Section  13.3 for prohibited medications and medications to be administered 
with caution, respectively.  
13.2 Prohibited Medications  
Medications not permitted include the following: 
• Non-study systemic or topi[INVESTIGATOR_714987] a per -
subject basis  
• Other investigational drug(s) 
• Strong CYP3A4/5 inhibitors, CYP3A4/[ADDRESS_973971] P -gp substrates (refer to 
Appendix B [ Section 21.2] for the full list of prohibited medications).  
See Appendix B [ Section 21.2] f or the full list of prohibited medications  
13.3 Medications to be Administered with Caution  and Monitored as 
Appropriate  
CYP3A4 moderate substrates : In vitro , ibrexafungerp was an inhibitor of CYP3A  mediated 
metabolism of midazolam but was only a weak inhibitor of metabolism of testosterone. The 
clinical significance of this inhibition is unknown; caution should be exercised when administering 
ibrexafungerp with drugs known to be CYP3A sensitive substrates with narrow therapeutic index. 
Subjects receiving sirolimus, tacrolimus, or warfarin are permitted for enrollment in the study and these medications may be administered 
with ibrexafungerp with close monitoring.  The 
administration of either sirolimus or tacrolimus should be offset by [CONTACT_246392] 2 hours with the 
administration of ibrexafungerp. At a minimum, blood levels of sirolimus and tacrolimus or 
prothrombin time/partial thromboplastin time/international normalized ratio for subjects on warfarin should be measured after the first dose of ibrexafungerp and when the subject has received 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 55 between 3 and 7 days of ibrexafungerp (at which time ibrexafungerp concentrations will have 
reached steady state). Dosing adjustments and subsequent monitoring of sirolimus, tacrolimus and 
warfarin should be undertaken in accordance with product prescribing information for the 
respective agents.  
Refer to Appendix B ( Section 21.2) for further details.  
13.4 Study Restrictions 
There are no study restrictions other than those described in Sections 11.2 (Exclusion Criteria ), 
Section  12.1.4 (Dietary Requirements ), Section  13.2 (Prohibited Medications) and Section  13.3 
(Medications to be Administered with Caution). 
14.[ADDRESS_973972] dose of study drug (Baseline [Day  1]). For follow -up visits, days, weeks and months are counted relative to the EOT visit. The 
Screening visit and Baseline (Day 1) visit may occur on the same day.  
14.[ADDRESS_973973] provide written informed consent 
prior to participating in any s creening evaluations or any other study activities (see Section 19.3).  
14.1.[ADDRESS_973974] identification 
(ID) number that will be composed of a 3- digit study number (301) and a 2- digit site number 
followed by a [ADDRESS_973975] a 3 -digit site 
identification number, instead of a 2- digit number for U.S. sites. 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 56 Subjects who are screen failures or who are not eligible for treatment will be recorded as such in 
the site’s subject screening log. The subject numbers assigned to eligible subjects will be recorded 
on the electronic Case Report Form (eCRF).  Only one subject number will be assigned to each 
eligible subject.  
For subjects who signed an ICF (i.e., are assigned a subject number) but were NOT treated because they did not meet all of the inclusion/exclusion criteria, the Screening visit pages of the eCRF will be completed. The criteria that were not met for enrollm ent will be documented on the eCRF.  
All eligible subjects must be approved by [CONTACT_941] S ponsor (or Sponsor designee) for enrollment
. An 
Eligibility Form will be used to request eligibility confirmation from the Sponsor  or Sponsor designee . 
14.1.[ADDRESS_973976] demographics such as age, sex, race and ethnicity will also be collected. For subjects  with ABPA, the number of Asthma and 
ABPA Exacerbations in the six months prior to enrollment should be recorded. For subjects  with 
chronic pulmonary aspergillosis ( CPA ), the latest available result on the Six-Minute Walk Test 
and St . George ’s Respi[INVESTIGATOR_696] Q uestionnaire prior to Screening should be recorded on the eCRF .  
Data available to support inclusion / exclusion criteria collected as SOC prior to signature [CONTACT_715076].  
14.1.[ADDRESS_973977] qualifies for the 
trial at Screening and at Baseline/Day 1.  
14.1.[ADDRESS_973978] will be performed by [CONTACT_715051] , except  those with VVC . Pregnancy tests may be conducted more often (e.g., 
on a monthly basis) , per local regulations.  
14.1.6  Prior and Concomitant Medications  
Refer to Section  13.0 and Section  21.2 for details.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 57 14.1.7  Study Drug Dispensing, Collection and Accountability Review 
For subjects who are not hospi[INVESTIGATOR_057], the study drug will be dispensed at Baseline/Day 1 and every 
14 days. Study drug will be collected for accountability review every 14 days up to EOT, at EOT 
and at unscheduled visits (see Section  12.4 for further details regarding treatment compliance 
evaluation). Any unused study drug will be re-dispensed to the subject. 
For VVC subjects, study drug will be dispensed at Baseline/Day 1 and will be collected at EOT 
(Day 7), when treatment compliance will be assessed.  
14.1.8  Study Drug Dosing 
For all subjects except VVC subjects, study drug doses will be administered daily through EOT, as needed, depending on the fungal disease. Subjects with VVC will receive ibrexafungerp on 
Day 1 [Baseline], Day 4 and Day 7 [EOT]).  
Further details of the study treatment and dietary requirements for administration of ibrexafungerp 
monotherapy and combination therapy are provided in Section 12.1.1, Section  12.1.[ADDRESS_973979] the date/time of study medication dosing, daily symptoms, other medical concerns or 
complaints, and concomitant medications. 
For all subjects except VVC subjects, diaries will be dispensed at Baseline/Day 1 and will be 
reviewed every 14 days during treatment  up to EOT, at unscheduled visits, and at EOT, when they 
will be collected.  For VVC subjects, diaries will be dispensed at Baseline/Day 1 and will be 
collected at TOC . 
14.2 Efficacy Procedures  
14.2.1  Targeted Physical Examination, Including Clinical Evaluation of Signs 
and Symptoms  
A targeted examination of the fungal disease site, including the signs and symptoms of the fungal  
infection , will be conducted for all subjects , excluding VVC subjects, at Screening  and 
Baseline/Day 1 (prior to treatment) , and at the per-protocol visits displayed in Table 9 . 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 58 Table 9 Schedule of V isits for Targeted Physical E xaminations by F ungal Disease  
(Excluding VVC)  
Study Days Every 14 
days during 
Txa D42 cD84 dD90 D180  EOT  Unsch.  
Visits  FU 1  
(6-WK)  FU 2 &  
FU 3  
Allowable window  ±2 d ±7 d ±7 d  ±7 d ±14 d  ±3 d AP ± 7 d AP 
Acute or Chronic IC  X X    X X X  
EC, OPC  X X    X X X  
CMCc X X X   X X X  
D/I DF   X X X   X X X  
CPAd Day 14  X  X Xb X X X  
ABPAd Day 14  X  X Xb X X X X  
IPA X X X   X X X  
Other emerging fungi  X X X   X X X  
Abbreviations: ABPA=allergic bronchopulmonary aspergillosis; AP = as applicable; CMC=chronic mucocutaneous 
candidiasis; CPA=chronic pulmonary aspergillosis; D=day; DF=dimorphic fungi; D/I= disseminated/ invasive; 
EC=esophageal candidiasis; EOT=end of treatment; FU=follow up; FU 1=6 -Week FU; FU 2=3 -Month FU; FU 3=6-
Month FU; IC=invasive candidiasis; IPA=invasive pulmonary aspergillosis; OPC=oropharyngeal candidiasis; 
Tx=treatment; unsch.=unscheduled; VVC=vulvovaginal candidiasis; WK=week  
a: As clinically indicated for disease . 
b: Efficacy procedures for CPA and ABPA subjects will be performed every [ADDRESS_973980] is still on treatment.  
c:    For CMC subjects, D84 is TOC visit  unless EOT occurs first  
d:    For CPA and ABPA subjects, D90 is TOC visit  unless EOT occurs first  
 
For subjects with VVC, targeted physical exams will be done at Screening, Baseline/Day 1 (prior 
to treatment), EOT (Day 7) , TOC (Day 17  [±3]) and 25- Day FU visit (25 days after EOT). A 
targeted  physical exam (vaginal examination) will also be conducted at the 35- Day FU  visit (35 
days after EOT)  if the subject is symptomatic . The EOT visit and the 35- Day FU  visits will be a 
phone contact [CONTACT_715052].  
Note:  For subjects who are suspected to have a relapse of infection during the study follow -up 
period, evaluations relevant to the signs and symptoms of infection should be performed before 
starting non- study antifungal therapy. The results of these studies should be documented on the 
eCRF.  Subjects who have a recurrence after TOC (VVC) or EOT (all other diseases), may be 
considered for re -enroll ment upon discussion with the Sponsor. 
The signs and symptoms of fungal infection include, but are not limited to, the following: 
• General signs and symptoms: 
o Fever, defined as oral temperature ≥38.3°C (≥101°F) on one occasion or >37.8°C 
(>100°F) on two measurements at least 4 hours apart  
o Clinically significant hypothermia <36°C (<96.8°F) 
o Hypotension (systolic blood pressure <90 mmHg or a >30 mmHg decrease below normal baseline)  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 59 o Tachycardia  
o Local signs and symptoms of inflammation 
• Disease- specific signs and symptoms:  
o OPC: White patches or plaques on the tongue and other oral mucous membranes, 
redness or soreness in the affected areas, difficulty swallowing, cracking at the corners of the mouth (angular cheilitis)  
o EC: White plaques and/or ulcers on the lining of the esophagus or narrowing of the 
lumen, pain when swallowing, difficulty swallowing, heartburn  
o CMC:  Extensive scaling, skin lesions, thickened nails  
o Other signs and symptoms of candidiasis and other fungal diseases, as applicable  
Subjects who are discharged from hospi[INVESTIGATOR_714988] , and the signs and symptoms will also be assessed by [CONTACT_715053].  The site will assess whether the signs and symptoms recorded on the 
subject diary are related to the fungal disease.  
14.2.2  Mycological Testing  
[IP_ADDRESS]  Vulvovaginal Candidiasis  
Samples for fungal culture will be collected at Screening, EOT (Day 7) , TOC (Day 17 [ ±3]) and 
25-Day FU (25 days after EOT; [ADDRESS_973981] dose). Additional samples will be obtained, if 
applicable, at Baseline/Day 1  and at any unscheduled visits. For symptomatic subjects, samples 
will also be collected at the 35 -Day FU visit (35 days after EOT; [ADDRESS_973982] dose).  
[IP_ADDRESS]  All Other Fungal Diseases Excluding Vulvovaginal Candidiasis  
Mycological samples will be obtained for all subjects at Screening and/or Baseline/Day 1 (prior to treatment), and as applicable for each subject and fungal disease while on therapy. In addition, 
samples will be collected at the per -protocol visits displayed in Table 10 . 
 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 60 Table 10 Schedule of V isits for Mycological A ssessments by [CONTACT_715054] D isease ( Excluding 
VVC)  
Study Days D42 D84b D90c D180  EOT  Unsch.  Visits  FU 1  
(6-WK)  FU 2 &  
FU 3  
Allowable window  ±7 d ±7 d  ±7 d ±14 d  ±3 d AP ± 7 d AP 
Acute or Chronic IC  X    X  X  
EC, OPC  X    X  X  
CMCb X X   X  X  
D/I DF   X X   X  X  
CPAc   X Xa X  X  
ABPA          
IPA X X   X  X  
Other emerging fungi  X X   X  X  
Abbreviations: ABPA=allergic bronchopulmonary aspergillosis; AP = as applicable; CMC=chronic 
mucocutaneous candidiasis; CPA=chronic pulmonary aspergillosis; D=day; DF=dimorphic fungi; D/I= 
disseminated/ invasive; EC=esophageal candidiasis; EOT=end of treatment; FU=follow up; FU 1=6 -Week FU; 
FU 2=3 -Month FU; FU 3=6-M onth FU; IC=invasive candidiasis; IPA=invasive pulmonary aspergillosis; 
OPC=oropharyngeal candidiasis; Tx=treatment; unsch.=unscheduled; VVC=vulvovaginal candidiasis; WK=week  
Note: Mycological response will be assessed by [CONTACT_433018], KOH and other fungal stains, T2 testing, and serological testing (including, GMI, Coccidioides  titers, and β -D-glucan levels, among others  [Section  14.2.4] ), if 
applicable . 
a: Efficacy procedures for CPA subjects will be performed every [ADDRESS_973983] is 
still on treatment.  
b:    For CMC subjects, D84 is TOC visit , unless EOT occurs first  
c:    For CPA and ABPA subjects, D90 is TOC visit  unless EOT occurs first  
[IP_ADDRESS].1  Candida Infections Excluding VVC  
Blood cultures: Two sets of blood cultures will be collected at Screening and repeated daily or 
every other day until blood cultures are negative for at least 48 hours (if it is only possible to obtain 
1 set of blood cultures, a reason should be documented). Blood should be drawn peripherally 
[directly from a vein]; however, if this is not possible, blood may be drawn from a central IV 
catheter.  Follow- up cultures will be performed as clinically indicated.  
Non-bl ood cultures: Follow -up cultures from subjects who have non -blood sites of Candida 
infection should be performed as clinically indicated. 
EC: F ollow -up KOH or fungal stains and/or mycological cultures from biopsy or brushing 
indicating yeast infection will be performed as clinically indicated.  
OPC and CMC : F ollow -up KOH or fungal stains and/or mycological cultures for Candida spp. 
obtained from the affected site will be performed as clinically indicated.  
Urine cultures: for subjects with urinary tract infections, urine samples for fungal cultures are 
recommended to be collected every 48-72 hours until negative. 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973984] ing: 
• The diagnosis should be based on two consecutively positive T2 tests. 
• For subjects diagnosed based on positive T2 tests, in addition to Screening, samples for T2 
testing will be collected every 48 hours until negative . 
[IP_ADDRESS].2  Other Fungal Diseases 
Baseline mycological assessment (Screening) of the subject’s fungal disease will be performed 
according to best local practice using local laboratories, including suitable samples for fungal culture and isolation as well as samples from the infected site f or histology and cytology. Outside 
of these time points, mycological assessment will be performed as clinically indicated and/or in 
line with standard clinical management for the subject’s specific fungal disease and anatomic site 
involved. The results of all mycological assessments, both culture and non- culture based 
(including negative results), performed during the study and relevant to the fungal infection will be recorded on the eCRF.  
[IP_ADDRESS]  General Notes for Mycological Testing  
The study site’s local microbiology laboratory will perform identification and in vitro  
susceptibility testing as per their local standards.  The Investigator should ensure that fungal  
isolates obtained from all cultures performed during the study period (and wherever possible, the 
isolate from the initial positive culture) are sent to the central microbiology laboratory, as described 
in the laboratory manual. The central microbiology laboratory will repeat the identification and 
perform in vitro  susceptibil ity testing of the isolates as per CLSI M27 -A4 and or EUCAST 
guidelines.10,[ADDRESS_973985] of care 
antifungals in the drug panels to determine resistance patterns.  
Further evaluation to identify the potential mechanism of resistance may be performed. Isolates 
may be maintained in a repository for potential future use, for subjects that provide consent for 
future use.  
Identification of the fungi isolate by [CONTACT_715055], PCR, matrix -assisted laser desorption/ionization ( MAL DI-
TOF ) or others that are approved for such use or are considered acceptable in the state of the art 
and current guidelines.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 62 Table 11:  Fungal I solates to  be Collect for the S tudy.  
Fungal isolate  Definition  When to Send to Central 
Laboratory 
Initial Isolate  The isolate from the culture that resulted in 
the initial diagnosis of invasive fungal disease will be considered the “initial” 
isolate. All subjects except those diagnosed 
solely based on non- culture tests like T2, 
PCR or serological tests will have an isolate from an initial culture.  End of Study for each subject.  
Screening Isolate  Subjects with refractory  or resistant  fungal 
disease will have cultures that are positive after the initial positive culture (thereby [CONTACT_715056] “refractory  or 
resistant ” for study eligibility).  This will be 
referred to as the “Screening” Isolate.  For subjects refractory or resistant to an echinocandin, the isolate should be sent at 
the time of enrollment per the 
laboratory manual 
instructions. 
Otherwise, screening isolates 
may be sent at End of Study 
for each subject . 
Study Isolate  All fungal isolates recovered during study 
while the subject is receiving ibrexafungerp 
or during the follow -up window. End of Study for each 
subject.  
For subjects who are suspected to have a relapse of infection during the study follow -up period, 
cultures should be collected and other evaluations relevant to the signs and symptoms of infection 
should be performed before starting non- study antifungal the rapy. Results of all mycological tests, 
including both culture and non- culture based (including negative results), relevant to the fungal 
infection under treatment should be documented on the eCRF.  
Sites should make every attempt to save the initial isolate for the study.  However, it is not 
mandatory to have the initial isolate for enrollment. In the absence of baseline isolates, all post-
Baseline pathogens collected in the context of clinical failure and associated with the fungal 
disease will be stored and shipped to central laboratory for identification of fungal species and 
susceptibility testing. If the identities of the pathogens differ betwee n the central and local 
laboratories, the central lab oratory results will take precedence over the local results for all study 
purposes.  
 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973986]:  
• Suitable samples for fungal culture and isolation (blood/ tissue cultures). 
• Follow -up culture samples from non- bloodstream infections are not mandatory but, if 
obtained, results should be recorded. Histological or cytological findings are regarded as supportive evidence of invasive fungal disease and should be recorded, if available.  
• For outcome assessment of fungal blood stream infections, confirmed (two consecutive) 
negative blood cultures are required.  
• All isolates should be identified to species level. All baseline and EOT isolates will be 
stored and shipped for central retesting. The central laboratory results will be considered definitive.  
• Biopsy/biological fluid samples from the infected site for histology and cytology. 
14.2.3  Imaging  
For subjects with fungal diseases where diagnosis and assessment of outcome are based on imaging, imaging scans (e.g., X -ray, ultrasound, computed tomography [CT], magnetic resonance 
imaging [MRI]) will be obtained for the assessment of infection.  
Imaging scans will be obtained for all subjects at Screening as applicable for each subject and fungal disease. Imaging scans  will also be collected at the recommended per-protocol visits 
displayed in Table 12. In addition to the scheduled time points, imaging scans will be collected 
anytime during t herapy , as clinically indicated.  The window for EOT imaging may range from ±  3
 
to ± 7 days, depending on the fungal disease.  
Data available to support patient eligibility collected as SOC prior to signature [CONTACT_715076].  Baseline radiological assessments for invasive fungal diseases  should be performed ideally within 72 hours of Screening. However, assessments 
performed up to 7 days before/after the first administration of study medication may be used to 
confirm the diagnosis of the fungal disease if non e exists within the ideal window.  Radiological 
assessments should ideally be made by [CONTACT_3610] (HRCT if available) or MRI. T he same radiologic 
methodology used at Baseline should be used for subsequent assessments . For lung, bone and 
abdominal infections, imaging at EOT is strongly recom mended, since they are critical for 
outcome assessment.  
Bronchoscopic assessments should be performed as clinically indicated. When performing 
bronchoscopic examinations, samples obtained should be sent for the following tests: culture, histology/cytology and GM. If BAL samples are obtained at B aseline, an additional sample should 
be stored for shippi[INVESTIGATOR_396550].  For other time points, any residual BAL sample 
after routine SOC testing is complete should be stored for shippi[INVESTIGATOR_396550].  
The results of these imaging studies should be documented on the eCRF.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 64 Table 12  Schedule of V isits for Recommended Imaging A ssessments by [CONTACT_715054] D isease , 
if obtained for Routine Care  (Excluding VVC)  
Study Days D42 D84d D90e D180  EOT  Unsch.  
Visits  FU 1  
(6-WK)  FU 2 &  
FU 3  
Allowable window  ±7 d ±7 d  ±7 d ±14 d  ± 3 to ± 7  AP ± 7 d AP 
Acute or Chronic ICa X    X  X  
EC, OPCa X    X  X  
CMCa, d X X   X  X  
D/I DF   X X   X  X  
CPAe   X Xb X  X  
ABPAe X  X Xb X  X X 
IPAc X X   X  X  
Other emerging fungia  X X   X  X  
Abbreviations: ABPA=allergic bronchopulmonary aspergillosis; AP = as applicable; CMC=chronic 
mucocutaneous candidiasis; CPA=chronic pulmonary aspergillosis; D=day; DF=dimorphic fungi; D/I= 
disseminated/ invasive; EC=esophageal candidiasis; EOT=end of treatment; FU=follow up; FU 1=6 -Week FU; FU 
2=3-Month FU; FU 3=6-M onth FU; IC=invasive candidiasis; IPA=invasive pulmonary aspergillosis; 
OPC=oropharyngeal candidiasis; Tx=treatment; unsch.=unscheduled; VVC=vulvovaginal candidiasis; WK=week  
a: If applicable.  
b: Efficacy procedures for CPA and ABPA subjects will be performed every [ADDRESS_973987] is still on treatment.  
c: For  IPA subjects, a chest CT scan within - 7 days of Baseline and ±3 to ±7 days of EOT is required
. 
d: For CMC subjects, D84 is TOC  unless EOT occurs first  
e: For CPA and ABPA subjects, D90 is TOC  unless EOT occurs first  
14.2.4  Serological Testing 
Serological tests will be obtained for all subjects, excluding VVC subjects, at Screening and at  
Baseline/Day 1 (prior to treatment), as applicable for each subject and fungal disease. Samples 
will also be collected at the recommended per protocol visits displayed in Table 13 . 
 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 65 Table 13 Schedule of V isits for Recommended Serological  Assessments by [CONTACT_715006] ( Excluding VVC)  
Study Days D3- 
D5 D7-
D10 Every 14 
days  
during Tx  D42 D84 D90 D180  EOT  Unsch.  
Visits  FU 1  
(6-WK)  FU 2 &  
FU 3  
Allowable window  ±2 d ±2 d ±2 d ±7 d ±7 d  ±7 d ±14 d  ±3 d AP ± 7 d AP 
Acute or Chronic IC             
EC, OPC             
CMC             
D/I DFa    Day 14  X X       
CPAb  as applicable    X Xc X  X  
ABPAd  as applicable  X  X Xc X  X X 
IPAe X X X X        
Other emerging fungia             
Abbreviations: ABPA=allergic bronchopulmonary aspergillosis; AP = as applicable; CMC=chronic 
mucocutaneous candidiasis; CPA=chronic pulmonary aspergillosis; D=day; DF=dimorphic fungi; D/I= 
disseminated/ invasive; EC=esophageal candidiasis; EOT=end of treatment; FU=follow up; FU 1=6 -Week FU; 
FU 2=3 -Month FU; FU 3=6-M onth FU; IC=invasive candidiasis; IPA=invasive pulmonary aspergillosis; 
OPC=oropharyngeal candidiasis; Tx=treatment; unsch.=unscheduled; VVC=vulvovaginal candidiasis; WK=week  
a: Serological tests will be conducted as clinically indicated . 
b: Change in total Ig G and Aspergillus -specific Ig G will be evaluated if elevated at Baseline . 
c: Efficacy procedures for CPA and ABPA subjects will be performed every [ADDRESS_973988] is still on treatment.   
d: Serum samples will be collected for total IgE .  
e: Serum samples will be collected for GM determination at Week 1, Week 2, Week 4 and Week 6.  
 
For subjects diagnosed exclusively by ß-D- glucan tests:  
• The diagnosis should be based on two consecutively positive ß-D-glucan tests.  
• Samples for ß -D-glucan testing will be collected every 72 hours until negative. 
For subjects with CPA: 
• Serum samples will be collected at Day 90 and Day 180 for Ig, Aspergillus -specific Ig G 
and total Ig G. 
For subjects with ABPA: 
• Serum samples will be collected for total IgE at Day 42, Day 90, Day 180 and every 3 
months following Day 180 while receiving study medication, at EOT  and at the  3-Month 
FU and 6-Month FU visits. 
For subjects with invasive aspergillosis, including IPA: 
• A single value of ≥ 0.7 or two consecutive values each of ≥ 0.5 - < 0.7 (i.e., from two 
separate blood draws) will be considered a positive result unless deemed false positive due 
to the presence of known interacting agents. Subjects with serum GM meeting the 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973989] dose of study medication 
are eligible for enrollment.  
• BAL for GM specimens may be processed locally, but an additional aliquot of BAL fluid 
will be collected for shipment to the central laboratory as well, when feasible. A single GM 
value ≥1 will be considered a positive result unless deemed false positive due to the 
presence of known interacting agents. For the current invasive aspergillosis epi[INVESTIGATOR_1865], the 
results available for all previous GM determinations in the preceding 3 months  (e.g. before 
enrollment) will be collected on the eCRF.  
For subjects with IPA:  
• Serum samples will be collected at Week 1, Week 2, Week [ADDRESS_973990]’s signs and symptoms of EC have persisted since initial diagnosis.  A repeat esophagoscopy is required at EOT  for all subjects , if this 
complies with SOC . Additional esophagoscopi[INVESTIGATOR_714989] [ADDRESS_973991]’s participation in the study should 
be included in the study database.  
14.2.[ADDRESS_973992] will be conducted at Screening or Baseline/Day 1 (prior to treatment) for all 
ABPA subjects . A repeat spi[INVESTIGATOR_714990] [ADDRESS_973993]. George’s Respi[INVESTIGATOR_6015] (SGRQ)  
For subjects with CPA, the latest available result on the St. George’s Respi[INVESTIGATOR_714991] . Additionally, 
subjects with CPA will be administered the St. George’s Respi[INVESTIGATOR_714992]/Day 1 (prior to treatment), Day 90, Day 180, every 3 months while on therapy beyond 
Day 180, at EOT  and at the 6- Week  FU visits.  
SCYNEXIS, Inc.  IND # 107,[ADDRESS_973994]  and Medical Research Council (MRC) Dyspnea Scale  
For CPA subjects, the latest available result on the Six -Minute Walk Test prior to Screening should 
be recorded on the eCRF as part of their medical history . Additionally, subjects with CPA will 
undergo a Six -Minute  Walk Test at Screening or Baseline/Day 1 (prior to treatment), Day 90, and 
Day 180. Subject’s disability will be graded using the MRC Dyspnea Scale at the same time  points. 
14.2.9  Recurrence  
Recurrence will be assessed at the 25 -Day FU visit ([ADDRESS_973995]  dose) 
for subjects with VVC and at the 6- Week FU (42 days after EOT) for all other subjects as a 
secondary efficacy endpoint. For CPA subjects, recurrence will also be assessed at Day 180.  
14.2.10  Survival  
Survival status (collected as ACM ) will be recorded at Day 30 for IC/cand idemia  subjects and at 
Day 42 for all diseases . ACM will be also recorded at Day 84 for subjects with IPA, 
disseminated/invasive dimorphic fungi and other emerging fungi, and at Day 90, Day [ADDRESS_973996] has died, the date and cause of death along with the reporting of SAE details will be 
recorded on the eCRF.  
14.2.11  Assessment of Efficacy 
Efficacy procedures will depend on each  fungal disease. Efficacy will be assessed primarily in 
terms of Global Response  at TOC for VVC , CMC, CPA and ABPA, and at EOT for all other 
fungal diseases . Global Response at other time  points and Clinical Response and Mycological 
Response will also be assessed as secondary endpoints. In addition, secondary e fficacy 
assessments will include disease -specific endpoints for selected fungal diseases . See Section  14.2  
for detailed efficacy procedures and Section  18.4.1 for a detailed discussion of efficacy 
assessments.  
The following study procedures will be performed to assess treatment outcome for all subjects:  
• Clinical signs and symptoms of fungal disease ( Section  14.2.1)  
• Mycological testing (including, but not limited to, fungal cultures, T2 testing , KOH and 
other fungal stains) ( Section  14.2.2)  
• Radiological assessments including esophagoscopy and other imaging scans, as applicable 
(e.g., X -ray, ultrasound, CT and MRI) ( Section  14.2.3 and Section  14.2.5)  
• Serological testing (including, but not limited to, GM, Cocci dioides  titers, or ß -D glucan 
level s) (Section  14.2.4)  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 68 Additional procedures ( i.e., spi[INVESTIGATOR_038], SGR Q, 6-Minute W alk Test and MRC Dyspnea Scale) 
will be conducted for selected fungal diseases.  See Section 14.2.6, Section  14.2.7 and 
Section  14.2.8, respectively.  
14.3 Safety Procedures  
14.3.1  Vital Signs  
Vital signs, including blood pressure (systolic and diastolic), heart rate, respi[INVESTIGATOR_697], weight 
and body temperature, will be measured at Screening, Baseline/Day 1, EOT and unscheduled visits as appropriate. For CPA subjects, weight will also be determined at the Day [ADDRESS_973997] blood drawn on Day 90 and 
Day 180 for albumin, platelet count, CRP and plasma viscosity assessment. 
For VVC subjects, safety labs will be collected at Screening, EOT (Day 7)  and 25- Day FU ([ADDRESS_973998] dose).  Safety labs will be repeated at any unscheduled visit, if applicable.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 69 The following laboratory parameters will be determined:  
Hematology  
 White blood cell (WBC) counta  Hemoglobin  
 Red blood cell (RBC) count   Hematocrit  
 Platelet countb  C-reactive proteinb 
  Plasma viscosityb 
a: Differential WBC count will include percentages for segmented neutrophils, lymphocytes, 
monocytes, eosinophils and basophils, and absolute counts for neutrophils, lymphocytes, 
monocytes, eosinophils and basophils.  
b: On Day 90 and Day 180 for CPA subjects only.  
Blood Chemistry  
 Sodium   Glucose  
 Potassium   Albumina 
 Alkaline Phosphatase   Aspartate aminotransferase (AST/SGOT)  
 Chloride    Alanine aminotransferase (ALT/SGPT)  
 Blood urea nitrogen (BUN)   Gamma glutamyl transferase (GGT)  
 Creatinine   Lactate dehydrogenase (LDH)  
 Total creatine phosphokinase  (CPK)   Bilirubin (total, direct, and indirect)  
 Total protein   Prothrombin ( PT) and international 
normalized ratio ( INR) 
a: On Day 90 and Day 180 for CPA subjects only  if still on treatment.  
 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 70 Urinalysis  
 Appearance (clarity, color)   Glucose   
 Specific gravity   Ketones   
 pH  Protein   
 Blood   Leukocytes   
 Bilirubin    Urobilinogen  
 
Reflex Microscopic Evaluation  
 Bacteria   Mucous  
 Casts   RBC 
 Crystals   WBC 
 Epi[INVESTIGATOR_1663]   
14.3.[ADDRESS_973999] observation in the study. AEs and SAEs will be reviewed 
at all scheduled and unscheduled study visits from the time  the informed consent is signed. See 
Section 16.0 for details regarding safety assessment and monitoring. 
14.4 Pharmacokinetic Procedures  
For subjects who are willing to participate in the PK sampling, u p to three (3) blood samples should 
be collected at the following visits and sampling windows: Day 2 (one sample collected anytime post dosing), Days 3 to 5 (one sample collected predose on any of these days), and Days 7 to 10 (one sample collected predose on any of these days). Additional blood PK samples will be collected when clinically indicated.  
Procedures for collecting, storing, and shippi[INVESTIGATOR_714993]. The sparse samples collected in this study will be analyzed using Population PK (Pop PK) analysis methods to estimate PK parameters (C
max, AUC, clearance/fraction absorbed [CL/F]) 
as applicable. Further analysis of possible metabolites may be performed.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3 Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 71 In addition to blood samples, other fluid and tissue samples may be collected for ibrexafungerp 
PK determination when clinically indicated.  Tissue samples collected as part of SOC procedures 
(e.g., biopsies) may be sent for drug concentration analysis, when available.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 72 15.0 Study Schedules 
Detailed schedules of all study visits and procedures for all subjects (except VVC subjects) are presented in  Table 14 and detailed 
schedules of all study visits and procedures for VVC subjects are presented in Table 15 . 
Table 14 Schedule of Treatment Visits and Procedures (All Fungal Diseases Except VVC)  
|PROCEDURE  
Visit  Screena BL/ 
D1a D2 
(PK 
Only)  D3-
D5 D7-
D10 Study Day 
14 and 
then 
Every 14 
days 
during Tx   D42 D84t  
D90u 
 D120  D180  EOT  Unsch.  
Visits  FU 1b 
(6-
WK)  FU 2 - 
FU 3b 
Days (allowable window)  -1 (-3) Prior to 
Tx  ±2 d ±2 d  ±2 d ±7 d ±7 d  ±7 d ±14 d  ±14 d  ±3 d AP ± 7d AP 
GENERAL   
Informed Consent  X               
Subject Enrollment and ID Assignment  X               
Medical History and Demographics  X               
Inclusion/Exclusion Criteria  X X              
Pregnancy Tests X           X    
Prior and Concomitant Medications  X ------------------------------------------------------------------------------------------------------------------------- X  
Study Drug Dispensingc  X    X          
Study Drug Collection and 
Accountability Review       X      X X   
Study Drug Dosing   X X X-------------------------------------------------------------------------- Xd    
Subject Diary Dispensing and 
Collection   X    X      X X   
EFFICACY   
Targeted PE including S&Sv X X    X Xd Xd Xe,f  Xe,f Xd  Xd Xf 
Mycological Testingg,j Xd Xd  Xd  Xd Xe  Xe Xd  Xd  
Imagingh Xd,r      Xd Xd Xe,f  Xe,f Xd,i  Xd,i  
Serological Testingj,k Xd Xd   Xd  Xd Xd Xe,f  Xe,f Xd  Xd Xf 
Esophagoscopyl Xm      Xl     Xl Xl  Xl  
Spyrometry Xf Xf     Xf         
SGRQ Xe Xe       Xe  X e Xe  Xe  
6-Minute Walk Test Xe Xe       Xe  Xe     
MRC Dyspnea Scale  Xe Xe       Xe  X e     
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 73 |PROCEDURE  
Visit  Screena BL/ 
D1a D2 
(PK 
Only)  D3-
D5 D7-
D10 Study Day 
14 and 
then 
Every 14 
days 
during Tx   D42 D84t  
D90u 
 D120  D180  EOT  Unsch.  
Visits  FU 1b 
(6-
WK)  FU 2 - 
FU 3b 
Days (allowable window)  -1 (-3) Prior to 
Tx  ±2 d ±2 d  ±2 d ±7 d ±7 d  ±7 d ±14 d  ±14 d  ±3 d AP ± 7d AP 
Assessment of Recurrence            Xe   X  
Subject Status (alive/ deceased)        X Xo Xe,f Xe, f Xe, f     
Assessment of Efficacy        Xd Xd Xd  Xd Xd  Xd Xf 
SAFETY   
Vital Signs  X X         Xp X X   
General Physical exam  X           X  X  
Clinical Laboratory Safety Assessments  X     X n X n X n X n, e Xn X n,e X Xn Xn  
AEs X----------------------------------------------------------------------------------------------------------------------------- ------- X 
PHARMACOKINETIC   
PK Assessmentsq   X X X           
Abbreviations: AE = adverse event; ABPA = allergic bronchopulmonary aspergillosis; AP = as applicable ; CPA=chronic pulmonary aspergillosis;  d = day; D = Day; 
EC=esophageal candidiasis; eCRF=electronica case report form; EOT = End of Treatment; FU = Follow-up; ID = identification; IPA = invasive pulmonary aspergillosis; 
MRC = Medical Research Council; PK=pharmacokinetic; Screen. = Screening; S&S = signs and symptoms; SGRQ = St. George’s Respir atory Questionnaire; Tx = 
treatment; Unsch. = unscheduled; W = Week.  
Note: Study days, weeks and months are counted relative to the first dose of study drug (Baseline [Day 1]). For FU visits, we eks, months and years are counted relative to the 
EOT visit.  
a. Screening and Baseline (Day 1) may occur on the same day.  
b. FU visits will occur 6 weeks (6 -Week FU = FU 1), 3 months (3-M onth FU = FU 2) and 6 months (6-M onth FU = FU 3) after the EOT visit. FU visits FU [ADDRESS_974000] infections, urine samples for fungal cultures are recommended to be collected every 48 -72 hours until negative.  
h. In addition to the scheduled time points, imaging scans will be collected anytime during therapy, as clinically indicated.  
i. The window for EOT imaging may range from ± 3 to ± 7 days, depending on fungal disease.  
j. For subjects diagnosed exclusively by ß -D-glucan tests, the diagnosis should be based on two consecutively positive T2 or ß -D-glucan tests. For those subjects diagnosed 
based on positive T2 tests, samples for T2 testing will be collected every 48 hours until negative. For those subjects diagnosed based on positive  ß-D-glucan tests, samples 
for ß -D-glucan testing will be collected every 72 hours until negative.  
k. For disseminated/invasive dimorphic fungi subjects, serological tests may be conducted at other time points, as clinically indicated.  
l. For EC subjects only.  A repeat esophagoscopy is required at EOT for all subjects , if allowable per SOC practice. Additional esophagoscopi[INVESTIGATOR_714994] 
[ADDRESS_974001] practices.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 74 |PROCEDURE  
Visit  Screena BL/ 
D1a D2 
(PK 
Only)  D3-
D5 D7-
D10 Study Day 
14 and 
then 
Every 14 
days 
during Tx   D42 D84t  
D90u 
 D120  D180  EOT  Unsch.  
Visits  FU 1b 
(6-
WK)  FU 2 - 
FU 3b 
Days (allowable window)  -1 (-3) Prior to 
Tx  ±2 d ±2 d  ±2 d ±7 d ±7 d  ±7 d ±14 d  ±14 d  ±3 d AP ± 7d AP 
m. For subjects who have EC, results of the most recent esophagoscopy that confirmed the diagnosis must be available for Screeni ng. A repeat esophagoscopy is not required at 
Screening if the subject’s signs and symptoms of EC have persisted since initial diagnosis.  
n. If clinically indicated.  
o. For IPA subjects, subjects with disseminated/invasive dimorphic fungi and subjects with other emerging fungi.  
p. At Day 180, weight will be determined for CPA subjects only. No other vital sign measurements will be collected for CPA or any other subjects.  
q. Sparse PK samples for Population PK analysis will be collected during the following time windows on Day 2 (anytime post dosing); between Days 3 to 5 (predose) and 
between Days 7 to 10 (predose).  Additional blood PK samples will be collected when clinically indicated.  The time of dosing and sample collection must be recorded on the 
subject diary and eCRF.  In addition to blood samples, other fluid and tissue samples may be collected for ibrexafungerp PK determination when clinica lly indicated .  Tissue 
samples collected as part of SOC procedures (e.g., biopsies) may be sent for drug concentration analysis, when available.  
r. Baseline radiological assessments for invasive fungal disease should be performed ideally within 72 hours of Screening. However, assessments performed up to 7 days before/after the first administration of study medication may be used to confirm the diagnosis of the fungal disease if none exists within the ideal window . 
s. Pregnancy tests may be conducted more often (e.g., on a monthly basis), per local regulations . 
t. For CMC D84 is TOC  unless EOT occurs first  
u. For CPA and ABPA D90 is TOC  unless EOT occurs first  
v. Targeted Physical Examinations (clinical evaluation of signs and symptoms) should be performed if subject comes in for PK assessments  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 75 Table 15 Schedule of Treatment Visits and Study Procedures for VVC  
Study Visit/  
Day Screena BL/ 
Day 1a D4 EOT 
D7 TOC  
D17 25-
DAY 
FU 
D32b 35-
DAY 
FUc 
D42 Unsch  
Visits  
Study Procedures  -1 (-3) Prior 
to Tx   Phone/ 
On-sitec ± 3 
days  Phone/  
On-
sitec  
GENERAL   
Informed Consent  X        
Subject Enrollment and ID 
Assignment  X        
Medical History and 
Demographics  X        
Inclusion/Exclusion Criteria  X X       
Pregnancy Test  X        
Prior and Concomitant 
Medications  X------------------------------------------------------------X X 
Study Drug Dispensing   X       
Study Drug Collection and 
Review          
         
Subject Diary Dispensing and 
Collection   X   X    
EFFICACY   
Targeted PE including 
Clinical Evaluation of Signs 
and Symptoms of Infection  X X  X X X If 
applic.d  
Mycological Testing (fungal 
culture)  X If 
applic.   X X X If 
applic.d If 
applic.  
Assessment of Recurrence       X   
Subject Status (alive/ 
deceased)        X  
Assessment of Efficacy     X X X X  
SAFETY   
Vital Signs  X X  X    X 
General Physical exam  X   X     
Clinical Laboratory Safety 
Assessments  X   X  X  If 
applic.  
Adverse events  X------------------------------------------------------------------------ X 
PHARMACOKINETIC   
PK Assessmentse   Xe Xe     
Abbreviations: applic . = applicable; BL = Baseline; D = day; eCRF = electronic case report Form; 
EOT = end of treatment; FU = Follow -up; ID = identification; PE = physical exam; PK = 
pharmacokinetic; Screen = Screening; TOC = test of cure; Tx = treatment; Unsch. = unscheduled.  
a. Screening and Baseline/ Day 1 can occur on the same day.  
b. The 25- Day FU visit will occur on study Day 32 (i.e., [ADDRESS_974002] dose of study 
drug and 25 days after EOT). 
c. The 35 -Day FU visit will occur on study Day 42 (i.e., [ADDRESS_974003] dose of study 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 76 Study Visit/  
Day Screena BL/ 
Day 1a D4 EOT 
D7 TOC  
D17 25-
DAY 
FU 
D32b 35-
DAY 
FUc 
D42 Unsch  
Visits  
Study Procedures  -1 (-3) Prior 
to Tx   Phone/ 
On-sitec ± 3 
days  Phone/  
On-
sitec  
drug and 35 days after EOT ). This will be a telephone call and only a full on -site visit if the 
subject is symptomatic.  
d. Vaginal examination and samples for mycological testing to be done if the subject is still 
symptomatic.  
e. For subjects who give consent, sparse PK samples for Population PK analysis should be 
collected during the following time windows between Days 3 to 5 (predose) and between 
Days 7 to 10 (predose). The time of dosing and sample collection must be recorded on the 
subject diary and eCRF.  Additional PK samples will be collected when clinically indicated.  
16.[ADDRESS_974004] medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom or disease 
temporally associated with the use of a study drug/study intervention, whether or not related to the study drug/study intervention. 
Any laboratory abnormality that is  deemed to be clinically significant in the opi[INVESTIGATOR_714995] , whether or not 
it is related to the study drug. For non- fungal infection- related AEs (e.g., bacterial sepsis, 
bacterial intra- abdominal abscess) the positive cultures related to the AE  should also be 
recorded on the eCRF.  
Stable chronic conditions that are present prior to clinical trial enrollment and do not 
worsen are not considered AEs  and will be accounted for in the subject ’s medical history.  
The following can be considered AEs: 
• An exacerbation of a pre- existing illness  
• An increase in frequency or intensity of a pre -existing epi[INVESTIGATOR_3756] 
• A condition detected or diagnosed after the initiation of treatment with study 
medication, even though it may have been present prior to the start of the study 
• Continuous persistent disease or symptoms present at Baseline (Day 1) that worsen 
after signing the informed consent or following the initiation of treatment with 
study medication 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 77 The follow ing are not  considered AEs:  
• Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction or 
transfusion); the condition that leads to the procedure is an AE  
• Pre-existing disease or conditions present or detected at the start of the study that 
do not worsen  
• Situations where an untoward medical occurrence has not occurred (e.g., 
hospi[INVESTIGATOR_27352]/convenience 
admissions)  
• The disease being studied or signs or symptoms associated with the disease, unless more severe than expected for the subject ’s condition or a worsening of the disease 
being studied 
16.2 Definition of a Serious Adverse Event  
A SAE is defined as an AE meeting one of the following outcomes:  
• Death  
• Life-threatening event  
• Inpatient hospi[INVESTIGATOR_158979] 
• Persistent or significant disability/incapacity  or substantial disruption of the ability 
to conduct normal life functions  
• Congenital anomaly or birth defect  
Any other important medical event that may not result in one of the above outcomes may be considered a SAE  when, based upon appropriate medical judgment, the event may 
jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. 
A life -threatening AE is any AE that places the subject , in the view of the I nvestigator, at 
immediate risk of death from the AE as it occurred. It does not include an AE that, had it 
occurred in a more severe form, might have caused death.  
16.[ADDRESS_974005] (ECIs)  if they occur after dosing , 
and must be reported by [CONTACT_27438] : 
• ALT or AST >[ADDRESS_974006], if new compared to Baseline, confirmed by [CONTACT_15013] 
• ALT or AST >[ADDRESS_974007] for more than 2 weeks and if new compared to Baseline, 
confirmed by [CONTACT_715057], Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 78 • ALT or AST >[ADDRESS_974008] and total bilirubin >[ADDRESS_974009] and if new compared to 
Baseline, confirmed by [CONTACT_15013]  
• ALT or AST >[ADDRESS_974010], confirmed by [CONTACT_15013], with the appearance of 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)]  
16.[ADDRESS_974011] be 
reported to the Sponsor within 24 hours of the site becoming aware of the pregnancy.  If 
the pregnancy ends for any reason before the anticipated date, the Investigator should 
notify the Sponsor . At the completion of the pregnancy, the Investigator will document the 
outcome of the pregnancy. If the outcome of the pregnancy meets the criteria for immediate classification as an SAE (i.e., postpartum complication, spontaneous abortion, stillbirth, 
neonatal death or congenital anomaly), the I nvestigator should follow the procedures for 
reporting an SAE.  
16.6 Unexpected  Adverse Event  
An AE is considered “unexpected” if it is not listed in the I nvestigator’s Brochure  or is of 
greater specificity or severity than those that have been observed with the parti cular study 
drug being tested. For example, under this definition, hepatic necrosis would be unexpected 
(by [CONTACT_14213]) if the Investigator’s Brochure referred only to elevated hepatic enzymes or hepatitis.  Similarly, cerebral thromboembolism and cerebral vasculitis 
would be unexpected (by [CONTACT_14214]) if the Investigator’s Brochure listed 
only cerebral vascular accidents. "Unexpected," as used in this definition, also refers to 
AEs that are mentioned in the Investigator’s Brochure as occurring with a class of drugs or 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 79 as anticipated from the pharmacological properties of the drug but are not specifically 
mentioned as occurring with the particular drug under investigation. 
16.7 Grading of Adverse Events  
The severity (or intensity) of an AE refers to the extent to which it affects the subject ’s 
daily activities and will be classified by [CONTACT_57746], moderate or severe using 
the following criteria:  
• Mild: Awareness of sign or symptom, but easily tolerated. Not likely to require 
medical attention.  
• Moderate:  Discomfort enough to cause some interference with daily activity . May 
require medical intervention. 
• Severe:  Intense enough to disrupt daily activities . Likely requires medical 
intervention. 
Clarification of the difference in meaning between “severe” and “serious”  
The term “severe” is often used to describe the intensity (severity) of a specific event (as in mild, moderate or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). This is n ot the same as 
“serious”, which is based on the outcome or action criteria usually associated with events 
that pose a threat to life or functioning. Seriousness (not severity) serves as a guide for 
defining regulatory reporting obligations.  
16.8 Causality Assessment  
The Investigator will assess causality (i.e ., whether there is a reasonable possibility that the 
study drug caused the event) for all AEs and SAEs. The relationship will be characterized 
using the following classification:  
• Related:  The temporal relationship of the AE with the study drug makes causality 
possible  and less likely due to another cause such as other drugs, a surgical 
intervention or an underlying disease.  
• Not related:  The temporal relationship of the AE with the study drug makes 
causality improbable and can be due to another cause such as other drugs, a surgical 
intervention or an underlying disease.  
SCYNEXIS, Inc.  IND # 107,[ADDRESS_974012] occurred in baseline sign s and symptoms. 
All AEs and SAEs will be collected in the eCRF . 
For subjects who experience a severe AE or a SAE that is deemed related to the study drug, a blood sample should be drawn (if possible) for determination of the concentration of ibrexafungerp. 
16.[ADDRESS_974013]/Ethics Committee 
(IRB/EC) in accordance with its regulations and guidelines. 
16.11  Adverse Event and Serious Adverse Event Follow-up  
All AEs and SAEs will be followed up to resolution (the subject ’s health has returned to 
his or her baseline status or all variables have returned to normal) or until an outcome is reached, stabilization occurs (the Investigator does not expect any further improvement or 
worsening of the event) or the event is otherwise explained, regardless of whether the subject  is still participating in the study. All appropriate therapeutic measures should be 
undertaken and recorded. Where appropriate, medical tests and  examinations will be 
performed to document resolution of the event (s). 
16.12  Serious Adverse Event Reporting – Procedures for Investigators 
Initial Reports and Follow -Up SAE Reports : To report an SAE, the SAE eCRF form within 
the Electronic Data Capture (EDC) system must be completed. All SAEs, whether or not 
deemed drug- related or expected, must be reported  by [CONTACT_715058] [ADDRESS_974014] becoming aware of the event. The Investigator/qualified designee 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_974015].  
In case of any technical issues in EDC system, the investigator will fill the Paper SAE 
form, sign it and send the scanned copy via email to the dedicated centralized email ID:  
[EMAIL_436] or send via Fax [PHONE_11940]- 769-3213 within 24 hours of their 
awareness. Site can also reach out at AWINSA’s safety hotline +[ADDRESS_974016] be 
updated within 24 hours of knowledge/receipt of SAE follow -up information. 
Upon return of the availability of EDC system, the SAE information must be entered into 
the EDC system as soon as possible. The SAE form within the EDC system must be 
updated within 24 hours of knowledge/receipt of SAE follow -up information. 
 
16.[ADDRESS_974017] 
Management  
17.1 Data Collection and Reporting  
Data for this study will be collected  using eCRFs . The I nvestigator and study site staff will 
receive training  regarding the completion of the e CRF . Visit- specific data should be 
entered into the e CRF  and be ready for review as soon as possible, but no later than 5 days 
after each  visit/time  point . 
All protocol -required information collected during the study must be entered by [CONTACT_715059] e CRF . All data entry, 
modification  or deletion will be recorded indicating the individual subject , original value, 
the new value, the reason for change, who made the change, and when the change was 
made.  All data changes will be clearly indicated with a means to locate prior values. The 
Investigator will maintain a list of individuals who are authorized to  enter or correct data 
on the e CRFs . 
The Investigator or, if allowed per local regulations, a designated sub- investigator, 
following review of the data in the eCRF, will confirm the validity of each subject’s data by [CONTACT_17094]. 
SCYNEXIS, Inc.  IND # 107,[ADDRESS_974018] in accordance with accepted regulatory requirements. The P rincipal Investigator 
(PI) must make all the subject data available to the monitor for review during the planned 
site monitoring visits. Arrangements for monitoring visits will be made in advance, except in emergency cases.  
17.3 Investigator Study Files  
The PI [INVESTIGATOR_27357] -related documents in study files. The 
Sponsor will notify the PI  [INVESTIGATOR_27358]. The 
following documents will be kept in the study files or be readily accessible:  
• original protocol and all amendments;  
• signed agreement or protocol;  
• signed and dated study staff roles and responsibilities log;  
• copy of the current curriculum vitae  of the PI  [INVESTIGATOR_714996] s ub-investigators ; 
• IRB/EC membership list and all IRB/EC approvals for the protocol and amendments, 
informed consent documentation and all updates, advertisements, and written information provided to subject s; all IRB/EC correspondence; documentation that the 
Investigator’s Brochure  and subsequent revisions have been submitted to the IRB/EC; 
documentation that all SAEs and any periodic safety reports have been submitted to the IRB/EC; and annual IRB/EC renewals (as required);  
• updated laboratory certification and the laboratory’s normal values (covering the entire time interval of the study for all laboratory tests conducted during the study);  
• all confirmations of investigational drug receipt, drug accountability logs and drug 
return records;  
• a CD  or DVD containing final subject  CRF  data;  
• all correspondence to or from the Sponsor or its designees;  
• blank informed consent form;  
• Investigator’s Brochure;  
• subject  screening log;  
• subject  list (contains subject  initials and /or protocol -specific subject  number);  
• all subject s’ original signed informed consents; and  
• monitoring visit log.  
17.[ADDRESS_974019]. These documents should be retained for a 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 83 longer period, however, if required by [CONTACT_195843] . 
The Sponsor will inform the PI /institution in writing of the need for record retention and 
will notify the PI /institution in writing when the trial- related records are no longer needed.  
An investigator who withdraws from the responsibility of maintaining study records or 
wishes to move them to a new location has the obligation to place them in safekeepi[INVESTIGATOR_714997]. 
18.0 Analytical Plan  
All statistical analys es will be performed using SAS® version 9.3 or later.  
Descriptive statistics (i.e., number of subjects, mean, standard deviation, median, minimum, maximum) will be presented for all continuous variables; number and 
percentage of subjects will be presented for categorical variables. For parameters measured 
over time, observed data and changes from B aseline will be described for each time point.  
All analyses for  ibrexafungerp  will present the results by [CONTACT_715018] , disease category  
and enrollment category .  Overall response will be present ed for all disease categories 
combined.  
Unless otherwise stated, data will be analyzed as is with no imputation.  Details of the 
statistical analysis will be provided in a statistical analysis plan, which will be approved 
prior to final database lock. 
18.[ADDRESS_974020] intolerance to or 
demonstrated toxicities resulting from an approved SOC  antifungal treatment.  
18.2 Analysis Populations  
The study populations to be used in the analyses are defined as follows:  
• Intent -to-Treat Population: The intent -to-treat (ITT) population will include all 
subjects who are enrolled in the study and receive at least 1 dose of study drug.  
• MITT: the Myco -ITT population will include al l ITT subjects with confirmed 
pathogens and who also had all necessary cultur es or mycology test s to estimate 
mycological response.  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 84 • Per-Protocol Population:  The per -protocol (PP) population will include all ITT 
subjects who receive enough study drug (ibrexafungerp) to enable clinical efficacy 
judgement as determined by [CONTACT_16009] , who have an EOT (TOC for VVC , CMC, CPA 
and ABPA ) assessment and who have no major protocol violations.  
• Safety Population:  The safety population will include all subjects who receive at least 
one dose of study medication and have at least one safety assessment post Baseline.  
• Pharmacokinetic Population: The PK population will include all enrolled subjects 
who provide at least one PK sample and no deviations significant enough to affect 
the interpretability of PK data.  
18.3 Interim Analyses and Supplemental Analysis  
No interim analyses are planned for this study.  If subjects on long- term treatment (CMC, 
ABPA and CPA) are ongoing at the time of planned data base lock, their data up to TOC visit will be included in the analyses, and data collected after TOC will be reported in a 
Supplementary Analysis.   
18.[ADDRESS_974021]’s 
enrollment reason will be assessed by [CONTACT_715016] : 
• Refractory  
• Intolerant  
• Resistant  (includes step -down cases)  
• Toxicities  
• Relapse  
18.4.2  Efficacy Assessments  
Response will be assessed by [CONTACT_715014]. The primary efficacy 
endpoint of the study is the percentage of subjects who achieve  Global Response at TOC  
for VVC (Day 17), CMC (Day 84), CPA (Day 90), ABPA (Day 90) and at EOT for all 
other diseases , as determined by [CONTACT_715060]. In cases where EOT for CMC, CPA or ABPA 
subjects occurs before the planned TOC days, EOT will be TOC assessment. Secondary 
efficacy endpoints include  the percentage of subjects who achieve Global Response, 
Clinical Respo nse and Mycological Response by [CONTACT_715061] ( type 
of fungal disease ) at several time  points  as assessed by [CONTACT_715014] . 
The percentage of subjects with a recurrence, ACM and time to death will also be assessed.  
See Section  9.0 for detailed study endpoints and Section  14.2 for efficacy procedures.   
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 85 Efficacy outcomes will be based on the definitions captured in Table 16  and Table 17 . 
Criteria for the DRC assessment of response will be further detailed in the DRC Charter. 
Criteria for the Investigator is outlined in Section 18.4.5. 
[IP_ADDRESS]  Efficacy Time Points and Outcome Definitions  
The efficacy time points and outcome definitions for  the primary and secondary endpoints 
are detailed in Table 16 .  
 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 86 Table 16  Efficacy Tim e Points and Outcome Definitions for Primary and Secondary Endpoints  
Fungal disease  Primary time  point  
 (Secondary time  points)  Primary Outcome Definition  Secondary Outcome Definitions  
(disease -specific outcome definitions, if not previously defined)a, e 
Acute or chronic 
invasive candidiasis, 
including candidemia  EOT  
(EOT, Day 42, 6 -Week 
FU) 
 Global Response = Global 
Response  based on MSG -
EORTC outcome response 
definitionsb, e Global Response (as defined)  
Clinical Response  (including radiological outcome) and 
Mycological Response  = Clinical and Mycological Responses 
based on MSG -EORTC outcome response definitionsb 
Acute  or chronic severe 
mucocutaneous candidiasis , including:  
• Esophageal 
candidiasis (EC)  
• Oropharyngeal candidiasis (OPC)  
• Chronic 
mucocutaneous 
candidiasis (CMC)  
• Vulvovaginal candidiasis (VVC)  For EC and OPC : 
EOT  
(EOT, Day 42, 6 -Week 
FU) 
 For EC and OPC:  
Global Response = Global 
Response  based on MSG -
EORTC outcome response 
definitionsb For EC and OPC:  
Global Response (as defined)  
Clinical Response  (including radiological outcome  if done as 
SOC ) and  
Mycological Response  = C linical and Mycological Responses 
based on MSG -EORTC outcome response definitionsb 
For CMC:  
TOC (Day [ADDRESS_974022])  
(EOT, Day 42, Day 84, 
6-Week FU)  
 
 For CMC:  
Global Response = Global 
Response  based on MSG -
EORTC outcome response 
definitionsb For CMC:  
Global Response (as defined)  
Clinical Response  (including radiological outcome) and 
Mycological Response  = Clinical and Mycological Responses 
based on MSG -EORTC outcome response definitionsb 
For VVC:  
TOC (Day 17)  
(Day 17, 25- Day FU 
[Day 32], 35 -Day FU 
[Day 42])  For VVC:  
Global Response = Clinical 
Success , defined as at least 50% 
reduction from baseline in total composite score, without use of 
additional antifungal  For VVC:  
Global Response  (as defined)  
Clinical Response = Clinical Cure , defined as complete resolution 
of all signs and symptoms  (VSS = 0)  without use of additional 
antifungal (Reference FDA guidelines 2016) ; Resolved VVC 
infection (score <3)  
Mycological Response  = m ycological eradication for the baseline 
pathogen  
Symptom resolution at FU  ( clinical cure, resolved infection, 
clinical success)  
Responder outcome (Clinical Cure and mycological eradication) 
at TOC and FU   
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 87 Fungal disease  Primary time  point  
 (Secondary time  points)  Primary Outcome Definition  Secondary Outcome Definitions  
(disease -specific outcome definitions, if not previously defined)a, e 
Disseminated/invasive 
dimorphic fungi:  
• Coccidioidomycosis  
• Histoplasmosis  
• Blastomycosis   EOT  
(EOT, Day 42, Day 84, 
6-Week FU)  
 Global Response = Global 
Response  based on MSG -
EORTC outcome response definitions
b Global Response (as defined)  
Clinical Response  (including radiological outcome) and 
Mycological Response  = Clinical and Mycological Responses 
based on MSG -EORTC outcome response definitionsb 
Chronic Pulmonary 
Aspergillosis (CPA)  TOC (Day [ADDRESS_974023] ) 
(EOT, Day 90, Day 180, 
every 3 months while on Tx if beyond Day 180, 6-Week FU)  
 Global Response = Successful 
Overall CPA Response, 
defined as  subjects who are 
judged to have shown improvement of the disease by [CONTACT_2085], radiological and 
mycological parameters and 
those that achieved stable disease after entering the study with a rapi[INVESTIGATOR_714998].  Global Response  (as defined)  
Clinical Response  = defined as a decrease in the St. George’s 
Respi[INVESTIGATOR_6015] (SGRQ) score by ≥4 points  
SGRQ outcomes will be categorized as follows:  
• Improvement: Decrease in SGRQ by ≥4 points  
• Stability: Change in SGRQ between: increase by <4 to 
decrease by <4  
• Deterioration: Increase in SGRQ by ≥[ADDRESS_974024] scan and 
will be categorized as:  
• Radiological Improvement: >30% decrease in volume of 
fungus ball AND/OR 20% decrease in cavity wall thickening 
AND/OR 20% improvement in pleural thickening.  
• Radiological Deterioration: >30% increase in volume of fungus ball AND/OR 20% increase in cavity wall thickening AND/OR 20% increase in pleural thickening. Subjects with measurements fulfilling any of the criteria for radiological 
deterioration will be cla ssified as deteriorated, even if they also 
fulfil a criterion for improvement.  
• Radiological Stability: No notable change in radiological 
image.  
 
Mycological Response  =  
reduction in Aspergillus  IgG by ≥20%  
AND/OR  
negative sputum culture for Aspergillus  
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 88 Fungal disease  Primary time  point  
 (Secondary time  points)  Primary Outcome Definition  Secondary Outcome Definitions  
(disease -specific outcome definitions, if not previously defined)a, e 
Allergic 
Bronchopulmonary 
Aspergillosis (ABPA)  
 TOC (Day [ADDRESS_974025] ) 
(EOT, Day 90, Day 180, 
every 3 months while on Tx if beyond Day 180, 
6-Week FU)  
 Global Response = Composite 
ABPA Response , defined as 
>75% improvement from 
Baseline in cough and dyspnea, 
partial (≥50%) or total clearance of chest radiographic lesions (if present prior to treatment 
initiation), AND decline in 
serum total IgE by ≥ 25%
c,d Global Response (as defined)  
Clinical Response  = >75% improvement from B aseline in cough 
and dyspnea AND partial (≥50%) or total clearance of chest radiographic lesions (if present prior to treatment initiation  
Mycological Response  =
  decline in serum total IgE by ≥ 25%   
 
Disease -specific outcome definitions not previously defined:  
Clinical Improvement  in cough and dyspnea is documented on a 
four point scale, as follows:  
1. no improvement or worsening;  
2. mild improvement (<25% reduction from B aseline);  
3. moderate improvement (25% -75% reduction from B aseline); 
and 
4. significant improvement (>75% reduction from B aseline).  
ABPA exacerbation : clinical and/or radiological worsening along 
with doubling of the serum total IgE over the previous B aseline 
value  
Asthma exacerbation: clinical worsening in cough and dyspnea 
with no radiological worsening or doubling of serum total IgE . 
Invasive Pulmonary 
Aspergillosis (IPA)  
 EOT  
(EOT, Day 42, Day 84, 
6-Week FU)  
  Global Response = Global 
Response  based on MSG -
EORTC outcome response 
definitionsb Global Response (as defined)  
Clinical Response  (including radiological outcome) and 
Mycological Response  = Clinical and Mycological Responses 
based on MSG -EORTC outcome response definitionsb 
• Other emerging fungi 
including yeasts and molds  (e.g., 
sachromycetes , 
scopulariopsis ) EOT  
(EOT, Day 42, Day 84, 6-Week FU)  
 Global Response = Global 
Response  based on MSG -
EORTC outcome response 
definitionsb Global Response (as defined)  
Clinical Response  (including radiological outcome) and 
Mycological Response  = Clinical and Mycological Responses 
based on MSG -EORTC outcome response definitionsb 
Abbrev: ABPA = allergic bronchopulmonary aspergillosis; CMC=chronic mucocutaneous candidiasis; CPA=chronic pulmonary aspergil losis; CT = 
computed tomography; EC=esophageal candidiasis; EOT=end of treatment; FDA = Food and Drug Administration; FU = Follow -up; Ig = immunoglobulin; 
IPA = invasive pulmonary aspergillosis; MSG -EORTC = Mycosis Study Group and European Organization for Research and Treatment of Cancer 
SCYNEXIS, Inc.  IND # 107,521  
PROTOCOL SCY -078-30 1 AM3  Version 4.0 
21 NOV 2022  CONFIDENTIAL  Page 89 Fungal disease  Primary time  point  
 (Secondary time  points)  Primary Outcome Definition  Secondary Outcome Definitions  
(disease -specific outcome definitions, if not previously defined)a, e 
Consensus Criteria; OPC=oropharyngeal candidiasis; SGRQ = St. George’s Respi[INVESTIGATOR_6015]; TOC = Test of Cure; Tx = tr eatment; 
VVC=vulvovaginal candidiasis.  
a: See disease- specific secondary endpoints in Section 9.2.2 for disease -specific time points.  
b: Segal BH,  Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study 
Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis. 2008;47(5):674– 683. Doi:10.1086/590566 
c: Agarwal R, Dhooria S, Singh Sehgal I, et al. A randomized trial of itraconazole vs prednisolone in acute -stage allergic bronchopulmonary aspergillosis 
complicating asthma. Chest. 2018;153(3):656 -664. Doi:10.1016/j.chest.2018.01.005.  
d: Agarwal R, Dhooria  S, Singh Sehgal I, et al. A randomized trial of voriconazole and prednisolone monotherapy in acute -stage ABPA complicating 
asthma. Eur Respir J. 2018; in press. Doi:10.1183/13993003.[ZIP_CODE]- 2018.  
e: When the MSG_EORTC criteria is not fully applicable for a specific case, the DRC will adjudicate outcome based on acceptable criteria, per their 
judgement.  
 
 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 90 As specified in Table 16 , the EORTC -MSG12 outcome definitions will be used for the 
assessment of efficacy for all fungal diseases except for ABPA, CPA , CMC  and VVC. 
EORTC -MSG general criteria for global responses to antifungal therapy are provided in 
Table 17 .  
 
Table 17 EORTC -MSG General Criteria for G lobal Responses to A ntifungal 
Therapy  with adaptations a and b  
Global Response  Outcome Criteria  
Success  Complete Response: Survival within the prespecified period of 
observation, resolution of all attributable symptoms and signs of 
disease and radiological abnormalities, and mycological evidence 
of eradication of disease  
a For subjects  who were enrolled for step -down therapy  and who 
were asymptomatic at baseline : no new symptoms or signs 
suggestive of disease and no new  positive cultures.  
Partial Response:  Survival within a prespecified period of 
observation, improvement in attributable symptoms and signs of 
disease and radiological abnormalities, and evidence of clearance 
of cultures or reduction of fungal burden, and no new positive 
cultures, as assessed by a quantitative and validated laboratory 
marker  
Failure  Stable Response: Survival within a prespecified period of 
observation and minor or no improvement in fungal disease, but no evidence of progression, as determined on the 
basis of a 
composite of clinical, radiological and mycological criteria.   
Progression of Fungal Disease: Evidence of progressive fungal 
disease based on a composite of clinical, radiological and 
mycological criteria  
Death: Death during the prespecified period of evaluation, 
regardless of attribution 
b Not Evaluable  Outcome cannot be assessed due to missing data  
a Definition added for subjects enrolled for step- down therapy 
b Category added for non- evaluable subjects due to missing data  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 91 When the MSG_EORTC criteria is not fully applicable for a specific case, the DRC will adjudicate 
outcome based on acceptable criteria, per their judgement.  
[IP_ADDRESS]  Recurrence  
Recurrence is defined as Global Response at EOT but re- emergence of the baseline fungal 
disease during the post treatment follow -up. Re-emergence of the fungal disease is required 
to be with the same species and involving the same site that was initially identified at 
Baseline.  
Recurrence will be assessed at the 25 -Day FU visit ([ADDRESS_974026]  
dose) for subjects with VVC and at the 6- Week FU (42 days after EOT) for all other 
subjects as a secondary efficacy endpoint. For CPA subjects, recurrence will also be 
assessed at Day 180.  
[IP_ADDRESS]  Survival  
Survival status (collected as ACM) will be recorded at Day 30 for IC/Ca ndidemia  and at 
Day 42 for all. ACM will be also recorded at Day 84 for subjects with IPA, 
disseminated/invasive dimorphic fungi and other emerging fungi, and at Day 90, Day 120 and Day 180 for subjects with CPA and A BPA. 
Information on survival status on Day 30 (IC/Candidemia ), Days 42, 84, 90, [ADDRESS_974027] has died, the date and cause of death along with the reporting of SAE details will be recorded on the eCRF.  
18.4.3  Efficacy Analyses  
The primary efficacy endpoint  is the percentage of subjects with Global Response (clinical, 
radiological and mycological) as determined by [CONTACT_941] D RC at TOC for VVC (Day 17), CMC  
(EOT or Day 84) , CPA and ABPA ( EOT or Day 90)  (whichever comes first) , and at EOT  
for all other diseases . Results  will be presented separately for each disease category along 
with a 95% confidence interval (CI) for a single binomial proportion in the ITT , Myco -ITT 
and PP populations  where sufficient cases are available. In addition, the number of subjects 
with a successful response across all disease categories will be summarized as a response 
rate and 95% CI.  
Secondary endpoints will be presented with 95% CIs for the ITT , Myco -ITT and PP 
populations using the same approach as for the primary endpoint. 
The estimated response rates and 95% C Is outlined will also be assessed relative to the 
external data described in S ection 10.1. 
The percentage of subjects surviving at the defined time  points will be presented for the 
ITT, Myco -ITT and PP populations. A Kaplan Meier plot will also be produced 
SCYNEXIS, Inc.  IND #107,[ADDRESS_974028] was known to be alive.  
For primary and overall secondary endpoints, presentations by [CONTACT_715027], 
if numbers allow.  
Data for all subjects will be presented by [CONTACT_715018], disease category , reason for 
enrollment and receipt of combination therapy (Yes/No). If data are missing and the subject 
has not been deemed a success or failure the outcome will be categorized as unknown/not evaluable.  
18.4.[ADDRESS_974029] C Charter will provide detailed criteria to be used for the baseline and outcome 
analysis of subjects in this study. The analysis criteria will be based on EORTC -MSG 
Consensus Criteria12 for all diseases except ABPA, CPA , CMC  and VVC. Adaptations to 
the EORTC -MSG criteria adopted by [CONTACT_941] D RC will be documented in the DRC C harter.  
18.4.5  Investigator’s Assessment of Overall Response  
The Investigator will be asked to provide his/her opi[INVESTIGATOR_121479]’s response as 
follows:  
 
Clinical Response (all non- radiological clinical symptoms and physical findings) : 
1. Resolution of all attributable clinical symptoms and physical findings (i.e., 
resolution of all clinical symptoms and physical findings of fungal disease present 
at Baseline and/or resolution of those that appeared at a subsequent visit)  
2. Resolution of some attributable clinical symptoms and physical findings (i.e., 
resolution of some but not all clinical symptoms and/or physical findings of fungal disease present at Baseline and/or of those that appeared at a subsequent visit)  
3. No resolution of any attributable clinical symptoms and physical findings and/or worsening (i.e., no resolution or worsening of any clinical symptoms and/or physical findings of fungal disease present at Baseline and/or of those that appeared at a subsequent visit)  
4. Results not available/subject unevaluable (i.e., visit and/or assessment of clinical symptoms and physical findings of fungal disease was not performed at any time  
point)  
5. No attributable signs and symptoms at Screening (i.e., no clinical symptoms or 
physical findings of fungal disease present at Baseline)  
 
Radiological Response : 
 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 93 1. ≥90% improvement  
2. ≥50 to < 90% improvement  
3. ≥25 to < 50% improvement  
4. < 25% improvement  
5. No signs on radiological images at Screening  
6. Results not available (i.e., visit and/or radiological assessment was not performed 
at any time  point)  
 Mycological Response:  
1. Eradication (eradication of the original causative organism cultured or identified by [CONTACT_27183]/cytology/serology at Baseline)  
2. Presumed eradication (missing documentation of the eradication of the original causative organism at Baseline plus resolution of all or some clinical symptoms and physical findings of fungal disease present at Baseline and/or of those that appeared at a subsequent visit)  
3. Persistence (persistence of the original causative organism cultured or identified by [CONTACT_27183]/cytology at Baseline or emergence of a new causative organism)  
4. Presumed persistence (missing documentation of the persistence of the original causative organism at Baseline plus no resolution or worsening of any clinical symptoms and physical findings of fungal disease present at Baseline and/or of those that appeared at a subsequent  visit)  
5. No mycological follow -up results available, for whatever reason (no diagnostic 
test done at any time point)  
6. No mycological evidence at Screening (up to Day 7) ( any negative diagnostic 
test(s) obtained or not done at Baseline [from Screening up to Day 7, inclusive])  
Mycological response will be confirmed by [CONTACT_941] D RC and will include central laboratory 
results.  
If relevant mycology findings occur after successful mycological response (proven or 
presumed eradication), an evaluation will be made as to whether the infection is recurrent 
(same species as at B aseline) or emergent (different species compared with B aseline). 
Subjects with recurrent or emergent infection will be classified as mycological failure from 
the visit onwards where positive cultures were reported, i.e. positive cultures before the FU Visit will be categorized as mycological failure and overal l non -successful response on the 
primary efficacy assessment.  
18.5 Pharmacokinetics  
18.5.1  Pharmacokinetic Assessments 
See Section  14.4 for details.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 94 18.5.2  Pharmacokinetic Analyses  
The concentration versus time data from the sparse PK samples collected in this study will 
be analyzed using a Pop PK model to estimate Cmax, AUC and CL/F, as applicable.  
The PK analysis will be conducted on the PK Population. 
Further analysis of possible metabolites may be performed.  
18.6 Safety  
18.6.1  Safety Assessments  
Safety will be evaluated throughout the study, including the following parameters: AEs, 
treatment discontinuations, general physical examination, vital signs, safety laboratory 
tests and concomitant medications . Prior and concomitant medications are discussed in 
Section  13.1. Other s afety procedures are described in Section  14.3.  
18.6.2  Safety Analyses  
All safety analyses will be conducted in the safety population; all safety variables will be listed.  
Incidence and severity of treatment -emergent AEs, AEs leading to discontinuation and 
SAEs and their relationship to treatment will be summarized. Also data on AEs leading to 
death, AEs of special interest, AEs leading to withdrawal and AEs by [CONTACT_715062].  
Early discontinuation of study drug treatment will be presented and will include the reasons 
for and timing of such discontinuations. Abnormal physical examinations associated with 
adverse events will be listed. Concomitant medications will be summarized.  
Laboratory evaluations will be summarized as observed values and changes from Baseline; 
shifts with respect to the laboratory reference range will be summarized.  
Vital signs will be summarized as observed values and changes from Baseline.  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and presented by [CONTACT_6657].  Concomitant medications will be 
classified based on the World Health Organization´s (WHO) Drug Dictionary terminology. 
SCYNEXIS, Inc.  IND #107,[ADDRESS_974030] of the Study  
The study will be conducted in accordance with the protocol, the ethical principles 
established by [CONTACT_44484] (as amended in Fortaleza, Brazil, October 2013), 
the International Conference on Harmonisation (ICH) Good Clinical P ractice (GCP) 
Guidelines, the [LOCATION_002]  Code of Federal Regulations (CFR) sections that address 
clinical research studies, applicable European Union regulations and/or other national and 
local ethical and legal requirements, as applicable.  
19.[ADDRESS_974031] /Ethics Committee Review  
The PI [INVESTIGATOR_714999]/EC with all appropriate materials, including a copy 
of the subject ICF . The study will not be initiated until the PI  [INVESTIGATOR_715000]/EC, and copi[INVESTIGATOR_168902] . Appropriate reports on the progress of this 
study will be made by [CONTACT_978]  [INVESTIGATOR_27365]/EC, m edical monitor, and Sponsor in accordance 
with applicable government regulations and in agreement with policy established by [CONTACT_429] . 
19.[ADDRESS_974032]. In the case of a minor, according to the local definition (e.g., below 16 or 18 years 
of age), a parent or legal representative should also si gn and date the ICF. Additional local 
regulatory requirements may be applicable for participation of subjects below the age of consent. The original signed subject ICF will be retained with the study center’s records. 
Each subject will receive a copy of hi s or her signed subject ICF. In addition, the PI, or his 
or her designee, must document in the case history that informed consent was obtained 
before study participation.  
SCYNEXIS, Inc.  IND #107,[ADDRESS_974033] in vivo and/or in vitro  testing of new 
or existing medication antifungals or analysis of mechanisms of action/resistance.  
Human biological samples collected from this study such us plasma or tissue for PK determination of ibrexafungerp or its metabolites and/or fungal pathogen identification will be maintained in a central repository for as long as deemed useful for the speci fied research 
purposes.  
All samples will be identified only by a coded number to maintain subject confidentiality. Researchers requesting samples or information from the repository must have a research protocol approved by [CONTACT_3551] (IRB)/Ethics Committee (EC) . Human 
biological s amples will only be retained for subjects who provide consent for future use.  
19.[ADDRESS_974034] , except as necessary for monitoring by 
[CONTACT_7195], IRB/EC, the Food and Drug Administration ( FDA ), the Sponsor  or 
where required by [CONTACT_2371]. All local privacy laws must be followed.  
19.6  Study Termination  
The PI, the Sponsor , the FDA, and the IRB/EC each reserve the right to terminate the study 
in the interest of subjects’ safety and welfare. The S ponsor reserves the right to terminate 
the study at any time for administrative reasons.  
19.[ADDRESS_974035] be 
collected prior to study initiation and 1 year following the completion of the clinical trial.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 97 20.0 References 
1. Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of 
invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis  pneumonia . 
Swiss Med Wkly. 2016; 146:w14281. 
2. Magill SS, Edwards JR, Bamberg W, et al. Multistate point -prevalence survey of 
health care- associated infections. NEJM 2014;370:1198-208. 
3. Centers for Disease Control and Prevention [ Internet]. Atlanta, GA: Centers for 
Disease Control and Prevention. Fungal Diseases: Invasive Candidiasis Statistics; 
[updated 2016 Dec 12; cited 2016 Dec 27 ]; [about 5 screens ]. Available from: 
http://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html . 
4. Farmakiotis  D, Kyvernitakis A , Tarrand JJ  et al. Early initiation of appropriate 
treatment is associated with increased survival in cancer patients with Candida 
glabrata fungaemia: a potential benefit from infectious disease consultation. Clin 
Microbiol Infect [Internet]. 2015 [ cited 2016 Dec 27] ;21(1):79- 86. Available from: 
http://www.clinicalmicrobiologyandinfection.com/article/S1198 -743X(14)[ZIP_CODE]-
2/pdf . doi: 10.1016/j.cmi.2014.07.006. 
5. Larkin E, Hager C, Chandra J, Mukherjee PK, et al. The Emerging Candida auris : 
Characterization of Growth Phenotype, Virulence Factors, Antifungal Activity, and Effect of SCY -078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and 
Biofilm Formation. Antimicrob Agents Chemother. [ADDRESS_974036], et al. Clinical Practice Guideline for the 
Management of Candidiasis: 2016 Update by [CONTACT_228132]. CID 2016:62(4):e1-50. 
7. Perfect  JR, Marr  KA, Walsh  TJ, et al. Voriconazole Treatment for Less -Common, 
Emerging, or Refractory Fungal Infections. Clin Infect Dis 2003; 36 (9): 1122-1131. doi: 10.1086/374557. 
8. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet 2007; 369: 1519–27. 
9. Odabasi  Z, Mattiuzzi  G, Estey  E, et al. β- d - Glucan as a Diagnostic Adjunct for 
Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clin Infect Dis 2004; 39 (2): 199-205. doi: 10.1086/421944. 
10. CLSI. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27- S4. Clinical and 
Laboratory Standards Institute, Wayne, PA. 
11. European Committee on Antimicrobial Susceptibility Testing ( EUCAST ) 
Guidelines. 
12. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study 
outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and 
SCYNEXIS, Inc.  IND #107,[ADDRESS_974037] Dis. 2008;47(5):674–683. doi:10.1086/590566. 
13. Andes DR, Safdar N, Baddley JW et al. Impact of Treatment Strategy on Outcomes 
in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. Clinical Infectious Diseases 2012;54: 80:1110- 22. 
 
  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 99 21.0 Appendices 
21.1 Appendix A: Protocol Revision History  
21.1.1  Protocol Amendment 3 
Current Version and Date: Protocol Amendment 3 (Protocol Version 4.0) dated 
[ADDRESS_974038] 2019 (Amendment 2) listed 
below. 
Amended to include the bolded text and delete the strikethrough text  
Protocol Amendment 3  
Main affected 
Protocol Sections Change and Rationale  
o Synopsis  Updated based on changes listed in this Revision History  
o Background  Updated with more recent information  
o Study Objectives  
o Study Endpoints 
Overall Description 
of the study  Additions and clarifications as a pplicable for fungal diseases .  
Changes implemented throughout the document  
o Primary study 
objective  
 
 
o Primary endpoints To evaluate the efficacy of ibrexafungerp in the treatment of severe 
fungal diseases by a Data Review Committee (DRC) at the primary 
time point for the fungal disease  
 
Efficacy as measured by [CONTACT_715063] (Day 17), CMC (EOT or Day 84), CPA 
(EOT or Day 90) and ABPA (EOT or Day 90) (whichever comes 
first)  and at EOT for all other diseases as determined by a DRC  
o Overall secondary 
objectives and  
  
 
 
o Secondary 
endpoints o To determine the efficacy of ibrexafungerp by [CONTACT_715037]  
o To evaluate the efficacy of ibrexafungerp  by [CONTACT_715064] (refractory, resistance, relapse, intolerance, toxicity, need for oral therapy)   
 o ACM at Day 30 (Invasive candidiasis and candidemia) and  
Day 42 for all diseases  
o Disease specific 
secondary 
endpoints ADDED - Acute Invasive candidiasis / Candidemia  
o Completion of study drug antifungal treatment (i.e. no 
recurrence, no use of other antifungal treatment, no 
discontinuation for any reason) 
ADDED Acute or Chronic Severe Mucocutaneous Candidiasis  
o Percentage subjects with mycological cure at Day 84  
o Percentage subjects with clinical response by [CONTACT_2006] 30 and Day 
84 
SCYNEXIS, Inc.  IND #107,[ADDRESS_974039] a recurrence after TOC (VVC subjects) 
or EOT (other subjects), may be considered for re enrollment upon discussion with the sponsor  
Clarified combination therapy requirement  
 Ibrexafungerp given as combination therapy will be required for 
all subjects with refractory or relapsing IPA , mucormycosis and 
other molds with unpredictable ibrexafungerp activity.  
o Study Population 
and enrollment 
reasons Clarification of enrollment reasons: 
Subject has a documented eligible fungal disease that has been refractory or resistant to SOC, has relapsed after, or the subject 
has intolerance to or demonstrated toxicities resulting from an 
approved SOC antifungal treatment (as defined in Table 5). The subject is also eligible if, in the judgement of the Investigator, 
long-term IV antifungal therapy is not feasible or desirable due 
to clinical (isolate is resistant to or has a high MIC and is 
unlikely to respond to antifungal SOC) or logistical circumstances or if other antifungal alternatives are not 
appropriate  
o Study Procedures  Medical History and Imaging – added  
Data available to support inclusion/exclusion criteria collected  as SOC prior to signature [CONTACT_715077] – updated to remove central reading  
Radiological assessments should ideally be made by [CONTACT_3610] 
(HRCT if available) or MRI and all radiological images and 
local reports pertaining to the fungal disease will be forwarded to 
the central reading laboratory for independent review. 
Esophagoscopy – added  
A repeat esophagoscopy is required at EOT for all subjects, if 
this complies with SOC.  
Tissue simples - added 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 101 Protocol Amendment 3  
Main affected 
Protocol Sections  Change and Rationale  
Tissue samples collected as part of SOC procedures (e.g., 
biopsies) may be sent for drug concentration analysis, when 
available.  
o Analytical Plan  Clarified as follows:  
All analyses for ibrexafungerp will initially  present the results by 
[CONTACT_715018] , disease category and enrollment category .  
Overall response will be  presented  for all disease categories 
combined. 
o Sample size  Increased from 200 to 220 (+10%)  
o Analysis 
Population Added Myco -ITT and clarified PP  
o Myco -ITT: the Myco -ITT population will include al l ITT 
subjects with confirmed pathogens and who also had all necessary  cultures or mycology tests to estimate mycological 
response.  
o Per-Protocol Population: The per-protocol (PP) population will 
include all ITT subjects who receive enough study drug 
(ibrexafungerp) to enable clinical efficacy judgement as 
determined by [CONTACT_715060], who have an EOT (TOC for VVC, 
CMC, CPA and ABPA) assessment and who have no major protocol violations that would impact the assessment of efficacy . 
o Interim Analysis  
and Supplementary Analysis Added a clause for Supplemental Analyses 
No interim analyses are planned for this study.  If subjects on 
long-term treatment (CMC, ABPA and CPA) are ongoing at 
the time of planned data base lock, their data up to TOC visit will be included in the analys is, and data collected after TOC 
will be reported in a Supplementary Analysis.   
o Enrollment 
Categories  Added Section 18.4.[ADDRESS_974040]’s enrollment reason will be 
assessed by [CONTACT_715016]:  
o Refractory  
o Intolerant  
o Resistant (includes step -down cases – need for oral 
therapy)  
o Toxicities  
o Relapse  
o Efficacy 
Assessment  Updated as follows:  
The primary efficacy endpoint of the study is the percentage of 
subjects who achieve Global Response at TOC for VVC (Day 
17), CMC (Day 84), CPA (Day 90), ABPA (Day 90)  and at 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 102 Protocol Amendment 3  
Main affected 
Protocol Sections  Change and Rationale  
EOT for all other diseases, as determined by [CONTACT_16009]. In cases 
where EOT for CMC, CPA or ABPA subjects occurs before 
the planned TOC days, EOT will be TOC assessment.  
o Efficacy 
Timepoints and 
Outcome 
Definitions  for 
primary and secondary 
endpoints Primary Efficacy Timepoints changed as follows:  
CMC: TOC (Day [ADDRESS_974041])  
CPA: TOC (Day [ADDRESS_974042])  
ABPA: TOC (Day [ADDRESS_974043])  
Outcome definitions changed as follows:  
o EC and OPC  
Clinical Response (including radiological outcome if done as SOC)  
 
o VVC  Primary Outcome Definition:  
Global Response = Clinical Success Improvement , defined as 
at least 50% reduction from baseline in  complete or partial 
resolution of signs and symptoms with total composite score 
not >1, without use of additional antifungal 
 
o VVC Secondary Outcome Definition :  
Global Response (as defined)  
Clinical Response = Clinical Cure, defined as complete 
resolution of all signs and symptoms (VSS = 0)  without use of 
additional antifungal (Reference FDA guidelines 2016); 
Resolved VVC infection (score <3)  
Mycological Response = mycological eradication for the 
baseline pathogen 
Symptom resolution at FU (clinical cure, resolved infection, 
clinical success)  
Responder outcome (Clinical Cure and mycological 
eradication) at TOC and FU  
 
EORTC -MSG table for General Criteria for Global Responses to 
Antifungal therapy (Table 17) – additions as follows: 
o Global Response - Success definition for step -down therapy 
added: 
For subjects who were enrolled for step -down therapy 
and who were asymptomatic at baseline : no new 
symptoms or signs suggestive of disease and no new positive cultures.  
o Partial Response: Survival within a prespecified period of observation, improvement in attributable symptoms and 
signs of disease and radiological abnormalities, and evidence 
of clearance of cultures or reduction of fungal burden, and 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 103 Protocol Amendment 3  
Main affected 
Protocol Sections  Change and Rationale  
no new positive cultures , as assessed by a quantitative and 
validated laboratory marker  
o Added a category “Not Evaluable” 
Not Evaluable – Outcome cannot be assessed due to 
missing data 
o Added a statement:  
When the MSG_EORTC criteria is not fully applicable 
for a specific case, the DRC will adjudicate outcome 
based on acceptable criteria, per their judgement.  
o Survival  Updated: 
Survival status (collected as ACM) will be recorded at Day 30 for 
IC/Candidemia and at Day 42 for all.  
Protocol Amendment 3 
Administrative and/or General Changes  
o Cover Page, 
headers and footers  o Updated protocol version details. 
o Contact [CONTACT_7171]  
o Protocol Approvals o Updated contact [CONTACT_715065].  
o Spelling and typographic errors  o Corrected throughout 
o Section 16.[ADDRESS_974044].  
o Appendices o Added Protocol Amendment 3 under Revision History (Section 21.1.1) 
o Renumbered appendices accordingly.  
 
  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 104 21.1.2  Protocol Amendment 2 
Current Version  and Date: Protocol Amendment 2 (Protocol Version 3.0) dated 
[ADDRESS_974045] 2019  
Revisions to Protocol dated 23 MAR 2017 (Amendment 1) listed below.  
 
Protocol Amendment 2  
Main Affected 
Protocol Sections  Change and Rationale  
(Major changes shown as underlined font)  
Overall document  Updated protocol organization to current template 
organization . 
o Synopsis  o Updated based on major and minor/general changes listed in 
this Revision History . 
o Schematic of 
Study Design  o Updated to reflect current study design . 
o Background 
Information  o Updated to describe current ibrexafungerp knowledge.  
o Study Objectives  
o Study Endpoints 
o Rationale for the 
study 
o Overall Description of the 
Study  o Revised study objectives and endpoints to account for all 
eligible diseases.  
o Added disease -specific objectives and endpoints for selected 
fungal diseases.  
o Overall 
Description of the 
Study  o Updated to reflect current study design  
o Study Duration  
o Overall Description of the 
Study  o Updated to a total study duration of approximately [ADDRESS_974046] fulfill all inclusion criteria at 
Screening and/or Baseline (as applicable).  
o Added the following fungal diseases as eligible for inclusion in the study:  
 vulvovaginal candidiasis (VVC) 
 disseminated /invasive dimorphic fungi 
(coccidioidomycosis, histoplasmosis, blastomycosis) 
 chronic pulmonary aspergillosis (CPA) 
 allergic bronchopulmonary aspergillosis (ABPA) 
 invasive pulmonary aspergillosis (IPA) 
 other emerging fungi including yeasts and molds (e.g., 
sachromycetes, scopulariopsis)  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 105 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o Added eligibility criteria for the above -listed fungal 
diseases.  
o Updated relapse and refractoriness criteria for eligible 
fungal diseases.  
o Added “and/or legal guardian” to inclusion criteria No. 5 and No. 6. 
o Revised contraception wording.  
o Exclusion Criteria  o Clarified that subjects will be excluded if they meet any of 
the exclusion inclusion criteria at Screening and/or Baseline (as applicable).  
o Revised exclusion criterion No. [ADDRESS_974047] an invasive fungal disease with central nervous system involvement, unless they are planned to receive combination therapy with ibrexafungerp and other antifungal. 
o Removed exclusion criteria for subjects with VVC and invasive fungal diseases of the bone and/or joint. 
o Removed exclusion criteria based on absolute neutrophil 
count and QTcF interval.  
o Discontinuation 
Criteria  o Added  instructions for discontinuation procedures to be 
conducted depending on time of discontinuation.  
o Study Treatments  
o Overall Description of the Study o Added a dedicated section (Study Treatment Groups) for 
study treatments, as per current protocol template, including subsections with detailed dosing instructions and dietary requirements for:  
 ibrexafungerp monotherapy for all fungal diseases except VVC  
 ibrexafungerp monotherapy for VVC, and 
 ibrexafungerp combination therapy for certain subgroups of subjects 
o Clarified that for subjects on continuous feeding via an NG or PEG tube, the tube should be flushed with approximately 20 mL of water before and after drug administration. 
o Clarified that ibrexafungerp will be packaged in bottles containing 30 tablets and that ibrexafungerp should be stored at a maximum temperature of 25°C with allowable 
excursions to 30°C.  
o Non-Study 
Treatments  o Developed a separate, dedicated section for non -study 
treatments, as per current protocol template.  
o Prior and 
Concomitant 
Medications  o Revised the time period for recording prior and concomitant 
medications depending on fungal disease. 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 106 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o Clarified specific time period for recording prior use of 
immunosuppressants and antifungals.  
o Study Procedures  o Reorganized study procedures as General Procedures, 
Efficacy Procedures, Safety Procedures and 
Pharmacokinetic Procedures to match new order in Schedule of Study Procedures. 
o Added clarification that study days, weeks and months are counted relative to the first dose of study drug (Baseline [Day 1]) and that, for follow-up visits, days, weeks and months are counted relative to the EOT visit. Clarified that 
Screening and Baselin e/Day 1 may occur on the same day.  
o Informed Consent  o Added “legally authorized representative” as potential 
person giving consent.  
o Enrollment and 
ID Assignment 
o Study Rationale 
o Overall Description of the Study 
o Appendix B o Added clarification that an Eligibility Form will be used to 
request eligibility confirmation from the Sponsor. 
o Name [CONTACT_366595] “Enrollment Form” to “Eligibility 
Form”.  
o Included updated sample Eligibility Form in Appendix B. 
o Clarified that non -US sites will have a [ADDRESS_974048] at EOT for all female subjects, except VVC subjects.  
o Clarified that pregnancy tests may be conducted more often 
(e.g., on a monthly basis), per local regulations.  
o Prior and 
Concomitant Medications  o Separated AE and medication procedures to accommodate 
to the new organization of the Schedule of Study Procedures.  
o Cross -referred to Non -Study Treatments section and 
Appendix B, for clarity.  
o Study Drug 
Dispensing, Collection and Accountability 
Review  o Clarified that, for non -hospi[INVESTIGATOR_715001], study drug will be dispensed at Baseline/Day [ADDRESS_974049].  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 107 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o Added dispensing and collection details for VVC (dispensed 
at Baseline/Day 1 and collected at EOT).  
o Study Drug 
Dosing  o Added entire procedure with overall details for study drug 
dosing.  
o Subject Diaries  o Clarified that, for all subjects except VVC subjects, diaries 
will be reviewed every [ADDRESS_974050] infections. 
o Provided general requirements for baseline mycological, identification and susceptibility testing and testing during the study. 
o Added discussion regarding the requirements for fungal isolates and incorporated table to define Initial, Screening and Study Isolates. 
o Clarified that, if a relapse is suspected, samples for fungal culture should be collected before starting any new 
antifungal treatment.  
o Imaging  o Added recommended timepoints and requirements specific 
for each fungal disease. 
o Clarified radiological requirements for enrollment and for the duration of the study. 
o Added requirements for bronchoscopi[INVESTIGATOR_014].  
o Serological  o Added recommended timepoints and requirements specific 
for each fungal disease.  
o Esophagoscopy  o Clarified timepoints and requirements for EC subjects.  
o Spi[INVESTIGATOR_038]  o Added as new procedure (required for ABPA subjects).  
o Saint George’s 
Respi[INVESTIGATOR_6004]  o Added as new procedure (required for CPA subjects).  
o Six-Minute Walk 
Test and MRC 
Dyspnea Scale  o Added as new procedures (required for CPA subjects).  
o Recurrence  o Added as a procedure with timepoints and requirements 
specific for each fungal disease.  
o Survival  o Added as a procedure with timepoints and requirements 
specific for each fungal disease.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 108 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o Assessment of 
Efficacy  o Updated based on current endpoints and added fungal 
diseases.  
o Moved outcome definitions to the efficacy portion of the 
Analytical Plan section of the protocol.  
o Vital Signs  o Added weight to vital sign measurements.  
o Clarified that, for CPA subjects, weight will also be 
determined at the Day [ADDRESS_974051] observation in the study.  
o PK Procedures  
o Overall Description of the Study o Removed “optional” for Day 2 sampling to clarify  that all 
PK sampling is optional (i.e., for consenting subjects only). 
o Added that additional blood PK samples will be collected when clinically indicated.  
o Clarified that, in addition to blood samples, other fluid and tissue samples may be collected for ibrexafungerp PK 
determination when clinically indicated.  
o Study Schedules  
o Overall Description of the Study o Developed two separate schedules: one for VVC and a 
separate one for all other fungal diseases.  
o Reorganized study procedures for both schedules as General Procedures, Efficacy Procedures, Safety Procedures and Pharmacokinetic Procedures.  
o For all diseases except VVC : added study visits for Day 42, 
Day 84, Day 90, Day 120, Day 180, 3-month FU and 6-
month FU and added spi[INVESTIGATOR_038], SGRQ, MRC Dyspnea Scale, [ADDRESS_974052], Recurrence, Survival and Study 
Drug Dosing as study procedures based on revised endpoints and newly incorporated eligible fungal diseases. 
o F
or VVC : developed a schedule with VVC- specific 
procedures and the following VVC- specific visits: Day 4, 
EOT (Day 7), TOC (Day  17), 25- Day FU ([ADDRESS_974053] 
dose) and 35 -day FU ([ADDRESS_974054] dose) . 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 109 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o For all fungal diseases : removed 12 -lead ECG for all fungal 
diseases including VVC. 
o Updated schedules based on changes made to the procedure 
descriptions and footnotes accordingly.  
o Definition of an 
Adverse Event  o Clarified that for non -fungal infection -related AEs (e.g., 
bacterial sepsis, bacterial intra-abdominal abscess) the 
positive cultures related to the AE should also be recorded on the eCRF.  
o Events of Clinical 
Interest  o Clarified that an event will be considered an ECI if it occurs 
after dosing. 
o Removed QTc elevations as ECIs.  
o Removed INR elevations as ECIs.  
o Causality 
Assessment  o Clarified definition for Related AEs as those with a temporal 
relationship with the study drug that makes causality possible and less likely due to another cause. 
o AE Collection 
Timeframe  o Clarified that blood samples should be drawn (if possible) to 
determine ibrexafungerp concentrations for subjects who experience a severe AE or a SAE if such AE is deemed related to the study drug therapy. 
o SAE Reporting 
Requirements  o Clarified that the PI [INVESTIGATOR_715002]/or central IRBs.  
o Data Collection 
and Reporting o Clarified that, following review of the data in the eCRF, a 
designated sub-investigator may confirm the validity of each 
subject’s data if allowed per local regulations.  
o Analytical Plan  o Clarified that all analyses for ibrexafungerp  will initially 
present results by [CONTACT_301481], and will then present 
results for all disease categories combined.  
o Sample Size 
Determination  
o Overall 
Description of the 
Study  o Increased sample size to a total of [ADDRESS_974055] 1 dose of 
study drug. 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 110 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o The PP Population was redefined to include all ITT subjects 
who receive at least 5 days (1 day for VVC) of study drug 
(ibrexafungerp), who have an EOT (TOC for VVC) 
assessment and who have no major protocol violations that would impact the assessment of efficacy . 
o Interim Analysis  o Added section to clarify that no interims analyses are 
planned for the study.  
o Efficacy 
Assessments  o Added this as an entire new section, based on current 
protocol template.  
o Efficacy 
Timepoints and 
Outcome Definitions  o Included table of efficacy timepoints and outcome 
definitions for primary and secondary endpoints for each fungal disease, as follows: 
 Efficacy timepoint and outcome definitions for the primary efficacy endpoint 
 Efficacy timepoints and outcome definitions for the overall secondary endpoints 
 Outcome definitions for disease-specific secondary efficacy endpoints 
o Added EORTC- MSG table of General Criteria for Global 
Responses to Antifungal Therapy.  
o Recurrence  
o Survival  o Added as new sections . 
o Efficacy Analyses  o Updated to address changes in eligible fungal diseases and 
study endpoints. 
o Revised to clarify that results (percentage with 95% CIs) for the response rates of the primary and secondary endpoints will be presented separately for each disease category, across all disease categories and by [CONTACT_209058] (if numbers allow).  
o Clarified that the estimated response rates and 95% CIs outlined will also be assessed relative to external data.  
o Data for all subjects will be presented by [CONTACT_715066]. 
o Revised confidence interval details to clarify that endpoints will be presented with 95% confidence intervals to fully outline the estimated responses and their uncertainty. 
o Described analyses for ACM and time to death.  
o Data Review 
Committee  o Added as new section . 
o Provided summary description of guidelines to be used by 
[CONTACT_16009].  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 111 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o Investigator’s 
Assessment of 
Overall Response  o Incorporated general guidelines for assessment of clinical, 
radiological and mycological response by [CONTACT_473]. 
o Pharmacokinetic 
Assessments 
o Safety 
Assessments  o Added as new sections based on current protocol template.  
o Safety Analyses  o Clarified that summary tables by [CONTACT_715067], AEs of special interest, AE’s 
leading to withdrawal and AEs. 
o Removed ECG from safety variables.  
o Informed Consent  o Added clarification that in the case of a minor, according to 
the local definition (e.g., below 16 or 18 years of age), a parent or legal representative should also sign and date the ICF and that additional local regulatory requirements may be applicable f or participation of subjects below the age of 
consent.  
o Future Use of 
Samples  o Added as new section based on current protocol template.  
o Prohibited 
Medications and 
Medications to be 
administered with 
Caution 
o Appendix B o Clarified that no antifungal treatment other than the study 
drug is allowed during the study except in subject subgroups 
where combination therapy is allowed or where an exception was granted by [CONTACT_17190] a per- subject basis.  
o Clarified that no investigational drugs (i.e., new chemical entities) other than the study drug are allowed within at least [ADDRESS_974056] before Screening and throughout the study. 
o Clarified that subjects exposed to prohibited medications may be allowed in the study when treatment options are limited, in discussion with the Sponsor based on a risk-benefit analysis, and that additional ibrexafungerp PK and/or therapeutic drug monitori ng may be needed in these cases.  
o Added fluconazole as a prohibited medication and clarified that fluconazole, itraconazole, posaconazole and voriconazole are prohibited except in subject subgroups where combination therapy is allowed or where an exception was granted by [CONTACT_17190] a per- subject basis.  
o Updated windows for prohibited medications. 
o Updated medications to be taken with caution. 
o Removed CYPC8 Substrates as prohibited medications. 
o Added vinblastine and talinolol as prohibited P- gp 
substrates . 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 112 Protocol Amendment 2  
Main Affected 
Protocol Sections Change and Rationale  
(Major changes shown as underlined font)  
o Removed moderate CYP3A4 inhibitors and OATP1B3 . 
substrates as medications to be administered with caution.  
o Clarified that the administration of either sirolimus or 
tacrolimus should be offset by [CONTACT_246392] 2 hours with the administration of ibrexafungerp. 
o Clarified that at a minimum, blood levels of sirolimus and, tacrolimus or prothrombin time/partial thromboplastin time/international normalized ratio for subjects on warfarin 
should be measured after the first dose of ibrexafungerp 
and when the subject has received between [ADDRESS_974057] prescribing 
information for the respective agents.  
o Appendix C  o Updated the sample eligibility form and c larified that 
eligibility form provided is a sample form that may be 
modified as needed.  
o Appendix D o Added Vulvovaginal Signs and Symptoms (VSS) Scale . 
 
Protocol Amendment 2  
Minor, Administrative and/or General Changes  
o Global Changes o Changed “SCY-078” to “ibrexafungerp”. 
o Changed “Treatment Day” to “Day”.  
o Changed “Data Monitoring Committee” to “Data Review Committee” . 
o Changed “Week -6 FU” to “6 -Week FU”. 
o Minor stylistic changes.  
o Cover Page, headers and footers  o Updated protocol version details. 
o Contact [CONTACT_7171]  
o Protocol Approvals o Updated contact [CONTACT_715065]. 
o Abbreviations o Updated list of abbreviations and abbreviations used in text. 
o References  o Updated reference list . 
o Appendices o Moved Revision Histories to Appendix A . 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 113 Protocol Amendment 2  
Minor, Administrative and/or General Changes  
o Renumbered appendices accordingly.  
21.1.3  Protocol Amendment 1 
Current Version and Date: Protocol Amendment 1 (Protocol Version 2.0) dated 
23 Mar 2017 
 Revisions to Protocol dated 30 Nov 2016 (original protocol) listed below:  
 
MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
o Inclusion Criteria  
o Table of Eligible Fungal Diseases  
o Other sections as applicable  Added clarification that subjects may be male or female and updated definition of eligible fungal diseases for clarity as follows: 
2. Subject has a documented eligible acute or chronic 
invasive candidiasis (including candidemia) and/or acute or 
chronic severe mucocutaneous candidiasis (excluding 
VVC)  (as defined in Table 1) that is refractory to or 
intolerant of, or has toxicities associated with at least one approved Standard of Care (SoC) antifungal treatment. The 
subject is also eligible if, in the judgement of the investigator, long-term IV antifungal therapy is not feasible or desirable due to clinical or logistical circumstances or if other oral antifungal alternatives are not appropriate. 
Added requirements for alternative diagnostic criteria for invasive candidiasis, as follows: 
Or 
Alternative approved diagnostic method such as T2 or ß-D-glucan (two consecutive positive test results) and at least 
one of the following: temperature ≥38°C or <36°C, systolic 
blood pressure  <90 mmHg or a decrease of >30 mmHg 
from normal baseline, local signs or symptoms or 
radiologic findings of invasive candidiasis 
Revised refractoriness criteria based on ß -D-glucan to clarify 
that elevated values (rather than persistently high values) equal to or increasing from baseline meet criteria for refractory 
invasive candidiasis including candidemia.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 114 MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
 
Revised requirements for acceptable contraceptive methods and added definitions of male and female subjects who are not of reproductive potential, for clarity. Clarified women of childbearing potential must have a negative pregnancy test 
before enrollment.  
o Exclusion Criteria  Added an exclusion criterion to clarify that subjects with invasive fungal disease of the bone and/or joint are excluded if they are expected to require treatment for more than 90 days.  
Added an exclusion criterion to clarify that subjects with vulvovaginal candidiasis are not eligible for the study except 
for subjects with chronic mucocutaneous candidiasis including 
vulvovaginal involvement. 
Deleted the exclusion criterion excluding subjects with a life expectancy < 3 days. 
Clarified that subjects with unconjugated hyperbilirubinemia with diagnosis of Gilbert’s disease are not excluded. 
Removed exclusion criterion that allowed neutropenic patients 
to participate in the study if they were expected to recover in 3-5 days following initiation of G- CSF treatment.  
o Study Objectives  
o Other sections as applicable  Efficacy objectives revised based on updated definitions of treatment outcomes (see Study Procedures, Efficacy Assessments).  
Efficacy exploratory objective simplified. 
Pharmacokinetic exploratory objective revised as follows:  
• To evaluate the pharmacokinetics (PK) of SCY -078 by 
[CONTACT_715068], Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 115 MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
o Study Endpoints  
o Other sections as applicable  Efficacy endpoints revised based on updated definitions of treatment outcomes (see Study Procedures, Efficacy Assessments).  
Primary efficacy endpoint revised as follows: 
• Efficacy as measured by [CONTACT_715069] (complete or partial global response) at EoT 
as determined by [CONTACT_715070]. 
Primary safety endpoint added. Pharmacokinetic exploratory endpoint revised as follows: 
• SCY -078 plasma concentrations by [CONTACT_715071]  
o Study Procedures, 
Targeted Physical 
Examination, including Clinical Evaluation of Signs and Symptoms  
o Other sections as applicable  Clinical evaluation of signs and symptoms included under 
targeted physical examination for convenience. 
Signs and symptoms of infection revised as follows: 
• General signs and symptoms: 
o Fever defined as oral temperature ≥38.3°C (≥101°F) on 
one occasion or >37.8°C (>100°F) on two measurements 
at least 4 hours apart 
o Clinically significant hypothermia <36°C (<96.8°F) 
o Hypotension (systolic blood pressure of <90 mmHg or a 
>30 mmHg decrease below normal baseline)  
o Tachycardia  
o Local signs and symptoms of inflammation 
• Disease- specific signs and symptoms: 
o OPC: White patches or plaques on the tongue and other 
oral mucous membranes; redness or soreness in the 
affected areas; difficulty swallowing; cracking at the 
corners of the mouth (angular cheilitis) 
o EC: White plaques and/or ulcers on the lining of the 
esophagus or narrowing of the lumen, pain when 
swallowing, difficulty swallowing; heartburn 
o CMC:  Extensive scaling, skin lesions, thickened nails 
• Other signs and symptoms of candidiasis  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 116 MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
o Study Procedures, 
Study- specific 
Testing, Mycological Testing  
o Other sections as applicable  Clarified mycological testing procedures to be performed during the study for eligible fungal diseases, as follows: 
Blood cultures:  […] Blood should be drawn peripherally 
[directly from a vein]; however,  if this is not possible, blood 
may be drawn from a central IV catheter).   […]  
Non-blood cultures:  Follow -up cultures from subjects who 
have non- blood sites of Candida infection should be 
performed as clinically indicated.  
EC: Follow -up KOH or fungal stains and/or mycological 
cultures from biopsy or brushing indicating yeast infection 
will be performed as clinically indicated.  
OPC and CMC: Follow-up KOH or fungal stains and/or 
mycological cultures for Candida spp. obtained from the 
affected site will be performed as clinically indicated . 
 
Clarified that local identification and susceptibility testing may be done according to the local lab´s standards and that central 
testing will be done as per CLSI M27 -A3 guidelines.  
o Study Procedures, 
Study- specific 
Testing, Radiological Testing and Esophagoscopy Study procedure identified as “Radiological Testing” changed to “Imaging” for clarity. 
Clarified that, for subjects whose diseases are assessed by 
[CONTACT_715072], imaging scans/esophagoscopi[INVESTIGATOR_715003]. The remaining imaging scans/esophagoscopi[INVESTIGATOR_715004].  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 117 MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
o Study Procedures, 
Pharmacokinetic Assessments 
o Other sections as applicable  PK sampling times and windows clarified, as follows: 
Up to three (3) blood samples will be collected at the 
following visits and sampling windows: Treatment Day 2 
(one sample collected anytime post dosing [optional]), 
Treatment Days 3 to 5 (one sample collected predose on any 
of these days), and Treatment Days 7 to 10 (one sample 
collected predose on any of these days)  
o Study Procedures, 
12-Lead 
Electrocardiogram  
o Other sections as applicable  Visit 4 ECG assessment removed  
o Study Procedures, 
Efficacy Assessments 
o Other sections as applicable  Updated definitions for the assessment of treatment outcomes 
for consolidation with other protocols in the SCY -078 
development program, as follows: 
Global outcome will be scored as global success (complete 
global response or partial global response) or global failure 
(stable disease or progressive disease)  
Global success: Global success is defined as a complete 
global response or a partial global response 
• Complete global response is defined as a complete 
clinical response (the resolution of all clinical signs and 
symptoms and/or radiological abnormalities from 
baseline attributable to Candida infection) and a 
mycological response (mycological clearance (direct 
and/or negative cultures  [when obtainable] and/or 
normal serological results [when appropriate]) 
• Partial global response is defined as a partial clinical 
response (major improvement of all clinical signs and 
symptoms and/or radiological abnormalities from 
baseline attributable to Candida infection) and a 
mycological response (mycological clearance (direct 
and/or negative cultures  [when obtainable] and/or 
normal serological results  [when appropriate]) 
Global failure: Global failure is defined as either stable 
disease and/or progressive disease  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 118 MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
• Stable disease is defined as minor or no clinical 
improvement but without deterioration and/or 
unchanged serological response. 
• Progressive disease is defined as clinical deterioration 
necessitating alternative antifungal therapy or resulting in death, and/or worsened serological response, and/or persistence of fungal infection  on the basis of culture, 
microscopic evaluation, or histopathological testing. 
Clinical success: clinical success is defined as a complete 
clinical response or a partial clinical response.  
Mycological success: mycological success is defined as a 
mycological response. 
Added definition of recurrence for completion and a summary 
list of the procedures that will be performed to assess treatment outcome. 
o Study Procedures, 
Subject 
Discontinuation Criteria  Added pregnancy as a subject discontinuation criterion. 
o Dosing and Drug 
Accountability Procedures, Prior and Concomitant Medications & Prohibited Medications and Medications to be Administered with Caution  
o Appendix A Clarified that subjects will record all concomitant medications used in the subject diary.  
Clarified that all medications used from 28 days before 
enrollment through the EoT visit will be recorded and that only the use of antifungal medications, antibiotics for any reason or medications to treat an AE will be recorded after EoT and through the Week 6 Follow-up visit. 
Clarified that no antifungal medications other than the study 
drug are allowed during the study treatment. 
Revised requirements for the timing of sirolimus and 
tacrolimus administration.  
o Dosing and Drug 
Accountability Procedures, Dietary Requirements for Clarified that the study drug should be taken with approximately 8 oz/240 mL of water, preferably with food. For subjects on continuous feeding via an NG or PEG tube, the drug should be crushed and administered with approximately 8 
oz/240 mL of water and t he tube should be flushed with 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 119 MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
Study Drug 
Administration  
o Other sections as applicable.  approximately 8 oz/[ADDRESS_974058] for clarity, as follows: 
• QTc > 500 ms or a > 60 ms change from Baseline, 
confirmed by [CONTACT_15013] 
• ALT or AST > [ADDRESS_974059] > [ADDRESS_974060] for more than 2 weeks and if new 
compared to Baseline,  confirmed by [CONTACT_15013]  
• ALT or AST > [ADDRESS_974061] and  either total bilirubin >[ADDRESS_974062] or INR >1.5) and if new compared to Baseline, 
confirmed by [CONTACT_15013] 
• ALT or AST > [ADDRESS_974063], confirmed by [CONTACT_15013], with 
the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (> 5%) 
o Safety 
Assessments and 
Monitoring, Overdose Clarified that an overdose is any dose higher than the protocol -
specified dose and that overdoses should be reported within [ADDRESS_974064] observation in the study (Week 6 Follow- up), new AEs will be collected only if deemed related to 
the study drug, if they are SAEs, or if they are related to a fungal 
infection .   
o Safety 
Assessments and 
Monitoring, SAE Reporting Updated requirements and details for the reporting of serious 
adverse events.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 120 MAJOR CHANGES  
Main Affected 
Protocol Sections Change and Rationale 
(Major changes shown as underlined font)  
o Analytical Plan, 
Sample Size Determination  Updated the planned sample size to a total of 60 subjects.  
o Analytical Plan, 
Efficacy Analyses  Revised confidence interval details to clarify that endpoints will 
be presented with 95% confidence intervals. 
o Ethics and 
Protection of 
Human Subjects, Declaration of Helsinki Revised language to include ICH GCP guidelines, US and EU regulations and other local requirements as applicable, in addition to the Declaration of Helsinki. 
o Appendix B, 
Enrollment Form Updated the Enrollment Form for the study. 
 
MINOR AND/OR GENERAL CHANGES  
o Abbreviations  Updated list of abbreviations and abbreviations used in text. 
o Synopsis  Updated based on major and minor/general changes listed in this Revision History  
Included only key inclusion and exclusion criteria for clarity and convenience.  
Revised storage conditions for SCY- 078 tablets to clarify that 
tablets do not need to be protected from moisture. 
Additional revisions made (language added or removed) for 
consistency with the body of the protocol amendment. 
o Schematic of 
Study Design Clarified that the End of Treatment visit will occur following a maximum of 90 days of treatment with SCY-078 and that Survival visits will occur 42 and 84 days after Baseline/Treatment Day 1.  
o Background 
Information  
o Rationale for the Study Updated to reflect the latest, currently available data for SCY -
078. 
o Rationale for the 
Study 
o Study Design Updated to reflect major and minor/general changes listed in this Revision History. 
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 121 MINOR AND/OR GENERAL CHANGES  
o Inclusion and 
Exclusion Criteria  Reorganized inclusion and exclusion criteria from key, 
protocol -specific criteria to standard, general criteria, and 
renumbered criteria accordingly.  
o Study Procedures  
o Study Schedule  Reorganized and updated description of study procedures for 
clarity and to ensure consistency with the Schedule of Visits 
and Procedures and vice versa.  
Added a ± 2 day window to the every- 14-day visit, the End of 
Treatment visit and the Week 6 Follow -up visit. 
o Ethics and 
Protection of Human Subjects, Financial Disclosure  Clarified timing for collection of financial disclosure forms.  
o References  Updated bibliographic cross references and citations.  
Miscellaneous  Updated protocol date and version.  
The following changes were made for clarity and for internal consistency and consistency with other protocols in the SCY -078 development program  
• Changed “proportion” to “percentage” in Study Endpoints  
• Changed “microbiological” to “mycological” throughout  
• Changed “radiographic” to “radiological”  
• Changed “biochemistry” to “blood chemistry” for safety laboratory tests  
• Changed “patient(s)” to “subject(s)”  
• Changed “Data Review Committee (DRC)” to “Data Monitoring Committee (DMC)”  
• Changed “Week 6 (follow up)” to “Week 6 Follow -up” 
• Changed “Baseline” and “Treatment Day 1” to “Baseline/Treatment Day 1” 
Introduced minor typographical and grammatical edits and reworded language slightly as needed for clarity. 
    
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 122 21.2 Appendix B: Prohibited Medications  and Medications to be 
Administered with Caution  
21.2.[ADDRESS_974065] basis. 
No investigational drugs (i.e., new chemical entities) other than the study drug are allowed within at least [ADDRESS_974066] before 
Screening and throughout the study. 
Subjects exposed to prohibited medications may be allowed in the study when treatment 
options are limited, in discussion with the Sponsor based on a risk- benefit analysis. 
Additional ibrexafungerp PK and/or therapeutic drug monitoring may be needed in thes e 
cases.  
 
Strong CYP3A4/5 inhibitors and CYP3A4/5 inducers  
CYP  Strong /Moderate Inhibitor s Inducera 
3A4/5 Reversible inhibitors :b 
• boceprevir  
• conivaptan 
• indinavir 
• ketoconazolec 
• lopi[INVESTIGATOR_054]/ritonavir 
• mibefradil  
• fluconazolec  
• nefazodone 
• nelfinavir 
• telaprevir  
• telithromycin  
• itraconazolec 
• posaconazolec 
• voriconazolec • avasimibe  
• carbamazepi[INVESTIGATOR_050]  
• phenytoin 
• rifampin  
• St. John’s wort  
Time -dependent inhibitors :a 
• clarithromycin  
• ritonavir 
• saquinavir 
a. The CYP3A4/5 inducers and strong time -dependent CYP3A4/5 inhibitors listed in this table are not permitted 
during the 14 days prior to enrollment and during study treatment.  
b. The reversible CYP3A4/5 inhibitors listed in this table are not permitted during 48 hours prior to the 
administration of  ibrexafungerp (except  for the antifungal drug administered for the eligible fungal disease),  and 
during the study . 
c. No antifungal treatment other than the study drug is allowed during the study . Fluconazole, i traconazole, 
posaconazole and voriconazole are prohibited except in subject subgroups where combination therapy is allowed or where an exception was granted by [CONTACT_17190] a per -subject basis.  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 123  
P-glycoprotein (P -gp) substrates  
P-gp Drug Substratea 
digoxin, colchicine, vinblastine, talinolol  
a. The P -gp substrates listed in this table are not permitted during the administration of ibrexafungerp.  
 
21.2.2  Medications to be administered with Caution and Monitored as 
Appropriate  
CYP3A4 substrates  
CYP  Substrates  
3A4 In vitro , ibrexafungerp  was an inhibitor of CYP3A mediated metabolism of midazolam, 
but was only a weak inhibitor of metabolism of testosterone. The clinical significance 
of this inhibition is unknown; caution should be exercised when administering 
ibrexafungerp  with drugs known to be CYP3A sensitive substrates with narrow 
therapeutic index.  
Subjects receiving sirolimus, tacrolimus or warfarin are permitted for enrollment in the 
study and these medications may be administered concomitantly with ibrexafungerp  
with close monitoring. The administration of either sirolimus or tacrolimus should be 
offset by [CONTACT_246392] 2 hours with the administration of ibrexafungerp. At a minimum, 
blood levels of sirolimus  and tacrolimus or prothrombin time/partial thromboplastin 
time/international normalized ratio  for subjects on warfarin should be measured after  the 
first dose of ibrexafungerp and when the subject has received between 3 and 7  days of 
ibrexafungerp (at which time, ibrexafungerp  concentrations will have reached steady 
state).  Dosing adjustments and subsequent monitoring of sirolimus , tacrolimus  and 
warfarin should be undertaken in accordance with product prescribing information for 
the respective agents.  
 
Sources:  
• FDA Draft Guidance for Industry. Drug Interaction Studies – Study Design, Data Analysis, 
and Implications for Dosing and Labeling. 2012.  
• Drug interactions in infectious disease by [CONTACT_27429] C. Pi[INVESTIGATOR_27366], Keith Rodvold (2007) . 
• UCSF -FDA Transportal .  
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 124 21.3 Appendix C: Sample Eligibility Form  
 
Note: The eligibility form shown below is a sample form.  This form may be modified as 
need ed for specific fungal diseases  and per local regulations. 
 
    
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 125  
  
 
    
SCYNEXIS, Inc.  IND #107,521  
PROTOCOL SCY -078-301 AM3  Version 4.0 
 
21 NOV 2022  CONFIDENTIAL  Page 126 21.4 Appendix D: Vulvovaginal Sig ns and Symptoms Scale  
 
SIGNS:  
To be rated by [CONTACT_715073]  
0 Mild  
1 Moderate  
2 Severe  
3 
Edema      
Erythema      
Excoriation or 
fissures      
Definitions: 
Absent: none 
Mild: slight 
Moderate:  definitely noticeable  
Severe:  marked, intense 
 
SYMPTOMS:  
To be rated by [CONTACT_27431]  
0 Mild  
1 Moderate  
2 Severe  
3 
Burning      
Itching      
Irritation      
 
Definitions: 
Absent: I have no discomfort (i.e., burning, itching, irritation) 
Mild: I have some discomfort (i.e., burning, itching, irritation), but it does not bother me 
much  
Moderate:  I  have discomfort (i.e., burning, itching, irritation), which is annoying, but not  
enough to affect what I am doing 
Severe: I have discomfort (i.e., burning, itching, irritation), which is annoying enough to 
affect what I am doing  